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Where proteins go to die: Elucidating the physiological and therapeutic significance of the 
Clp protease complex in Mycobacterium tuberculosis 
Abstract 
 Microbiologists have long focused on transcription as a main source of physiological 
regulation in bacterial adaptation. However, the time scale on which certain cellular responses 
must be coordinated dictates that a more rapid system be in place to deal with sudden 
environmental stresses. In eukaryotes, understanding the proteasome and ubiquitin-tagging has 
led to an appreciation for protein turnover as a mechanism for rapid adaptation.  
 Like eukaryotes, bacteria possess several proteolytic complexes that degrade proteins 
into smaller polypeptides and amino acids. These enzymes were discovered as maintainers of 
protein quality control, through recognition of aberrant protein products, but recent studies have 
suggested that they play an active role in regulation of cell processes through degradation of 
endogenous proteins. Surprisingly, a genome wide screen for essential genes in Mycobacterium 
tuberculosis (Mtb) found numerous proteases to be essential for growth, providing evidence that 
degradative regulation may be critical for survival. One essential complex, Clp protease, was 
intriguing as it appeared to have a divergent structure in Mtb, and was largely dispensable for 
growth in most other organisms. In order to study the importance of protein turnover and 
degradative regulation in Mtb, I chose to study Clp as a model.  
 I confirmed that Clp was required for normal growth in mycobacteria through targeted 
genetic engineering, and demonstrated that depletion of Clp was bactericidal. We hypothesized 
that a protease would be essential because it might prevent accumulation of toxic proteins or 
repressors of vital processes. To understand why Clp protease was so critical, I conducted 
proteomic analysis comparing wildtype and Clp-depleted cells to identify substrates of the 
protease. In line with our hypothesis, I identified WhiB1, a redox-sensitive transcriptional 
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repressor. Blocking degradation of WhiB1 by Clp resulted in death, suggesting that the 
importance of Clp can be partially explained by its action on the repressor.  
 Finally, taking advantage of known Clp-specific inhibitors in S. aureus, we showed that 
Clp could be targeted with small molecules in Mtb. The elucidation of novel drug targets and small 
molecules active against Mtb is crucial due to the overwhelming prevalence of the disease and 
rises in drug resistant forms.   
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Chapter 1:  
An introduction to the cell-associated, compartmentalized proteases of 
bacteria 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been submitted as a review article:  
Raju RM, Goldberg AL, Rubin EJ. The Bacterial Proteolytic Complexes are Key Regulators of 
Cellular Processes and Tractable Therapeutic Targets. Nature Reviews Drug Discovery 
submitted  
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Section 1.1 – Dissertation Overview and Attributions 
With the global prevalence of drug-resistant Mycobacterium tuberculosis (Mtb) on the rise, there 
is an urgent need to discover new antibiotics to aid in the fight against the deadly pathogen. An 
important step in the path to new antimycobacterial agents is the validation of vulnerable bacterial 
protein targets whose chemical modulation results in bacterial death. My doctoral work has 
focused on essential Clp protease in Mtb, with the dual purpose of understanding why this 
cytoplasmic protease is so important for cell survival and identifying small molecule modulators of 
Clp activity that could serve as lead compounds for antimycobacterial development.  
 
Clp protease belongs to a broader class of cell-associated, compartmentalized proteolytic 
complexes that, in broad strokes, resemble the eukaryotic proteasome. These enzymes maintain 
protein quality control in the cell by removing abnormal protein products. They also serve a post-
translational regulatory function, through the degradation of endogenous bacterial proteins. 
Despite our growing appreciation of the critical role that these enzymes play in both normal 
growth and virulence, there are currently no antibacterial protease modulators. This is especially 
surprising considering that proteases are frequently targeted in the treatment of certain cancers, 
coagulopathies, and viral illnesses.  
 
Given the potential of this class from a therapeutic perspective, I introduce the bacterial 
compartmentalized proteases in Chapter One, focusing on the important physiological processes 
they regulate and the current repertoire of specific small molecules that modulate their activity. 
This tripartite introduction (characterization of the proteases, physiological importance, and 
chemical modulation) sets the stage for and mirrors the three following chapters, where I focus on 
Clp protease in Mtb.  
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In Chapter Two, I set out to understand the requirements of Clp protease in mycobacteria for 
growth in vitro and during infection. Though Clp is an extremely well-studied enzyme in model 
organisms such as Escherichia coli and Bacillus subtilis, a targeted study of the complex in Mtb is 
warranted for several reasons. First, Clp is dispensable for normal growth in these organisms, but 
a genome wide screen for essential genes conducted in our laboratory suggested that the 
protease was absolutely required for normal growth in Mtb. Second, most organisms possess one 
clpP gene, which forms the proteolytic core of the enzyme, but mycobacteria encode two 
homologous genes, clpP1 and clpP2, situated in a single operon. Through a combination of 
genetic and biochemical studies, I was able to show that both clpP1 and clpP2 are independently 
essential for normal growth in Mycobacterium smegmatis (Msm, a non-pathogenic, fast-growing 
relative of Mtb that I often use as a model organism in this thesis) and that the Mtb forms of 
ClpP1 and ClpP2 interact together to form a single proteolytic core, denoted ClpP1P2. Taking 
advantage of this, we expressed active site mutants of ClpP1 in Mtb, which had a slight dominant 
negative effect on growth in vitro. These mutants, however, were highly attenuated in a mouse 
model of infection, suggesting that Clp protease has a role in infection as well.  
 
The logical question that follows after confirming the importance of Clp protease for growth and 
infection is “why?”. I focus on this in Chapter Three. I hypothesized that bacteria lacking Clp 
protease would die because the enzyme was required to degrade a set of proteins whose 
accumulation resulted in toxicity or repressed normal growth. To systemically identify the set of 
substrates degraded by Clp, I took advantage of conditional mutants in which the levels of Clp 
could be modulated, and conducted quantitative, global proteomic analysis comparing the 
proteomes of wildtype and Clp-depleted mycobacteria. This analysis revealed numerous proteins 
that were over-represented in mutant bacteria. After confirming that over-representation was due 
to lack of Clp-dependent proteolysis and not due to a non-specific stress response resulting from 
depletion of Clp, I identified a transcriptional repressor, WhiB1, as a putative Clp substrate. 
Interestingly, blocking the Clp recognition motif on WhiB1 resulted in an ultra-stable allele that 
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was toxic. As this altered allele of WhiB1 was still functional, it suggested that dysregulation of 
WhiB1 proteolysis results in WhiB1-dependent toxicity. While there are likely many important Clp 
substrates, these studies illustrate that the toxicity of Clp depletion can be partially explained by 
the stabilization of the transcriptional repressor, WhiB1, which may inhibit cellular processes 
required for normal growth.  
 
In addition to shedding light on important biology, the study of essential bacterial enzymes is also 
attractive for the development of new antibiotics. As genetic depletion of Clp protease in 
mycobacteria was rapidly bactericidal, Chapter Four addresses the hypothesis that small 
molecule inhibition would also be cidal.  In order to chemically validate Clp protease as a drug 
target, I took advantage of studies published on trans !-lactones as Clp-specific inhibitors in 
Staphyloccus aureus and Listeria monocytogenes. In these organisms, Clp protease is not 
essential for growth in vitro, but is required during infection. Accordingly, the !-lactones are not 
lethal in S. aureus or L. monocytogenes, but do abolish virulence. Given the divergent essentiality 
of Clp, however, I hypothesized that the !-lactones could act as growth inhibitors in mycobacteria. 
Accordingly, we identified a particular !-lactone, EZ120, that was bactericidal in both Mtb and 
Msm. The compound inhibited ClpP1P2 proteolysis in an in vitro purified protein peptidase assay, 
and by conducting activity-based protein profiling studies using derivitized lactones and intact 
mycobacterial cells, we were also able to show that the !-lactones interacted with Clp protease in 
vivo. Together, these studies demonstrate that the !-lactones inhibit Clp protease in mycobacteria, 
and that targeting Clp protease is an ideal strategy for the development of new antimycobacterial 
compounds.  
 
In Chapter Five, I conclude by summarizing the significance of these findings, and proposing 
further studies that would increase our understanding of how Clp protease and the other essential 
proteolytic complexes in mycobacteria regulate important biological processes. In my opinion, we 
are on the cusp of greatly enhancing our understanding of how bacteria adapt to new 
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environments (including survival in the host during infection) by taking into account the rapid 
adaptation that cells initiate through targeted proteolysis. It is also critical that, as an 
understanding of these important enzymes emerges, we exploit this knowledge towards the 
development of an increased antibiotic arsenal. As I hope to convey in this thesis, the study of the 
cell-associated, compartmentalized proteases is one of the key areas of microbiology where the 
elucidation of novel biology can go hand in hand with translational medicine.  
 
Attributions. The manuscript that comprises Chapter One was researched and written by myself, 
with valuable editorial input from Professors Alfred Goldberg and Eric Rubin.  
 
 
Section 1.2 – The bacterial proteolytic complexes are key regulators of 
cellular processes and tractable therapeutic targets 
Ravikiran M. Rajua, Alfred L. Goldbergb, Eric J. Rubina,1 
aDepartment of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, 
MA 02138 USA 
b Department of Cell Biology, Harvard Medical School, Boston, MA 02138 USA 
1 Corresponding author: erubin@hsph.harvard.edu, ph: (617) 432-3337 
 
INTRODUCTION 
In recent years, the dramatic rise of drug-resistant bacterial species has led organizations such 
as the World Health Organization to warn of a post-antibiotic era, in which the current 
antimicrobial regimens would be largely ineffective against infectious pathogens. In fact, well-
established resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and 
extremely-drug resistant Mycobacterium tuberculosis (XDR-TB) have already begun to erode 
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earlier advances in treatment and control. As resistance has now been documented in nearly 
every human pathogen, there is an urgent need to discover new antibiotics. The simplest way to 
circumvent resistance is to develop drugs with novel mechanisms of action, which will require a 
new set of antibacterial targets.  
 
Proteases, enzymes that hydrolyze the peptide bond between amino acids, are an attractive 
class of targets for the development of therapeutics. These enzymes are highly susceptible to 
inhibition with pharmacologically attractive compounds. In fact, proteases are targeted in the 
treatment of numerous diseases. Examples abound for easily accessible extracellular proteases, 
which function in blood pressure regulation and coagulopathies, and intracellular proteases as 
encoded by HIV and other viruses. Most recently approved for human use is boceprevir, an 
inhibitor of the Hepatits C virus (HCV) NS3/4A protease, which cleaves the HCV polyprotein into 
the mature proteins that allow viral packaging and replication1. Currently, it is estimated that 5-
10% of all pharmaceutical targets being pursued are proteases2. However, despite the 
pharmaceutical successes with protease modulators, there are currently no protease inhibitors 
used to treat bacterial infections.  
 
As in eukaryotes, bacterial proteases come in many flavors. They can be broadly separated into 
two major classes: proteolytic complexes that completely degrade proteins into amino acids and 
single subunit proteases that engage in site specific cleave of proteins into smaller protein 
products. These classes can be further divided based on their location, either intracellular or 
secreted. Significant attention has been given by biologists to the secreted proteases in 
pathogenic bacteria, due to their role in virulence. The majority of them are unique to specific 
pathogens and are single subunit enzymes that target a specific protein or set of substrates in an 
unregulated fashion. For example, organisms that thrive on mucosal surfaces, such as Neisseria 
gonorrhoeae and Streptococcus pneumoniae, secrete IgA1 proteases, which inactivate IgA and 
impair immune defense mechanisms at sites of infection3. As in the case of IgA1 protease, host 
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proteome modulation is a tool employed by other bacteria to promote disease. While the effect of 
most single subunit proteases is determined by their cleavage specificity of particular sequences, 
proteases involved in intracellular protein turnover generally have a broad substrate range and 
must therefore be tightly regulated to avoid excessive or non-selective proteolysis of endogenous 
bacterial proteins. There are several conserved bacterial proteolytic complexes, each tightly 
regulated by two key mechanisms. First, these enzymes are all large barrel-shaped, multimeric, 
compartmentalized complexes, in which the proteolytic active sites are isolated in a chamber 
away from the cellular environment. Protein substrates are taken up into these degradative 
chambers and hydrolyzed to small peptides in a highly processive manner. Second, each of 
these proteases contains regulatory components, either separate domains or proteins, that 
control accessibility to the active sites and specificity for particular proteins. Thus, despite 
carrying out a destructive process, these tightly regulated enzymes are able to provide an efficient 
mechanism for maintaining protein quality control by degrading misfolded polypeptides, and 
coordinating post-translational regulation through targeted degradation of endogenous proteins.  
 
Neglected from a drug development perspective until recently, the bacterial degradative 
complexes are attractive targets for several reasons. First, they are widely conserved among 
bacteria, thus increasing the chance of broad-spectrum coverage of any small molecule 
modulators. Second, these enzymes perform numerous essential functions in the cell. 
Degradative proteases were initially identified in Escherichia coli for their role in general quality 
control of the proteome, via the degradation of abnormal proteins, but were largely found to be 
non-essential. More recent studies in pathogenic bacteria have revealed that these proteases 
play numerous critical, regulatory roles in many physiological processes, and are in almost every 
case indispensable for either normal growth or virulence. For example, while Clp protease is non-
essential for vegetative growth in E. coli, it was found to be essential both in vitro and during 
infection in Mycobacterium tuberculosis4. Third, as these enzymes are large complexes with 
regulatory and catalytic components, numerous surfaces could be effectively targeted by small 
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molecules. Much work has gone into elucidating the biochemistry and structural biology of these 
key enzymes (at least in E. coli, although not in pathogens), which should facilitate target-based 
drug development approaches.  
 
We begin with a brief description of the general properties of these enzymes, and an introduction 
to the specific conserved, proteolytic complexes found in bacteria. Next, we validate a target-
based approach to drug development by discussing the physiological significance of these 
enzymes and highlighting key processes regulated by the bacterial proteolytic complexes. As the 
study of these enzymes has been the focus of many talented researchers, it is impossible to 
present a complete overview here. Instead, we aim to illustrate over-arching themes and 
concepts that facilitate a broad understanding of the degradative proteases and how they 
coordinate important cellular processes. Finally, we close with an in-depth look at the recent 
efforts to develop specific modulators of the degradative proteases and the lead compounds that 
could provide a direct path to a novel class of antibiotics.  
 
THE KEY PROKARYOTIC DEGRADATIVE PROTEASES 
Bacteria contain a key set of conserved, cell-associated degradative proteases  that are 
responsible for turnover of intracellular proteins. The main proteases include the Clp, FtsH, Lon, 
HslUV, the prokaryotic proteasome, and the HtrA family of enzymes. These complexes are found 
in every cell compartment: in the cytoplasm, on the cell membrane, and in the periplasm. With the 
exception of the bacterial proteasome, they are ubiquitous within the Eubacteria kingdom and are 
even conserved in the chloroplast and mitochondria of eukaryotes. Each protease can be broadly 
characterized as having two major components: a recognition domain that is responsible for initial 
binding to a protein substrate, and a proteolytic domain that carries out peptide bond hydrolysis. 
With the exception of the periplasmic HtrA family of proteases, these enzymes also possess a 
hexameric ATPase subcomplex, which provides energy for substrate unfolding, translocation into 
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the proteolytic domain, and also regulates the proteolytic compartment5. All these enzymes are 
hexameric or heptameric complexes that are much larger (between 500,000 and 1,000,000 kDa) 
and complex than the typical extracellular and single subunit intracellular proteases (20,000 to 
30,000 kDa). Lon, FtsH, and HtrA proteases encode both the recognition domain and proteolytic 
domain in polypeptide, while in Clp, HslUV, and the proteasome the recognition and proteolytic 
functions are separated on two separate protein complexes (Table 1.1). The proteases that 
exhibit ATPase activity fall into the broad class of AAA+ enzymes, or ATPases associated with 
diverse cellular activities, which have been well-characterized and studied in numerous 
organisms6. Though not covered in this review, these ATPase complexes have also been shown 
to act as independent chaperones, aiding in the remodeling of particular proteins7.  
 
Regardless of the structure of these domains, and unlike the majority of proteases which are 
single subunit enzymes, each of the degradative enzymes requires multimerization of subunits to 
form a barrel-shaped structure with the active sites of each proteolytic subunit facing inwards into 
a hollow chamber. This protected structure ensures efficient degradation of substrates delivered 
by the recognition domains, and prevents non-specific hydrolysis of random proteins. Typically, 
continued ATP hydrolysis and/or substrate binding catalyzes a conformational change of the 
complex that enables access of substrates to the hydrolytic active sites in the degradative 
chamber.  
 
Substrates are targeted for degradation by several mechanisms. All degradative proteases 
rapidly degrade proteins that lack well-defined tertiary structures. Some substrates possess a 
small, unfolded stretch of amino acids, which serves as a motif that interacts with the protease 
recognition domain and leads to targeting for degradation8.  In other cases, substrates require 
modification to unmask a hidden sequence that is recognized by the protease. For example, 
degradation motifs may be revealed through phosphorylation that causes a reorganization of 
exposed residues, initial cleavage by a site-specific protease, or loss of protein-protein 
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interactions that normally protect a specific protease recognition sequence9. Other substrates 
require adapter proteins to target them to a protease for degradation10.   
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Clp Protease 
Clp is a serine protease with a characteristic Ser-His-Asp catalytic triad. The active complex 
consists of individual ClpP proteolytic subunits stacked into two heptameric rings. Specificity for 
protein substrates is determined through separate ATPase complexes, hexameric rings that 
interact with the apical surfaces of the ClpP tetradecamer. In Gram positive bacteria, either of two 
ATPase complexes, ClpX and ClpC, can interact with ClpP to form the active ClpXP and ClpCP 
proteases, while in Gram-negative bacteria, ClpA and ClpX cap the proteolytic ClpP 
tetradecamer11. These ATPases can recognize a diverse set of motifs present almost anywhere 
within the protein; N-terminal, internal and C-terminal recognition motifs have been described. For 
instance, the “N-end rule” in prokaryotes states that the presence of an abnormal amino-terminal 
residue can lead to rapid degradation12. The adapter ClpS assists in the binding of polypeptides 
with large, hydrophobic N-terminal Phe, Leu, Trp or Tyr, and delivering proteins with these 
destabilizing N-terminal residues to ClpAP or ClpCP for degradation13. While the hexameric 
ATPases are capable of recognizing various proteins, additional adapters such as ClpS also 
interact with the ATPases to facilitate substrate degradation.  
 
FtsH Protease  
FtsH (also referred to as HflB in some organisms) is a homohexameric complex of Zn2+ 
metalloprotease subunits. With two N-terminal transmembrane domains, the C-terminal 
proteolytic machinery of FtsH lies in the cytosol, and thereby enables degradation of both 
cytoplasmic and membrane-associated proteins14,15. Unlike Clp, both ATPase and proteolytic 
function are encoded on the same polypeptide, and upon multimerization, ATPase domains 
extend outwards while the proteolytic machinery is protected and buried internally. FtsH is 
thought to recognize unfolded stretches of amino acids as well as specific recognition motifs 
present at either the ends or internally within a protein. Between the two transmembrane domains 
of FtsH, a periplasmic stretch coordinates interactions with the extracytoplasmic adapter complex 
HflKC, which inhibits degradation of membrane-associated proteins, thus favoring recognition of 
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cytoplasmic substrates16. In the cytoplasm, other adapters such as HflD and MgtR interact with 
the protease to enable degradation of specific proteins.  
 
Lon Protease 
Lon protease is a serine protease that contains a Ser-Lys catalytic dyad. The single polypeptide 
that multimerizes into the active hexameric complex contains the N-terminal substrate binding 
and oligomerization domain, the ATPase domain, the substrate sensor and discriminatory domain 
(SSD), and the C-terminal proteolytic domain17. Substrates are recognized by the substrate 
binding domain, then unfolded via ATPase activity, and finally threaded into the proteolytic 
chamber. As with Clp protease, Lon appears to recognize an extremely diverse set of motifs in 
proteins. Additionally, Lon interacts with small molecule adapters such as polyphosphate or 
chromosomal DNA to coordinate degradation of specific proteins during starvation when the 
intracellular polyphosphate concentrations are elevated and upon stresses that cause DNA 
damage18.  
 
HslUV Protease and the Prokaryotic Proteasome 
The HslUV protease and the proteasome comprise a unique family of cytoplasmic proteases that 
contain an N-terminal threonine residue responsible for hydrolysis. Lacking a canonical catalytic 
dyad or triad, these enzymes exhibit a unique mechanism of catalysis in which the threonine 
hydroxyl acts as the nucleophile to hydrolyze peptide bonds, while the N-terminal amino group 
acts as a general base to facilitate catalysis19.  The well-conserved HslUV protease (sometimes 
referred to as ClpYQ) resembles the ClpCP and ClpXP proteases in overall structure. While the 
HslU subunit is a member of the AAA+ ATPases and has significant homology to ClpX, the HslV 
subunit shares a high-degree of similarity with the proteolytic beta-subunits of the eukaryotic 20s 
proteasome20. Substrate recognition is afforded through the HslU ATPase which also provides the 
energy for unfolding and translocation.  
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The prokaryotic proteasome, however, is only present in a few pathogenic bacteria, including 
mycobacteria, nocardia, and Propionibacterium acnes. The bacterial proteasome is composed of 
four, stacked proteolytic rings and closely resembles the eukaryotic 20s proteasome with two 
inner hepatameric rings composed of PrcB (beta subunits) and two outer heptameric rings of 
PrcA (alpha subunits)21. However, while eukaryotes encode seven different but homologous 
alpha and beta subunits, the prokaryotic proteasome only contains one of each type of subunit. In 
addition, bacteria encode a proteasome regulatory ATPase hexamer, Mpa, but interaction with 
the 20s component has yet to be confirmed22. M. tuberculosis can conjugate a marking protein 
(Pup) to substrates leading to their recognition by Mpa and degradation by the prokaryotic 
proteasome23. Pup thus functions in a homologous manner to ubiquitin, although the structure 
and chemistry are divergent from eukaryotic ubiquitin. 
 
HtrA Protease 
The HtrA family (also known as Deg family) of serine proteases are different from the enzymes 
above in several key respects. First, HtrA proteases are secreted into the periplasm and are, 
therefore, responsible for degradation of outer membrane, periplasmic, and foreign proteins. 
Second, they lack an ATPase domain and do not require ATP for substrate hydrolysis. Third, they 
exhibit significant chaperone activity that is independent from their role as proteases. This 
chaperone activity appears to be crucial for the proper folding and localization of key outer 
membrane proteins24. Fourth, despite a funnel-shaped structure which also leads to 
compartmentalization of active sites, instances of limited processivity by HtrA have been 
documented25.  
 
Some bacteria contain two to three different HtrA-like proteins. All HtrA proteins share a similar 
domain structure, with an N-terminal protease domain and a C-terminal PDZ domain, which is 
broadly involved in protein-protein interactions and substrate recognition. In E. coli, which 
contains three HtrA proteins, DegS is a funnel-shaped trimer with protease domains forming a 
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central core, and the PDZ domains protruding outwards26. These protrusions play a critical role in 
substrate recognition. DegP is found as a trimer in its inactive state, but upon substrate binding to 
the PDZ domain, the trimer polymerizes into higher-order structures such as 12mers, 15mers or 
even 18mers27. In each of these arrangements, the protease domains always form a central 
chamber, while the PDZ recognition domains protrude outwards. DegQ, the third Htra-like 
protease in E. coli, is similar in structure to DegP. 
 
PHYSIOLOGICAL ROLES OF THE DEGRADATIVE PROTEASES 
One of the most critical components of target-based approaches to antibiotic development is to 
demonstrate the essentiality of a particular target. If genetic studies reveal that a protein of 
interest is required for the growth of a pathogen, either in vitro or in vivo, there is a strong 
likelihood that chemical inhibition of that target will result in bacterial death during infection. 
Despite the conservation of the degradative proteolytic complexes, no generalizable conclusions 
can explain their essentiality or conditional requirements, which seems to vary across species. 
For example, Clp protease is dispensable for in vitro growth of most pathogens, but is essential 
for virulence and in vivo survival. In M. tuberculosis, however, Clp is absolutely required for in 
vitro and in vivo growth in28. FtsH protease appears to be essential for normal growth in E. coli, 
while Lon only becomes essential during certain types of stress29. This diverse pattern highlights 
that though the proteases may be conserved across Eubacteria, they have evolved divergent 
functions. Nonetheless, all of these enzymes are largely essential for growth during infection, thus 
validating the proteases as broad targets for the development of anti-virulence agents, and in the 
case of some species, traditional growth inhibitors.  
 
Recent studies have begun to paint a rich portrait of how the degradative proteases are able to 
regulate numerous cellular processes, through targeted degradation of specific regulatory 
proteins. Though no unifying theme on the functional significance of these proteases has 
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emerged to date, there are several key aspects of physiology that they coordinate. These broad 
areas include general protein quality control, specific stress responses, cellular replication and 
differentiation, and virulence.  
 
General protein quality control 
It was the initial attempts to understand how cells eliminate abnormal proteins that led to the 
discovery of ATP-dependent protein degradation and the characterization of the proteolytic 
complexes, Lon and Clp. Protein abnormalities can arise in a variety of ways, including mutations 
in DNA, errors in transcription or translation, post-translational damage (ie. by heat or oxygen 
radicals), and spontaneous denaturation. All such changes can produce potentially toxic proteins, 
and the degradative proteases minimize the impact of this toxicity through three main 
mechanisms.   
 
First, all of the degradative proteases have an affinity for abnormally folded proteins. Generally, 
proteins are globular and hydrophobic regions are internal, but mutations and damage lead to 
loose, unfolded structures with exposed hydrophobic residues. As mislocalization and misfolding 
can occur in all cellular compartments, each space is equipped with general quality control 
enzymes. In the periplasm, HtrA is the predominant protease responsible for clearance of 
misfolded proteins. The PDZ domain of HtrA proteases binds unfolded stretches in misfolded or 
mislocalized proteins and directs them towards the proteolytic chamber for degradation30. In the 
cell membrane, the anchored FtsH insures protein quality control by degrading proteins that are 
misfolded or unassociated with other interacting partners. For example, individual components of 
the F1 ATPase, involved in generating the proton motive force, and the Sec secretion system that 
are inserted into the membrane without the full complex are targeted for degradation by FtsH15,31. 
In the cytoplasm, Lon appears to be the primary protease responsible for degradation of 
abnormal proteins. The N-terminal substrate binding domain has an affinity for linear 
arrangements of aromatic amino acid residues, hydrophobic residues that are normally buried 
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internally within a protein, and the carbonyl derivatives that can form upon reaction with reactive 
oxygen species8.  
 
Second, several proteases are involved in the ribosome rescue pathway, or trans-translation, 
which requires degradation of polypeptides that have stalled on the ribosome during translation. 
During translation, ribosomal stalling may occur upon truncation or oxidation of mRNA or a 
depletion of required tRNAs. In response, the mRNA can be displaced by a unique species, the 
transfer messenger RNA (tmRNA), which directs the addition of a C terminal peptide, the SsrA 
sequence32.  The modified polypeptide, once released from the ribosome, can be recognized and 
degraded by multiple proteases, primarily ClpXP, but also Lon and FtsH. Interestingly, recent 
work suggests that tmRNA pathway in M. tuberculosis is inhibited by the antituberculous drug 
pyrazinamide, which binds to and interferes with the function of ribosomal protein S133.  
 
Third, proteases themselves are upregulated during conditions that promote protein misfolding 
such as heat shock. In fact, Lon, Clp and HslUV were initially identified as heat shock proteins as 
they were induced during stress and promoted the degradation of misfolded proteins. In the 
cytoplasm, these proteins are induced together with other major heat shock proteins, such as 
DnaK, GroEL, and GroES, which function as molecular chaperones to promote unfolding and 
refolding of damaged proteins34. If chaperones fail to refold their substrates, these aberrant 
proteins can be targeted to the cytoplasmic proteases for degradation. In the periplasm, bacteria 
induce the unfolded protein stress response in response to misfolded polypeptides, and this 
pathway is critically regulated by and dependent on the degradative proteases. In the periplasm 
in E. coli, CpxP normally binds to and inhibits the transmembrane sensor kinase CpxA. In the 
presence of abnormal proteins, CpxP binds to them and targets them to DegP for degradation35. 
CpxA is then free to phosphorylate the cytoplasmic response regulator CpxR36. In the cell 
envelope, RseA, a membrane-bound anti-sigma factor, binds to and sequesters RNA polymerase 
σE (RpoE) at the cell membrane. In the presence of misfolded proteins, DegS is activated to 
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cleave RseA37. Together RpoE, which is now free in the cytoplasm, and phosphorylated CpxR 
induce the expression of genes that serve to maintain the cell envelope during stress38. As 
infection of the mammalian host is highly stressful, RpoE and CpxR have been found to be 
essential for the viability and virulence of numerous organisms including Salmonella enterica 
serovar typhimurium, and M. tuberculosis39,40.  
 
Coordination of stress responses 
In addition to coordinating the clearance of abnormally folded proteins and the cellular response 
to their presence, the degradative proteases are also involved in the regulation of numerous other 
stress responses. In stressful environments, bacteria must activate a diverse set of transcriptional 
responses. Each stress response can be characterized as having three phases: induction, in 
which transcriptional activation of effector proteins occurs, maintenance, during which key players 
coordinate adaptation to the stressor, and termination, which occurs after the stress has been 
relieved and cells must return to their normal physiological state. At each of these points, effective 
regulation of many stress responses is critically dependent on the degradation of particular 
proteins. These mechanisms have been most extensively studied in E. coli. 
 
The multiple levels at which proteolytic regulation modulates stress response induction in E. coli 
is best illustrated through the master regulator of the general stress response, RpoS (Figure 1.1). 
RpoS is a transcription factor critical for the induction of numerous pathways that promote stress 
adaptation including genes involved in heat shock, anaerobic metabolism, and DNA repair41. 
RpoS is transcribed and translated normally, but its level in cells remains low due to efficient 
degradation by ClpXP protease42. However, entrance into stationary phase or the presence of 
various stress-inducing signals such as UV irradiation, heat, or acid, results in a dramatic 
stabilization of RpoS. Proteolysis requires the adapter protein RssB which, when phosphorylated, 
binds RpoS and recruits the transcription factor to ClpXP43.  During stress induction, RssB is 
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sequestered by several different inducible anti-adapters, generally named Ira proteins, thus 
stabilizing RpoS44.  
  20 
  
Figure 1.1 Role of proteolysis in regulation of RpoS 
Levels of RpoS are regulated by several proteolytic circuits (degradation 
denoted by diamond arrow head). During normal, vegetative growth, RpoS 
levels are kept low by constitutive ClpXP degradation. Proteolysis requires 
the adapter protein RssB, which binds to RpoS and promotes recognition by 
ClpXP. During certain stresses, a set of Ira proteins are produced that bind 
and sequester RssB, thus stabilizing RpoS and allowing induction of stress 
adaptation. In an additional layer of control, the antitoxin MqsA inhibits 
transcription of RpoS during normal growth. Stressful environments favor 
degradation of MqsA by Lon protease, and subsequent activation of the 
cognate toxin MqsR, which induces the transcription of stress response loci 
including genes that promote inhibition of replication, such as CspD. 
Furthermore, CspD is also degraded by Lon protease, and this breakdown of 
CspD is required for cells to resume normal growth after surviving a stressful 
insult.  
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An additional layer of protease-mediated regulation of RpoS involves the MqsAR toxin-antitoxin 
(TA) module. Briefly, TA systems usually consist of two components: a stable, protein toxin that 
effects cell growth via a variety of mechanisms, and a rapidly degraded antitoxin, either a protein 
or RNA, that inhibts toxin activity. Under normal circumstances, both the toxin and antitoxin are 
co-transcribed. However, when transcription of the locus is inhibited, the unstable antitoxin is 
titrated away, most often through degradation, and the stable toxin is left uninhibited. Most 
commonly, toxins exhibit their toxicity through endonuclease activity. In some cases, such as for 
the MqsAR locus, both toxin and antitoxin can also act as transcription factors. In the absence of 
any stress, the antitoxin MqsA actively represses rpoS transcription45. However upon the 
induction of oxidative stress, Lon protease rapidly degrades MqsA. In addition to de-repression of 
the rpoS locus, the now-released MqsR toxin induces the transcription of stress response loci 
including a gene that promotes inhibition of replication, CspD46. CspD is also proteolytically 
regulated by Lon protease, and this breakdown of CspD is required for cells to resume normal 
growth after surviving a stressful insult47. Strikingly, the same protease that is involved in the 
induction of MqsR toxicity through degradation of the MqsA antitoxin, also attenuates the MqsR 
response through degradation of effector proteins. Polyphosphate, a Lon protease cofactor, might 
play a role in this process, favoring degradation of MqsA only in conditions of energy depletion 
when the intracellular concentration of polyphosphate increases.  
 
The degradative proteases are also important effectors during the maintenance phase of 
adaptation. In the face of altered nutrient availability, bacteria must have a rapid way to modulate 
metabolic activity and biosynthetic clusters. Degradative proteases are well-equipped to initiate 
rapid changes in the nutritional programming of a cell, by efficiently clearing away unneeded 
proteins, or degrading transcriptional regulators of key metabolic pathways. For example, in 
Bacillus subtilis, ClpCP down regulates central metabolic pathways during glucose starvation 
through degradation of GlmS (cell wall biosynthesis), IlvB (isoleucine biosynthesis), PurF (purine 
biosynthesis), and PyrB (pyrimidine biosynthesis)48. In addition, during carbon limitation, bacteria 
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also modulate ribosomal levels to conserve energy. In E. coli, Lon protease is responsible for 
targeted degradation of the ribosomal proteins S2, L9, and L13 during amino acid starvation49. 
This conditional regulation is facilitated by the fact that Lon protease only recognizes these 
ribosomal proteins when bound to the co-factor polyphosphate, which accumulates in response to 
starvation.  
 
Proteases are also important effectors as cells emerge from nutrient limiting conditions. ClpXP 
regulates the levels of Dps, a DNA binding protein that binds the chromosome non-specifically 
and protects the genetic material from damage while simultaneously preventing replication and 
transcription50. Moreover, ClpXP is required to degrade proteins involved in anaerobic and 
alternative carbon metabolism such as malate synthase and isocitrate lyase, which may facilitate 
adaptation once cells are shifted from a carbon-starved to a rich growth medium51.  
 
During the termination of stress responses, proteases can ensure rapid inhibition through the dual 
recognition of both transcriptional activators and effector proteins. For example, in E. coli, FtsH 
degrades sigma32, the key activator of the heat shock stress response and SoxS, a 
transcriptional activator in the oxidative stress response, to prevent aberrant induction of these 
pathways52,53. In M. tuberculosis there is an additional level of control.  A down-stream effector of 
SoxS, Superoxide disumutase A (SodA) is pupylated and targeted for degradation by the 
mycobacterial proteasome54. Similar degradation of effector proteins also occurs in the case of 
DNA repair enzymes that are induced by stress.  For example, the nucleotide excision repair 
(NER) machinery must be exquisitely controlled to prevent random mutagenesis. As NER is 
specifically equipped to remove thymidine dimers that result from UV damage of DNA, ClpXP 
actively controls the amount of UvrA, an essential protein in the NER complex present based on 
the frequency of thymidine dimers present in DNA55. Similarly, UmuDʼ, a component of the error-
prone DNA polymerase PolV complex, is degraded by ClpXP, preventing excessive chromosomal 
mutations after DNA has been repaired56.  
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Regulation of cellular replication and differentiation 
Efficient cellular replication requires the temporal coordination of several major steps including 
initiation of DNA replication, and cytokinesis or separation of daughter cells into progeny. 
Degradative proteases play a role in both DNA replication and in daughter cell division. In 
Caulobacter crescentus, the initiation of chromosomal replication is proteolytically controlled 
(Figure 1.2). Caulobacter has a complex life cycle with two morphologically distinct cell types, a 
non-replicating motile, swarmer cell type and a replicating, stalked type.  The switch between 
morphotypes and the initiation of DNA synthesis are both inhibited by a DNA-binding protein, CtrA.  
When phosphorylated, CtrA is a stable protein that binds tightly to the chromosomal origin, 
inhibiting DNA replication, and acts as a transcriptional factor that maintains the non-replicating, 
motile state57.  Upon dephosphorylation, CtrA can be released from DNA and degraded by ClpXP 
via a dedicated adapter protein, RcdA, which allows replication to commence.  Interestingly, at 
the time of the transition, CtrA degradation is localized at the nascent pole by ClpXP interactions 
with an anchoring protein, CpdR58.  The Clp system is essential in Caulobacter as loss of ClpXP 
prevents phase transition and DNA replication.   
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Figure 1.2 Proteolytic regulation of chromosomal replication in 
Caulobacter crescentus 
Model for CpdR and CtrA regulation and cell cycle progression. 
(A) Continuous and dashed lines indicate direct or possible indirect effects, 
respectively. The black boxes represent CtrA binding sites. (B) The 
differential spatial distribution of multiple regulatory elements that drive cell-
cycle progression are shown. PD, predivisional cell; SW, swarmer cell; ST, 
stalked cell.  
From Iniesta et al, 2008 [58] 
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In order to divide, cells must first eliminate the division machinery that is left over at the most 
recently created pole. In E. coli, FtsZ, a tubulin homolog forms a circumferential ring around the 
cell and is responsible for recruiting the divisome complex of proteins and providing the 
contractile force required for cytokinesis. ClpXP preferentially degrades polymerized FtsZ, 
allowing disassembly at the site of cytokinesis after separation and reassembly at the midcell of 
daughter cells that are priming for a new round of division59. In the Gram positive organisms B. 
subtilis and M. tuberculosis ClpXP might have a different role, acting as an inhibitor of FtsZ 
polymerization60.  In addition to directly degrading FtsZ, degradative proteases play a role in 
modulating the activity of proteins that interact with the divisome.  For example, in E. coli , SulA, a 
replication inhibitor protein induced during the bacterial SOS-response, binds directly to FtsZ 
inhibiting polymerization and contractile ring formation. Upon the resolution of the SOS response, 
both Lon and HslUV protease rapidly degrade SulA, thus allowing the resumption of cellular 
division61.  
 
In addition to replication, population-level survival also requires differentiation of cells to survive 
longer times in harsh environments. Key examples of cellular differentiation and reprogramming 
include sporulation and biofilm formation. While many spore-forming bacteria, such as Bacillus 
anthracis, Clostridium dificile, Clostridium botulinum, and Clostridium tetani, are important 
pathogens, sporulation has been best studied in Bacillus subtilis. Sporulation in B. subtilis is 
regulated by controlled degradation in several respects. In the pre-divisional cell, Spo0A is the 
master regulator of sporulation that is activated in response to nutrient limitation and induces 
asymmetrical division. As phosphorylation of Spo0A is required for full activity, phosphatases 
such as Spo0E act as inhibitors of Spo0A and sporulation62. It was recently found that FtsH 
degrades Spo0E both in vitro and in vivo, and that accordingly, FtsH mutants were deficient in 
their ability to sporulate63. SpoVM, a small polypeptide with slow degradation kinetics, is thought 
to act as a decoy substrate and an inhibitor of FtsH-dependent Spo0E degradation64. Moreover, 
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both Lon and ClpCP protease degrade Spo0H another transcription factor important in initiating 
sporulation65.  
 
Another type of differentiation, biofilm formation, is critical for attachment of some pathogens in 
the host and for survival in the face of a host immune response and antibiotic treatment. Recently, 
Clp protease has been shown to enhance biofilm production of Staphyloccus epidermidis, a 
common cause of prosthetic device infections, by degrading Spx, a negative regulator of 
biofilms65,66. As Spx is conserved in related pathogens, such as Staphylococcus aureus and 
Streptococcus pneumoniae, Clp may play an important role in these pathogenic biofilm-forming 
bacteria. 
 
Regulation of Virulence 
In almost every pathogenic bacterial species that has been examined, degradative proteases 
have been found to act as master regulators of critical aspects of virulence, including initial 
colonization and prevention of killing by host responses. Establishment of infection often involves 
upregulation of cellular processes that facilitate adherence, invasion, and survival inside the 
harsh host environment. By regulating the expression of proteins present at the outer surface of 
the bacteria, the HtrA proteases are critical for these initial events in numerous gut pathogens. In 
Campylobacter jejuni, a common cause of gastroenteritis, HtrA stimulates adherence to the 
gastrointestinal epithelium67. In another gut pathogen, Salmonella typhi HtrA mutants exhibited 
poor systemic spread after oral inoculation in a mouse model of infection. As spread of the mutant 
was not affected when mice were infected intravenously, HtrA was implicated in the initial 
penetration of the intestinal barrier during systemic spread of Salmonella68.  
 
In intracellular organisms, successful infection requires adaptation to the harsh intracellular 
environment of host cells. One protein, MgtC, is conserved in a number of intracellular pathogens 
that infect macrophages, including Salmonella typhimurium, M. tuberculosis, and Yersinia pestis. 
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In each organism, MgtC is required for growth in macrophages, presumably due to its role in 
magnesium uptake69. In Salmonella enterica, MgtC is not present in bacteria growing in vitro 
despite high levels of mgtC transcript. This appears to be due to FtsH-mediated degradation, an 
event that likely ensures proper timing of the induction of virulence and invasion pathways. 
Degradation requires a short peptide, MgtR that acts as an FtsH adapter70. In other cases of host 
adaptation, the substrates are not so clear.  For example, M. tuberculosis requires the prokaryotic 
proteasome for survival in the host, but it has been suggested that proteolytic activity of the 
complex may not be required for this survival effect71. Additionally, Clp protease is essential for 
normal growth in vitro and during infection in M. tuberculosis, but for unknown reasons28.  
 
Several Gram negative pathogens utilize a specialized protein secretory pathway, the type III 
secretion system, to transport proteins to host cells and modulate host processes to facilitate 
infection. Both Clp and Lon protease have been shown to have a role in the regulation of type III 
secretion (TTSS) in various organisms. Interestingly, Lon protease appears to have distinct 
effects on secretion in different bacterial species. In Yersinia pestis, Lon protease upregulates 
secretion of type III effectors by degrading YmoA, a transcriptional repressor of the TTSS locus72. 
However, In S. typhimurium, Lon protease represses secretion by targeting the transcriptional 
activators HilC and HilD for degradation73. Though Lon depletion led to massive induction of 
apoptosis in macrophages and enhanced invasion of epithelial cells in vitro, mutants were 
severely attenuated in mouse models of infection, presumably due to increased recognition by 
immune effectors due to over-secretion of virulence factors.  
 
Clp and HtrA proteases have also been implicated in the production and secretion of virulence 
factors in Gram positive organisms. Many syndromes caused by S. aureus result from a set of 
secreted toxins. One important protein, alpha-hemolysin, is a pore-forming toxin whose 
expression is dependent on the presence of ClpXP protease. Depletion of either clpX or clpP in S. 
aureus abolished transcription of the hla gene that encodes alpha-hemolysin, presumably by 
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stabilizing an as yet unidentified repressor, and abolished virulence74.  Similarly, production of 
listeriolysin O, a major virulence factor of L. monocytogenes, is abolished in a clpP mutant, thus 
abrogating virulence in this organism75.  
 
In some bacteria, HtrA may itself be a secreted virulence factor. The HtrA protease from 
Chlamydia trachomatis is specifically secreted into the host cell cytosol during intracellular 
infection, though its host substrates are unknown. In the extracellular gut pathogen Helicobacter 
pylori, HtrA is a secreted virulence factor that cleaves host E-cadherin leading to disruptions of 
tight junctions in the gut epithelia, promoting the development of H. pylori-mediated peptic ulcer 
disease25.   
 
DEGRADATIVE PROTEASES AS TARGETS FOR THERAPEUTIC DEVELOPMENT  
As outlined above, the degradative proteases are clearly required for many cellular processes. 
Despite their importance, conservation, and druggability, there are currently no commercial 
antibiotics that target this enzyme class in bacteria. In some cases, disruption of proteases should 
block cell growth; in others, modulation could limit host virulence. Targeting virulence pathways 
with small molecules represents a relatively new strategy in the development of antibiotics. The 
inhibition of virulence does not kill the organism during infection but prevents colonization of the 
host. Unable to establish a foothold in the host, bacteria targeted with anti-virulence antibiotics 
would be removed by the host immune system and other clearance mechanisms. The inhibition 
of Clp protease in the urinary tract pathogen, Staphylococcus epidermidis, is an ideal example of 
the potential efficacy of anti-virulence antibiotics. In S. epidermidis, Clp protease is not essential 
for normal growth, but does degrade the negative regulator Spx, a transcription factor that 
represses biofilm formation and the production of genes that facilitate primary attachment to the 
uroepithelium66. A small molecule that inhibited Clp protease function could prevent the ability the 
organism to colonize the urinary tract, and lead to clearance of the organism by the flow of urine.  
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The major benefit for anti-virulence strategies is thought to be the relatively low selective pressure 
that inhibiting virulence would exhibit at a population level76. Traditional antibiotics, which focused 
on targeting central processes within an organism, placed an enormous selective pressure on the 
population, which has partly contributed to the current pandemic of drug resistance. In theory, the 
inhibition of virulence would apply a milder evolutionary pressure, as most virulence pathways are 
not essential for normal growth. As no anti-virulence antibiotics currently exist on the market, 
however, it is not yet clear if these antibiotics will be less prone to the development of resistant 
strains in a clinical setting. 
 
Additionally, protease inhibitors may prove valuable in combination therapy regimens, as 
antibiotics tend to cause stress and may make these degradative complexes even more 
important for survival. In mycobacteria, partial Clp depletion enhances killing by aminoglycosides, 
which increase the intracellular concentration of abnormal polypeptides and may amplify the 
demand for Clp protease to remove these aberrant products4.  
 
One of the most attractive properties of proteases as antibiotic targets is their druggability. The 
active sites of protease are among the most well-studied in enzymology. Numerous chemical 
moieties, such as the peptide boronates, aldehydes,  !-lactones and epoxyketones, have been 
employed in the development of inhibitors of proteolytic activity77. Structurally analogous to actual 
protein substrates, these compounds either mimic the transition state of peptide hydrolysis or act 
as suicide inhibitors, forming stable complexes with the nucleophilic residue of the protease 
active site and preventing hydrolysis of normal substrates. Specificity of these compounds usually 
derives from the attached peptidyl backbone or adjacent peptidic structures. While the specific 
active site residues involved in peptide bond hydrolysis are similar among the different classes of 
proteases, amino acids in close proximity to the catalytic center, which form the protease 
specificity pocket, are much less conserved. These preferences can be identified via substrate 
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scanning using a large library of small peptides to determine the residues that best fit into pockets 
adjacent to the active site. As the development of the human proteasome inhibitor bortezomib 
illustrates, the peptides that are most efficiently recognized and cleaved can be linked to inhibitory 
groups to generate a specific active site inhibitor78.  
 
In the case of these large proteolytic complexes, there are also numerous other structural 
features beyond the protease active site that could serve as targets for modulators. The ATP-
dependent proteases have Walker box ATP-binding domains that could be inhibited with 
nucleoside analogs. In theory, cofactor analogs could also be used to modulate the function of 
Lon protease, which has been shown to bind polyphosphate and DNA in order to facilitate 
targeted degradation of numerous substrates. And because every protease exists as a multimer 
and often must dock with separate ATPases or adapters to facilitate protein degradation, 
compounds that inhibit these interactions could also affect protease function.  
 
While proteases can make very good targets, there are substantial problems that must be 
overcome. First and foremost is the issue of specificity. While the well-conserved active sites of 
the proteases make them extremely druggable targets, this same property presents a significant 
challenge to the development of specific modulators. As a result, promiscuous inhibitors that 
target broad classes of proteases have been described far more frequently than specific agents79. 
Second, the presence of homologous proteases in eukaryotes may result in significant toxicity 
from a protease modulator. Each of the degradative proteases in bacteria exists in the 
mitochondria of humans.  Moreover, the human proteasome resembles the proteasome found in 
M. tuberculosis. In general, however, empirical evidence described below and the fact that a 
broad array of currently used antibiotics target bacterial enzymes that have homologous 
counterparts in humans suggests there to be enough divergence between bacterial and 
eukaryotic structures to enable the development of specific modulators.  
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Third, target-based approaches to antibacterial development have not been very successful, on 
the whole. The failure rate of rational drug design strategies for antibacterials when compared to 
chronic diseases or even viral drug development has largely been attributed to the complex issue 
of accessibility80. Antibiotics must first be able to penetrate the site of infection.  Once there, a 
small molecule has to cross into the target bacterium, traversing various layers including the thick 
peptidoglycan layers of Gram positive organisms or the double membrane structure with 
intermingling peptidoglycan in Gram negative pathogens.  Once at its target, the compound must 
avoid being inactivated by bacterial metabolic processes and exported by efflux pumps.  It has 
not been easy to formulate a set of structural guidelines that fulfills all of these criteria, and the 
lack of rules has prevented targeted exploration of the ideal chemical space. Comparing the 
molecular weight and hydrophobicity of antibiotics to other commercially available 
pharmaceuticals reveals that that antimicrobials tend to have a higher mass and lower partition 
coefficients (defined as the ratio of concentrations of a compound in two phases of a mixture of 
octanol and water) then other developed drugs81. This may serve as evidence of the bias that the 
additional permeability obstacles have placed on attaining a successful development candidate 
for antibacterial drug design. 
 
While traditional target-based approaches have hit roadblocks, our understanding of the 
intracellular proteolytic complexes could allow development of unique target-based whole cell 
screening methods. In the easiest iteration, endogenous substrates degraded by a particular 
protease could be fused to a fluorescent protein resulting in a reporter protein that could measure 
specific protease activity modulation in a whole cell system (Figure 1.3, top). If done in duplex 
with a general whole cell screen, a library of compounds could be simultaneously tested for a 
general effect on bacterial growth and for activity through specific enzyme inhibition. In more 
complex forms, inhibition of adapter-protease interactions or the post-translational modification 
and subsequent degradation of critically regulated proteins could be tested by engineering a 
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reporter protein that was known to be modified through a specific mechanism (Figure 1.3, 
bottom).  
 
While this method has yet to be utilized in a productive manner, traditional whole cell and target-
based approaches have already yielded potential lead compounds that modulate activity of the 
degradative proteases. The exploration of these enzymes as therapeutic targets remains in its 
infancy, but promising examples exist for Clp, Lon, the mycobacterial proteasome, and HtrA. 
(Table 1.2).   
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Figure 1.3 Targeted whole cell screens can identify modulators of 
proteolysis 
Our understanding of substrate recognition and proteolysis by the degradative 
proteases can be harnessed to develop targeted whole cell screens that 
simultaneously identify cell-permeable small molecules that act in a certain 
pathway. For example, one could screen for inhibitors of Clp protease by 
fusing the SsrA tag to GFP. In wildtype cells expressing the fusion protein, 
fluorescence would be minimal (top left panel), but in the presence of Clp 
protease inhibitors, the GFP-SsrA would be stabilized and fluorescence would 
be preserved (top right panel). In a more complex screen, accessory pathways 
could also be exploited for drug development. In M. tuberculosis, the 
proteasome accessory factor (Paf) is responsible for the addition of the 
essential prokaryotic ubiquitin protein (Pup) to proteins destined for 
degradation by the prokaryotic proteasome. Though none have been reported 
to date, fusing a putative pupylation site to GFP would result in a strain that 
lacked fluorescence in an unperturbed state (bottom left panel), but would 
express stabilized GFP in presence of proteasome inhibitors or modulators of 
upstream proteins such as Paf or Pup (bottom right panel).  
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Clp protease 
To date, most efforts to modulate the degradative proteases have concentrated on Clp protease, 
and have produced three classes of compounds with markedly different mechanisms of action. 
The first class, !-lactones, were initially identified as naturally occurring compounds, some of 
which exhibited anti-microbial activity82. A large class of bioactive compounds, the !-lactones 
appear to interact with a variety of enzymes. However, activity-based protein profiling (ABPP) 
using chemical probes derived from aromatic and aliphatic derivitized trans !-lactones 
demonstrated that these particular compounds were Clp-specific inhibitors in the pathogenic 
organisms S. aureus and L. monocytogenes83,84. As Clp is not essential in these organisms, the 
trans-!-lactones fail to inhibit growth, but do inhibit virulence factor production. While the efficacy 
of the trans !-lactones as anti-virulence compounds has been well-established, it would be 
interesting to determine their utility as traditional growth inhibitors in M. tuberculosis, the only 
pathogenic organism where Clp protease is required for growth in vitro and in vivo.  
 
The second class of Clp-specific agents, ADEPs, were initially isolated from the fermentation 
broth of Streptomyces hawaiiensis, and found to have an inhibitory effect on growth in 
staphylococci, streptococci, and other Gram-positive organisms85. Sequencing of resistant 
mutants revealed that the potential target was Clp protease, but as Clp protease is not required 
for normal growth in these organisms, it was peculiar that ADEPs exhibited their bactericidal 
effect through an interaction with a dispensable protease86. Surprisingly, an in vitro peptidase 
assay using ClpP protease from Bacillus subtilis revealed that ADEPs activated proteolysis. 
ADEPs additionally prevented interaction between ClpP and cognate ATPase adapters, ClpX and 
ClpC, thus turning ClpP into an activated, unregulated proteolytic machine87.  Though ADEP-
activated ClpP compelxes were unable to degrade fully formed proteins, in vitro and in vivo 
transcription/translation assays demonstrated that the dysregulated enzyme cleaved newly 
forming polypeptides and unstructured proteins. Crystallization of ADEP-bound ClpP and X-ray 
analysis showed that ADEPs bound to ClpP at the same site where the IGF loops of ATPase 
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adapters interact when they activate the ClpP protease complex88. By binding at this site, which is 
formed by the interaction of two adjacent ClpP monomers in the assembled complex, ADEPs 
stabilize multimerization of ClpP subunits without the ATPases and reorient the N-terminal 
segment of ClpP (Figure 1.4). Binding with ADEPs disrupt the N-terminal hydrophobic 
interactions that normally convert the pore of ClpP from a closed to an open form, capable of 
degrading unfolded proteins and peptides in an unregulated manner. Promising targets for further 
development, the in vivo efficacy of ADEPs has been demonstrated in mouse infections with E. 
faecalis, S. pneumoniae, and S. aureus.  
 
Recently, the natural product cyclomarin was found to have bactericidal activity for M. 
tuberculosis. Sepharose-bound cyclomarin has been shown to bind to the essential ATPase 
adapter ClpC189. Its mode of action is not completely clear, though early experiments suggest 
that it increases protein degradation in vivo.  Thus, multiple components of the Clp protease could 
potentially serve as drug targets.   
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From Lee et al, 2010 [88] 
Figure 1.4 Crystal structure of ADEP-Bacillus subtilis (Bs) ClpP 
interaction reveals ADEP-dependent activation mechanism 
(Top left) The tetradecameric BsClpP-ADEP1 complex viewed along a 
sevenfold molecular symmetry axis. Monomers are alternatively colored red 
and magenta, with one monomer shown as green ribbon for clarity. Bound 
ADEP1 molecules are shown as stick models. (Top right) Side view of the 
BsClpP-ADEP1 interaction. (Middle left) Close up view of one of the 14 
ADEP1 binding sites boxed in top left. The binding site is a complementary 
pocket composed by two adjacent subunits of ClpP. (Middle right) Close up 
view of boxed region in top right, with transparent molecular surface showing 
the catalytic triads and ADEP1 on the peripheral surface. (Bottom) Electron 
density map derived form the structures of  free BsClpP1 (left) and BsClpP-
ADEP1 (right) illustrating the axial pore of the ClpP proteolytic core.  
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Lon protease 
Lon protease has been targeted using a mechanism-based design strategy. Taking advantage of 
the different cleavage specificity of the S. typhimurium and human mitochondrial homolog, a 
boronate-based compound was designed that specifically inhibits the bacterial enzyme90. In 
addition, a fluorescent dansyl moiety was conjugated to the compound to allow functional and 
enzymatic studies of inhibition. The resultant compound inhibited Lon protease purified from S. 
typhimurium via a two-step mechanism that required ATP binding. Initial binding of the boronate 
to the active site of Lon protease was followed by a conformational shift in the overall structure of 
the enzyme, leading to the stabilization of the transition state intermediate91. While this compound 
has yet to be developed further or tested in a whole bacterium or in vivo setting, it represents an 
important step forward in validating Lon protease as a drug target, especially in the case of S. 
typhimurium, where Lon protease regulates Type III secretion and is essential for full virulence. 
As overexpression of Lon protease is lethal in E. coli, activators may also provide tractable 
therapeutic targets, though none have yet been described.  
 
Mycobacterial Proteasome 
The proteasome of M. tuberculosis is an attractive target for drug development, given that the 
mycobacterial proteasome is essential for both virulence and survival under nitric oxide stress. 
Initial efforts to develop proteasome-targeting antibiotics exploited the differential substrate 
specificity between the eukaryotic and bacterial proteins. A single amino acid change in the 
eukaryotic boronate-based proteasome inhibitor, bortezomib, resulted in a compound with eight-
fold selectivity for the M. tuberculosis enzyme92. In order to obtain more specific and selective 
agents, an in vitro screen of 20,000 compounds identified two oxathiazol-2-one inhibitors that 
were highly specific for the M. tuberculosis proteasome, and had no measurable inhibitory activity 
on the eukaryotic homolog93.  Co-crystallization has shown that the specificity of these 
compounds lies in their interactions with non-conserved residues far outside of the active site that 
are brought close to the oxathiazol-2-one after compound-induced conformational changes. 
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Moreover, the compounds bind covalently to the active site, acting as irreversible inhibitors. 
These compounds are bactericidal against M. tuberculosis in culture, both in replicating and non-
replicating conditions.  As non-dividing M. tuberculosis may play an important role in the ability of 
bacteria to survive in the host for decades in a latent state, agents such as these could be very 
attractive weapons to add to the antituberculous arsenal.  
 
HtrA protease 
The HtrA proteases are the most accessible of the degradative proteases as they lie outside of 
the bacterial cytoplasm. Using structure-based virtual screening, a set of compounds were 
discovered that had the potential to act as small molecule inhibitors of Helicobacteri pylori HtrA, 
the enzyme that cleaves host E-cadherins94. Of the 22 compounds retrieved from virtual 
screening, six were shown to inhibit cleavage of E-cadherins by Hp HtrA in an in vitro proteolysis 
assay. One compound, HHI, was shown to preserve E-cadherin adhesions in an epithelial 
monolayer model of H. pylori infection. HHI is extremely specific for H. pylori HtrA and does not 
inhibit the human HtrA1 or a panel of other host proteases25.  
 
In a manner analogous to ADEPs, activation of HtrA protease might also provide an avenue to 
effective antibiotics. In fact, tripeptidic small molecules are able to activate DegS protease of E. 
coli. Tripeptides trigger DegS activation by binding to the PDZ domain via hydrophobic 
interactions, a manner similar to potential substrates95. Though we do not yet know if these 
molecules have activity against whole cells, targeting outside of the active site is a promising 
strategy to develop new, specific modulators.   
 
CONCLUDING REMARKS 
The degradative proteases offer a set of attractive targets for the development of antibacterial 
drugs.  In most cases, they fill roles that are required for growth and survival, either in vitro or 
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during infection.  Even “nonessential” proteases can be converted to toxic enzymes by activators 
such as ADEPs. If problems with specificity and accessibility can be overcome, the medicinal 
chemistry experience with protease inhibitors could be harnessed to exploit a plethora of 
vulnerable targets. 
 
In fact, understanding the role and mechanism of these proteases has already revealed additional 
potential targets beyond the active sites of these enzymes.  These include residues that are 
exposed upon conformational changes in the enzyme (e.g., the oxathiazol-2-one inhibitors of the 
bacterial proteasome), active sites in accessory enzymes (e.g., cylcomarin binding the ClpC1 
ATPase), regulatory regions of proteins (e.g, peptidic inhibitors that activate DegS through its 
PDZ domain), and interacting surfaces between members of a proteolytic complex (e.g., ADEPs 
in preventing interactions between ClpP and the ATPases).  Certainly, there may be more. For 
example, essential proteases are essential because certain substrates must be degraded. Agents 
that specifically blocked degradation of these substrates, perhaps through interaction with 
protein-specific degradation adapters, should have similar activity to inhibitors of the proteases 
themselves.  Identifying candidates for such approaches will require a deeper understanding of 
the physiological roles of many of the degradative proteases, and elucidation of each proteases 
“degradome,” or the entire set of proteins and pathways regulated by controlled proteolysis. 
Furthering our understanding of substrate degradation by these proteases can facilitate the 
development of innovative whole-cell target based screens for the identification of small molecule 
modulators.  
 
Despite the need for further studies to systematically understand the functional significance of the 
degradative proteases, we already have many important tools to discover and design new 
compounds to modulate their function.  Partial crystal structures, which exist for every enzyme, 
have already proven invaluable for designing inhibitors and accelerating the optimization of drug 
candidates by medicinal chemistry. In vitro assays of these enzymes can easily be turned into 
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screens for new inhibitors, and fusion of in vivo substrates to fluorescent proteins could even 
permit the design of whole-cell, pathway-based assays for compounds that not only modulate 
activity but also are capable of accessing the proteases in intact bacteria. 
 
Considerable challenges remain. Inhibitors of mitochondrial function, such as the many antibiotics 
that block protein synthesis at prokaryotic ribosomes, are often toxic, particularly upon prolonged 
exposure. In many ways, the most significant obstacle may be designing specific inhibitors that 
donʼt inhibit human homologs, although a precedent has been set with the development of the 
oxathiazol-2-one inhibitors of the mycobacterial proteasome. Additionally, many protease 
modulators are peptidic small molecules, which have poor pharmacologic properties, often 
lacking oral bioavailability with poor entry through the bacterial cell wall and degradation by 
peptidases in the host and bacterial cytoplasm. However, the combination of a deep 
understanding of the biochemistry and physiology of these proteins with the expertise that has 
come from developing a number of successful protease inhibitor drugs already makes the 
degradative proteases very compelling targets for antibacterial drug development. 
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Section 2.1 – Chapter Overview and Attributions 
In this chapter, I present our initial efforts to determine the requirements of Clp protease in 
mycobacteria. As mentioned above, the study of the Clp protease complex in mycobacteria is 
warranted for several reasons. First, Clp is dispensable for normal growth in model organisms 
where it has been extensively studied, but a genome wide screen for essential genes conducted 
in our laboratory suggested that the protease was absolutely required for normal growth in Mtb. 
Second, most organisms possess one clpP gene, which forms the proteolytic core of the enzyme, 
but mycobacteria encode two homologous genes, clpP1 and clpP2, situated in a single operon. 
Through a combination of genetic and biochemical studies, I present below, we were able to 
show that both clpP1 and clpP2 are independently essential for normal growth in Mycobacterium 
smegmatis (Msm) and that the Mtb forms of ClpP1 and ClpP2 interact together to form a single 
proteolytic core, denoted ClpP1P2 (APPENDIX 1). Taking advantage of this, we expressed active 
site mutants of ClpP1 in Mtb, which had a slight dominant negative effect on growth in vitro. 
These mutants, however, were highly attenuated in a mouse model of infection, suggesting that 
Clp protease has a role in infection as well. Scratching the surface of a functional understanding 
of Clp, we also show that Clp-dependent recognition of SsrA tagged proteins is conserved in 
mycobacteria, and that Clp plays a role in the degradation of abnormal protein products that 
accumulate in the cytoplasm. Together, these findings demonstrate that the Clp protease plays a 
critical role in mycobacterial physiology.  
 
Attributions. The manuscript in this chapter was published with both Meera Unnikrishnan and 
myself as co- authors. Meera pioneered the Clp project in our laboratory and laid the initial 
groundwork for the studies presented here. She constructed the pTtet_clpP2 conditional mutant 
described in Figure 2.2D and 2.2E, and conducted the experiments in Figure 2.3A. I constructed 
all other strains used in this chapter, and performed all experiments independently with the 
exception of Figure 2.1A-D, which was done with tremendous help from Tatos Akopian and Olga 
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Kandror in the laboratory of Alfred Goldberg. I wrote the manuscript with editorial input from all 
authors on the paper.  
Section 2.2 – Mycobacterium tuberculosis ClpP1 and ClpP2 function 
together in protein degradation and are required for viability in vitro and 
during infection 
Ravikiran M. Rajua,2, Meera Unnikrishnan a,2, Daniel H.F. Rubin a, Vidhya Krishnamoorthy a, Olga 
Kandror b, Tatos N. Akopian b, Alfred L. Goldberg b, Eric J. Rubin a,1  
a Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, 
MA 02138 USA 
b Department of Cell Biology, Harvard Medical School, Boston, MA 02138 USA 
1 Corresponding author: erubin@hsph.harvard.edu, ph: (617) 432-3337 
2 These authors contributed equally to this work.  
 
ABSTRACT 
In most bacteria, Clp protease is a conserved, non-essential serine protease that regulates the 
response to various stresses. Mycobacteria, including Mycobacterium tuberculosis (Mtb) and 
Mycobacterium smegmatis, unlike most well studied prokaryotes, encode two ClpP homologs, 
ClpP1 and ClpP2, in a single operon. Here we demonstrate that the two proteins form a mixed 
complex  (ClpP1P2) in mycobacteria. Using two different approaches, promoter replacement, and 
a novel system of inducible protein degradation, leading to inducible expression of clpP1 and 
clpP2, we demonstrate that both genes are essential for growth and that a marked depletion of 
either one results in rapid bacterial death. ClpP1P2 protease appears important in degrading 
missense and prematurely terminated peptides, as partial depletion of ClpP2 reduced growth 
specifically in the presence of antibiotics that increase errors in translation. We further show that 
the ClpP1P2 protease is required for the degradation of proteins tagged with the SsrA motif, a tag 
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co-translationally added to incomplete protein products. Using active site mutants of ClpP1 and 
ClpP2, we show that the activity of each subunit is required for proteolysis, for normal growth of 
Mtb in vitro and during infection of mice. These observations suggest that the Clp protease plays 
an unusual and essential role in Mtb and may serve as an ideal target for antimycobacterial 
therapy. 
 
AUTHOR SUMMARY 
Due to the significant and rapid rise in multidrug resistant Mycobacterium tuberculosis (Mtb), 
there is an urgent need to validate novel drug targets for the treatment of tuberculosis. Here, we 
show that Clp protease is an ideal potential target. Mtb encodes two ClpP genes, ClpP1 and 
ClpP2, which associate together to form a single proteolytic complex, referred to as ClpP1P2. 
Both proteins are required for growth in vitro and in a mouse model of infection. Depletion of 
either protein results in rapid death of the bacteria. Interestingly, this is rare among bacteria, most 
of which have only one ClpP gene that is dispensable for normal growth. We also show that Clp 
protease plays an important quality control role by clearing abnormally produced proteins. As 
known antimycobacterial therapeutics increase errors in protein synthesis, inhibitors of ClpP1P2 
protease in Mtb may prove synergistic with already existing agents. 
!
INTRODUCTION 
Intracellular protein degradation is critical for maintaining cellular homeostasis through protein 
quality control and regulation of numerous biological pathways1,2. In eukaryotes, the ubiquitin-
proteasome pathway constitutes the predominant degradation pathway3. Most prokaryotes, 
however, possess a variety of ATP-dependent serine protease complexes, such as Lon and Clp 
protease4, and some actinomycetes and archaea contain proteasomes, which are threonine 
proteases. Interestingly, Mycobacterium tuberculosis (Mtb) encodes both a proteasome and Clp 
protease. While recent work has explored the role of the Mtb proteasome5-7, little is known about 
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mycobacterial Clp protease. This serine protease was first discovered and is best characterized 
in Escherichia coli8,9. The Clp proteolytic complex is formed by the association of proteolytic 
subunits, ClpP, with ATPase adapters, ClpX or ClpA in Gram-negative organisms and ClpX or 
ClpC in Gram-positive organisms. E. coli ClpP is a tetradecamer composed of two stacked 
heptameric rings of identical ClpP subunits that form an internal proteolytic chamber10. This core 
associates with distinct hexameric ATPase adapters, ClpX and ClpC1 in mycobacteria, which 
provide substrate specificity and catalyze ATP-dependent unfolding of globular proteins11,12. In E. 
coli, the ClpXP protease is involved in the regulation of the DNA damage response and 
degradation of SsrA-tagged peptides stalled on the ribosome13,14. Clp proteolytic enzymes are 
also required for full virulence in several pathogenic organisms, including Listeria monocytogenes 
where the protease is required for the production of "-listeriolysin15,16. In most bacteria including 
E. coli, Clp protease is dispensable for normal growth, and in fact, until recently, the only 
organism in which clpP has been found to be essential is Caulobacter crescentus, where Clp 
degrades CtrA, an inhibitor of cell cycle progression17.   
 
Unlike most bacteria, which have a single ClpP subunit, the genome of Mtb encodes two closely 
related ClpP homologs, clpP1 and clpP2, in a single operon. A transposon-based mutagenesis 
screen for essential genes in Mtb predicted that ClpP2 and the ATPase adapters ClpC1 and 
ClpX, were required for normal growth18  while a recent publication has shown that ClpP1 is 
essential19. Here, we show that both ClpP1 and ClpP2 are required for growth, and that their 
activity is important for the removal of abnormal proteins.  Our data suggest that ClpP1 and ClpP2 
assemble to form a single proteolytic complex, referred to as ClpP1P2, that is required for normal 
growth in vitro and during infection. In related studies, we have found that although pure ClpP1 
and ClpP2 by themselves form tetradecamers, they are inactive. However, in the presence of low 
molecular weight activators they reassociate to form a mixed tetradecamer, ClpP1P2, which is 
capable of proteolysis20. The unusual properties of this heteromeric complex, the absence of such 
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an enzyme in the eukaryotic cytoplasm, and the essentiality of both subunits make ClpP1P2 
protease an attractive target for novel therapeutic development for the treatment of tuberculosis. 
 
RESULTS 
ClpP1 and ClpP2 subunits interact to form a single proteolytic complex 
Mycobacterial genomes contain two homologous ClpP protease genes, clpP1 and clpP2, 
arranged in a putative operon. To investigate whether the two proteins may function together in a 
complex, we co-expressed Mtb clpP1 and clpP2, each containing a different C terminal epitope 
tag, in Mycobacterium smegmatis (Msm). We used affinity chromatography with nickel resin to 
isolate 6x-His tagged Mtb ClpP2 together with associated proteins from the Msm cell lysate. As 
shown in Figure 2.1A, a fraction of the c-myc tagged ClpP1 bound to the Ni column and co-
eluted with ClpP2. To verify that ClpP1 and ClpP2 co-eluted from the Ni column may be 
associated in a complex, we applied the fraction from the Ni column containing both proteins to 
an anti-c-myc agarose column and analyzed by SDS PAGE. Figure 2.1B shows that a large 
fraction of the ClpP2 was associated with ClpP1. Incidentally, expression of the Mtb proteins in 
Msm also led to the co-isolation of Msm ClpP1 and ClpP2, as shown by tandem mass 
spectrometry of the purified complex. In each case, peptides present uniquely in Mtb or Msm 
ClpP1 and ClpP2 were detected (Figure 2.1C).  
 
If ClpP1 and ClpP2 do in fact associate to form a single proteolytic core, we reasoned that 
mutations blocking the catalytic activity of one subunit might reduce that activity of the enzyme. 
We identified likely active site residues of ClpP1 and ClpP2 by mapping the Mtb proteins onto E. 
coli ClpP and locating the catalytic triad of Asp-His-Ser, which is characteristic of serine 
proteases. In both cases, the serine likely to be responsible for nucleophillic attack was replaced 
by an alanine (ClpP1 S98A and ClpP2 S110A). To analyze the effects of these mutations, we 
expressed and purified 6xHis-tagged forms of each protein, and assayed their effect on the 
enzymatic activity of the wild type ClpP1P2 in an in vitro peptidase assay20. Enzyme activity of the 
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reconstituted ClpP1P2 complex was quantified using cleavage of the fluorescence reporter, Z-
Gly-Gly-Leu-AMC. As seen in Figure 2.1D, addition of an excess of mutated ClpP1 or ClpP2 to 
the active wild type ClpP1P2 complex inhibited proteolytic cleavage of a fluorescent peptide 
substrate, presumably by replacing the wild type subunits. These results suggest that the ClpP1 
and ClpP2 subunits interact to form a single proteolytic complex in vitro, that each active site is 
important for activity, and that these mutations can be used as dominant negative inhibitors.   
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Figure 2.1 Mtb ClpP1 and ClpP2 interact, forming a multi-component 
protease, and share substantial similarity with ClpP1 and ClpP2 
homologs in Msm.  
(A) C-terminally myc-tagged Mtb ClpP1 and 6xHis-tagged Mtb ClpP2 were 
expressed in Msm. Lysate (lane 1) was prepared and loaded onto a Ni-
column. After washing with PBS (lanes 2,3), Ni-bound material was eluted 
with 50 mM (lane 4), 100 mM (lane 5), 250 mM (lane 6, 7) of imidazole in 
PBS, and analyzed by immunoblotting using anti !-myc and !-6xHis 
antibodies.  
(B) Fraction 6 from (A) was applied to an anti-myc column (lane 1). The flow 
through (lane 2), and bound material (lane 3) were analyzed by immunoblot 
with !-myc and !-His antibodies. Bound material was released from the anti-
myc agarose beads by boiling in Laemmli buffer after washing with PBS.  
(C) Bands representing ClpP1 and ClpP2 from (B) were sequenced by 
MS/MS revealing the presence of both Mtb and Msm homologs. Msm 
specific peptides are indicated by black lines, those specific to Mtb are 
indicated by red lines.  
(D) Cleavage of fluorescent peptide Z-Gly-Gly-Leu-AMC was measured in 
the presence of 1 mg ClpP1, 1 mg Clp2, and the activating peptide Z-Leu-Leu 
(see accompanying paper). Addition of 5 mg of catalytically inactive mutants 
of either ClpP1 (ClpP1S) or ClpP2 (ClpP2S) markedly inhibited cleavage by 
the ClpP1P2 protease. Results graphed are a representative sample of results 
obtained. 
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Both ClpP1 and ClpP2 are required for normal growth in vitro 
We employed three complementary strategies to determine if ClpP1 and ClpP2 are required for 
normal growth in mycobacteria. First, using mycobacterial recombineering21, we replaced the 
endogenous promoter of clpP1 and clpP2 in Msm with a tetracycline-inducible promoter (Figure 
2.2A). Introduction of a tetracycline repressor resulted in a strain (ptet_clpP1P2) that could only 
be maintained in the presence of the inducer anhydrotetracycline (ATc) (Figure 2.2B). In the 
absence of this compound, growth did not occur, but could be restored by the presence of an 
episomal plasmid containing both clpP1 and clpP2. Plasmids expressing only clpP1 or clpP2 
alone could not rescue growth and depletion of either subunit resulted in bacterial death (Figure 
2.2C). Since complementation was conducted with Mtb homologs and subunits from different 
species associate into a functional tetradecamer, the ClpP1P2 complex is likely very similar in 
Msm and Mtb. Furthermore, active site mutants of either ClpP1 or ClpP2 were unable to 
complement ptet_clpP1P2 in the absence of ATc, suggesting that the activity of both subunits 
were required for normal growth (data not shown).   
 
Second, we inserted a tetracycline inducible promoter upstream of the clpP1P2 operon via 
homologous recombination in Msm creating a strain in which clpP2 was inducibly expressed 
(Figure 2.2D), and clpP1 was under the control of its native promoter (ptet_clpP2). In accord with 
the previous findings, the growth of this strain was dramatically inhibited in the absence of ATc 
(Figure 2.2E).  
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Figure 2.2 Both ClpP1 and ClpP2 are essential for normal growth in 
mycobacteria  
(A) Schematic representation of mycobacterial recombineering, employed to 
replace the endogenous promoter of the clpP1P2 operon with a ATc-inducible 
promoter (Msm strain ptet_clpP1P2). 
(B) Growth curves of Msm ptet_clpP1P2 in the presence (50 ng/mL) or 
absence of inducer ATc. Data are represented as mean CFU/mL +/- standard 
deviation. 
(C) Growth curves of Msm ptet_clpP1P2 complemented with clpP1, clpP2 or 
both clpP1 and clpP2 in the absence of inducer ATc. Data are represented as 
mean CFU/mL +/- standard deviation. 
(D) Schematic representation of genetic strategy used to create a tetracycline 
inducible conditional Msm ClpP2 mutant (Msm strain ptet_ClpP2) 
 (E) Growth curves of Msm ptet_clpP2 in the presence (50 ng/mL) or absence 
of inducer ATc. Msm ptet_clpP2 was also complemented with clpP2 in the 
absence of ATc. Data are represented as mean  OD600 +/- standard deviation. 
Dashed lines represent assumed growth rates until first measured growth 
point.  
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Third, we used a system of inducible protein degradation recently developed in Msm (Figure 
2.3A)22. Briefly, we employed mycobacterial recombineering to add an inducible degradation (ID) 
tag to the C-terminus of ClpP2 (clpP2_ID).  Upon cleavage of the tag by a tetracycline inducible 
HIV-2 protease, an SsrA sequence is revealed on the substrate that directs degradation of the 
protein. By inserting epitope tags C-terminally to the HIV-2 protease recognition motif (FLAG) and 
N-terminally to the SsrA tag (c-myc), we were able to monitor the amount of ClpP2 by 
immunoblotting.  As shown in Figure 2.3B, induction of HIV-2 protease resulted in degradation of 
the majority of ClpP2 and inhibited bacterial growth (Figure 2.3C). Using this system, we did not 
observe cell death, perhaps due to incomplete inhibition, as would be expected for a system 
where the protease targets itself. Loss of ClpP2, as measured by immunoblotting, was rapid and 
reached near completion within hours. Furthermore, the growth defect was complemented by 
expression of Mtb clpP2  using a constitutively active promoter. A similar approach with ClpP1 
was unsuccessful as extended C-terminal tagging was not tolerated, and the ID tag was 
indiscriminately cleaved. Collectively, these results confirm that both ClpP1 and ClpP2 are 
required for normal growth in mycobacteria, presumably because they function together in the 
ClpP1P2 complex.  
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Figure 2.3 Inducible protein degradation demonstrates requirement of 
ClpP2 for normal growth 
(A) Schematic representation of the inducible degradation system used to 
inducibly deplete ClpP2 (Msm strain clpP2_ID). Induction of HIV-2 protease 
with ATc leads to cleavage of the HIV-2 protease cutting site and exposure of 
a SsrA tag on the tagged protein. Cleavage by HIV-2 protease and subsequent 
degradation can be tracked via the FLAG (square) and c-myc (circle) epitope 
tags, respectively, included on the inducible degradation tag.  
(B) Degradation of ClpP2 in clpP2_ID was tracked by Western in the absence 
or presence of inducer ATc. Blots were probed !-FLAG (loss indicates HIV-2 
protease cleavage), !-myc (loss indicates target degradation), and !-RpoB 
(loading control).    
(C) Growth curves of Msm clpP2_ID in the absence or presence (50 ng/mL) 
of inducer ATc. Msm clpP2_ID was also complemented with clpP2 in the 
presence of ATc. Data are represented as mean  CFU/mL +/- standard 
deviation. 
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Mycobacterial Clp protease plays a role in protein quality control  
In other bacteria, Clp plays a role in degrading abnormal proteins such as SsrA-tagged peptides 
that stall on the ribosome23.  To determine the importance of ClpP1P2 protease in the 
degradation of misfolded proteins, we used antibiotics that alter protein synthesis in distinct ways 
including chloramphenicol, which blocks protein elongation without increasing mistranslation 
rates24, and streptomycin and amikacin, which induce translational errors resulting in missesnse 
or prematurely-terminated polypeptides25.  We found that the strain ptet_clpP2, in which clpP2 
expression is regulated by anhydrotetracycline, grows well in low or high concentrations of ATc, 1 
to 100 ng/mL (Figure 2.4A).  Treatment with sublethal concentrations of chloramphenicol 
resulted in no difference in viability between bacteria maintained on low or high concentrations of 
ATc (Figure 2.4A, bottom). In contrast, sub-MIC concentrations of the aminoglycosides 
streptomycin and amikacin significantly inhibited the growth of strains incubated in low 
concentrations of ATc, while they had no effect on growth of the strain maintained in high 
concentrations of ATc (Figure 2.4A, top). Together, these results suggest that ClpP1P2 protease 
protects against error-prone translation by catalyzing the degradation of misfolded proteins.   
 
To specifically assess whether ClpP1P2 is responsible for the removal of SsrA-tagged proteins in 
mycobacteria, we fused the mycobacterial SsrA-tag to the C-terminus of GFP (GFP-SsrA) and 
expressed the construct constitutively on an episomal plasmid. This construct was introduced into 
the strain clpP2_ID, in which ClpP2 degradation was regulated. In the presence of ClpP2 (and in 
wild type cells), there was no detectable GFP-SsrA. However, upon depletion of ClpP2, there was 
substantial accumulation of GFP-SsrA, as measured by both fluorescence and immunoblot 
analysis after four hours (Figure 2.4B, 2.4C). Quantitative PCR showed that the rise of GFP-SsrA 
was not due to transcriptional activation of the gene (Figure 2.4D). GFP lacking the SsrA tag is 
present at similar levels in all strains (data not shown).  Because we cannot detect GFP-SsrA in 
the presence of Clp activity, we were unable to accurately measure changes in protein stability.  
However, the rate of accumulation of GFP-SsrA was consistent with the time course of ClpP2 
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depletion, which occurred over six hours, as shown by immunoblotting. Thus, functional ClpP1P2 
protease is vital for the rapid clearance of SsrA-tagged substrates in mycobacteria.  
 
Functional Clp protease is required for growth of Mtb in vitro and during infection  
As shown above, catalytically inactive forms of ClpP1 and ClpP2 inhibit proteolysis by the wild 
type enzyme, possibly by replacement of wild type subunits with inactive ones. To assess 
whether ClpP1P2 activity is required for the growth of Mtb, we expressed a catalytically inactive 
form of Mtb clpP1, clpP1 S98A, on a tetracycline-inducible plasmid in wild type Mtb. Addition of 
ATc led to expression of the catalytically inactive mutant protein and resulted in a significant 
inhibition of growth (Figure 2.5A) while overexpression of wild type Mtb clpP1 had no effect. 
 
To determine if the dominant negative mutant of ClpP1 affected ClpP1P2 function during 
infection, we infected mice with a 3:1 mixture of Mtb expressing clpP1 S98A on a hygromycin-
resistant doxycycline inducible plasmid and wild type Mtb (containing a kanamycin-resistant 
control vector). Mice were fed either normal chow or chow infused with the inducer doxycycline. 
Growth of Mtb was monitored by assessing CFU in lung tissue at day 30 post-infection. While 
there were no differences in the growth of wild type Mtb between treated and untreated mice, 
expression of the active site mutant significantly inhibited growth (Figure 2.5B). Our results 
suggest that functional ClpP1P2 protease is required for the growth of Mtb both in vitro and during 
infection.   
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Figure 2.4 Clp protease is required for degradation of abnormal proteins 
and SsrA-tagged proteins in mycobacteria 
(  
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Figure 2.4 (continued) Clp protease is required for degradation of 
abnormal proteins and SsrA-tagged proteins in mycobacteria 
(A) Growth curves of Msm ptet_clpP2 in growth medium containing low (1 
ng/mL) or high (100 ng/mL) concentrations of inducer ATc, in the presence 
of either no drug, or amikacin (top left, 0.03 "g/mL), streptomycin (top right, 
0.125 "g/mL), and chloramphenicol (bottom, 7.5 "g/mL). Data are 
represented as mean OD600 +/- standard deviation. Dashed lines represent 
assumed growth rates until first measured growth point. 
(B) Increase in fluorescence (RFU, 485/520) and initial growth curve (OD600) 
of Msm clpP2_ID expressing the fusion construct GFP-SsrA on a 
constitutively expressing plasmid, in the presence and absence of inducer, 
ATc. Data are represented as mean RFU or OD600 +/- standard deviation.  
(C) Depletion of ClpP2 and increase in GFP-SsrA in Msm clpP2_ID 
expressing the fusion construct GFP-SsrA on a constitutively expressing 
plasmid was tracked by immunoblot. Blots were probed !-GFP, !-myc, !-
FLAG, and !-RpoB (loading control). 
D) Quantitative PCR of clpP2_ID was carried out to determine if increase in 
GFP-SsrA was due to transcriptional activation. RNA was isolated from 
clpP2_ID four hours after induction with ATc (+ ATc), and a culture of equal 
OD600 that was left uninduced (- ATc). Using both sigA (left) and 16s rRNA 
(right) as endogenous controls, there was no significant difference in 
transcription of GFP-SsrA between induced and uninduced cultures. Data are 
represented as mean fold change +/- standard deviation, with values 
normalized to those of the uninduced culture.  
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Figure  2.5  A catalytically inactive ClpP alleles inhibit Mtb growth in 
vitro and during infection 
(A) Growth curves for Mtb overexpressing wild type ClpP1 or ClpP1 S98A 
via an ATc-inducible expression vector. Data are represented as mean OD600 
+/- standard deviation. Dashed lines represent assumed growth rates until first 
measured growth point. 
(B) Growth of Mtb containing a doxycycline-inducible plasmid expressing the 
mutant allele ClpP1 S98A in lungs of C57BL/6 mice 30 days post aerosol 
infection. Mice were infected via aerosol with a 3:1 mixture of mutant and 
wild type bacteria.  Mice were fed either with chow containing (dark squares, 
N=5 mice) or lacking (gray triangles, N=5 mice) the inducer doxycycline. As 
a control, wild type Mtb was co-infected, and representative CFU/organs for 
the control are represented (right). Each point represents calculated total 
CFU/organ for each mouse.  Not all mice received enough wild type bacteria 
to quantitate. 
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DISCUSSION 
We find that the mycobacterial ClpP1P2 protease has two unusual properties that distinguishes it 
from other members of the prokaryotic ClpP family.  First, the protease consists of distinct types 
of subunits, each of which is required for full activity of a single proteolytic complex.  While other 
species do encode multiple ClpP subunits, two different proteolytic subunits forming a single 
protease has not been documented.  Second, unlike in most bacteria that have been studied, 
ClpP1P2 activity is absolutely required for normal growth.  This requirement is particularly striking 
as mycobacteria contain several cytoplasmic ATP-dependent proteolytic complexes, including 
FtsH, and the proteasome7,26,27.  Clearly, the mycobacterial ClpP1P2 proteolytic core has unique 
roles that are important for viability.  
 
The ClpP proteases that have been characterized biochemically in other bacteria and 
mitochondria are tetradecameric complexes containing a single type of proteolytic subunit. In 
mycobacteria, however, two different protein species contribute to protease activity. Although Mtb 
ClpP1 forms a tetradecameric complex, a crystal structure of Mtb ClpP1 lacks appropriate active 
site geometry to support proteolysis28. The presence of two ClpP subunits with distinct substrate 
preferences may facilitate an expansion of the peptide specificity of the complex, much like the 
eukaryotic proteasome. Interestingly, the Mtb proteasome is composed of a single type of 
subunit, and the presence of distinct subunits comprising a single proteolytic core is rare among 
prokaryotes.  
 
There is at least one example of an essential role for ClpP.  In Caulobacter crescentus, ClpXP 
degrades CtrA, a protein that normally inhibits cell cycle progression during cellular replication29.  
In this case, a single protein target is responsible for the essentiality of the enzyme.  ClpP1P2 
protease might play a similar role in mycobacteria.  While this may be true, screens for essential 
proteins in mycobacteria suggest that, in addition to the clpP1 and clpP2, multiple Clp-associated 
ATPase adapters (clpX and clpC1) are also essential18.  The requirement of multiple adapters 
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makes it possible that accumulation of multiple protein substrates contribute to the poor growth 
phenotype observed on depleting the ClpP1 and ClpP2 subunits in mycobacteria. 
 
ClpP1P2 might be important for other reasons. As shown here, ClpP1P2 protease is required for 
the clearance of SsrA-tagged proteins.  These tagged polypeptides are generated under 
conditions when protein synthesis is stalled and are required for ribosome release.  In the 
absence of ClpP1P2-mediated proteolysis, protein synthesis might eventually be inhibited.  In 
addition, ClpP1P2 protease is necessary for degrading abnormal proteins, such as those 
produced in the presence of certain antibiotics. Accumulation of such non-functional misfolded 
proteins might result in cellular stress in the absence of an effective system for their removal30.  
Clearance of damaged proteins might be particularly important in Mtb during infection, when cells 
are exposed to multiple oxidative and nitrosoative radicals that can induce protein damage. In 
fact, a transcriptional activator of the clpP1P2 operon, clgR, is critically activated upon reaeration 
of hypoxic Mtb and during Mtb growth within the macrophage31,32. Degradation of pre-existing 
proteins during such stressful transitions may be the initial event that triggers adaptation and 
facilitates the bacteriumʼs ability to handle a wide array of environmental challenges. Using a 
dominant negative overexpression mutant in Mtb, we have confirmed that optimal Clp proteolytic 
activity is required for growth during infection.  
 
The essential nature of ClpP1P2 protease makes it an attractive target for antibiotic development, 
particularly because the proteases as a class are druggable enzymes and have already been 
validated as therapeutic targets in the treatment of HIV, hepatitis, and cancer33. In organisms 
where ClpP is not essential, uncontrolled activation of ClpP activity can be toxic.  For example, in 
E. coli, acyldepsipeptide compounds reorganize the ClpP proteolytic core, causing dissociation 
from ATPase adapters, and indiscriminate protein degradation34. Compounds that produce a 
similar effect should result in toxicity in a broad range of organisms. In fact, it was recently 
discovered that the natural product cyclomarin kills Mtb by targeting the ClpC1 ATPase and 
  67 
presumably increasing Clp-mediated proteolysis, as demonstrated in a whole cell fluorescence-
based assay35.   In mycobacteria, where ClpP1P2 protease activity is required and depletion of 
either subunit is bactericidal, either non-specific activation or inhibition could effectively limit 
bacterial growth. An example of a ClpP inhibitor with potential therapeutic activity already exists.  
In S. aureus, !-lactones have been found to inhibit Clp protease activity and decrease the 
virulence of the organism36. Additionally, the synergistic nature of ClpP1P2 protease depletion 
with aminoglycosides, a class of drugs already used to treat tuberculosis, points to a potential 
combination therapy against Mtb. As ClpP1P2 protease is most likely involved in preventing the 
accumulation of misfolded proteins and the degradation of critical endogenous regulatory 
proteins, small molecule modulators of ClpP1P2 activity would target a critical aspect of Mtb 
physiology, and might prove useful in the face of growing multi-drug resistance in one of the 
worldʼs most successful pathogens.  
 
MATERIALS AND METHODS 
Ethics Statement 
The animal experiments were preformed with protocols approved by the Harvard Medical School 
Animal Management Program, which is accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care, International (AAALAC) and meets National Institute of 
Health standards as set forth in the Guide for the Care and Use of Laboratory Animals (Revised, 
2010). The institution also accepts as mandatory the PHS Policy on Humane Care and Use of 
Laboratory Animals by Awardee Institutions and NIH Principles for the Utilization and Care of 
Vertebrate Animals Testing, Research, and Training. An Animal Welfare Assurance of 
Compliance is on file with the Office of Laboratory Animal Welfare (OLAW) (#A3431-01). 
 
Bacterial strains and plasmids 
Msm mc2155 (Msm) or Mtb H37Rv were grown at 37°C in Middlebrook 7H9 broth with 0.05% 
Tween 80 and ADC (0.5% BSA, 0.2% dextrose, 0.085% NaCl, 0.003 g catalase/1L media). Mtb 
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was additionally supplemented with oleic acid (0.006%). For growth curves, overnight cultures 
were diluted into the appropriate media and growth was either measured by OD600 or colony 
forming units per mL. 
 
For complementation studies, wildtype Mtb ClpP1 and ClpP2 were amplified from H37Rv 
genomic DNA by PCR, using primers RMR01-RMR04, and ligated into the constitutively 
expressing plasmid pMV762zeo. C terminal 6X his or c-myc tags were added by PCR primers 
RMR05-RMR08 on Mtb ClpP1 and ClpP2 and recombined into the ATc inducible vector pTet 
using gateway recombination (Clontech). Site directed mutagenesis of ClpP1 and ClpP2 was 
carried out as described previously to generate various catalytic mutants used in the study. 
Catalytically inactive mutants were inserted into the ATc inducible vector pTet using gateway 
recombination. Processed Clp mutants were clonted into pTet or pMV762 vectors using primers 
listed above. The fusion GFP-SsrA was amplified from GFPmut3 wildtype DNA and cloned into 
pMV762zeo using primers RMR09-RMR12. Details of all plasmids and primers used in this study 
can be found below Table 2.1 and Table 2.2, respectively. 
 
Mycobacterial recombineering was employed, as described previously21, to create strains 
ptet_clpP1P2 and clpP2_ID. For strain ptet_clpP1P2, the tetracycline promoter, tetracycline 
repressor, and a hygromycin resistance marker were inserted into p96863 (Genscript). Both 
upstream and downstream of the insertion site, p96863 contained 200 bp fragments flanking 
either side of the native clpP promoter. A linear PCR product containing the regions of homology, 
the hygromycin resistance marker, and tetracycline repressor and promoter was generated using 
primers RMR13 and RMR14. Allelic exchange of the native promoter was carried out by 
transformation of this linear substrate into a Msm strain expressing mycobacteriophage 
recombinases gp60 and gp61 on a nitrile inducible, counter-selectable episomal plasmid. Counter 
selection on 10% sucrose led to loss of the recombineering plasmid. Successful integration of the 
desired sequence was confirmed by PCR, using primers RMR13 and RMR16. As RMR16 lies 
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outside of the homology region used for recombineering, specific integration into the endogenous 
chromosome could be verified (Figure 2.6).  
 
To create strain clpP2_ID, a linear DNA substrate was created in a similar fashion. The inducible 
degradation tag was inserted into p54689 (Genscript). Both upstream and downstream of the 
insertion site, p54689 contained 200 bp of homology to the C terminal end of clpP2 and the 3ʼ-
UTR of clpP2, respectively. A linear PCR product containing this homology and the inducible 
degradation tag was generated using primers RMR15 and RMR16. This PCR product was 
transformed into Msm as described above. Successful integration of the desired sequence was 
confirmed by PCR, using primers RMR13 and RMR16. As RMR13 lies outside of the homology 
region used for recombineering, specific integration into the endogenous chromosome could be 
verified (Figure 2.6).  
 
To make the clpP2_ID strain, the tetracycline promoter and ClpP1 were inserted into the suicide 
plasmid, pSES. Constructs were electroporated into a Msm strain containing an integrated 
pMC1s vector constitutively expressing the tetR repressor37. Integrants were screened by PCR 
using primers RMR17 and RMR18. 
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Table 2.1 – Plasmids utilized for study 
Plasmid Properties/Uses 
pTetOR::clpP1-myc Inducible expression of c-myc-tagged Mtb ClpP1 (to 
assess in vivo interaction with ClpP2) 
pTetOR::clpP2-his Inducible expression of 6xHis-tagged Mtb ClpP2 (to 
assess in vivo interaction with ClpP1) 
pTetOR::clpP1wt Inducible expression of Mtb ClpP1 (for in vitro 
degradation assay) 
pTetOR::clpP1S Inducible expression of Mtb ClpP1-Ser98A (for in 
vitro degradation assay, and overexpression in Mtb) 
pTetOR::clpP2S Inducible expression of Mtb ClpP2-Ser110A (for in 
vitro degradation assay, and overexpression in Mtb) 
pTetOR::clpP1H Inducible expression of Mtb ClpP1-His123A (for 
overexpression in Mtb) 
p96863 Non-expressing, synthesized plasmid (Genscript) 
containing regions of homology to ClpP1 5’UTR and 
ORF. Used to generate linear PCR product for 
recombineering to create Msm ptet_clpP1P2 
pKM339 Plasmid used to obtain tetracycline promoter, 
repressor, and hygromycin resistance marker, 
which were cut and inserted into p96863 for 
recombineering to create Msm ptet_clpP1P2 
p54689 Non-expressing, synthesized plasmid (Genscript) 
containing regions of homology to ClpP2 ORF and 
3’UTR. Used to generate linear PCR product for 
recombineering to create Msm clpP2_ID 
puc57::inhA-ID Plasmid used to obtain inducible degradation tag, 
which was cut and inserted into p54869 for 
recombineering to create Msm clpP2_ID 
pSES::ptet_clpP1 Plasmid used for homologous recombination to 
create Msm ptet_clpP2 
pMV762zeo::clpP1 Constitutively expressing plasmid expressing Mtb 
ClpP1 for complementation studies 
pMV762zeo::clpP2 Constitutively expressing plasmid expressing Mtb 
ClpP2 for complementation studies 
pMV762zeo::clpP1P2 Constitutively expressing plasmid expressing the 
entire clpP1clpP2 operon for complementation 
studies 
pMV762zeo::GFP-SsrA Constitutively expressing plasmid expressing the 
fusion construct GFP-SsrA to assess role of Clp 
protease in degradation of SsrA-tagged substrates 
pSES::ClpP1 Plasmid used for homologous recombination event 
to create strain, pTet_clpP2 
pNit::Che9c Plasmid expressing mycobacteriophage 
recombinases, used in mycobacterial 
recombineering 
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Table 2.2 – Primers utilized for this study 
Primer Name Primer Sequence (5’ to 3’) Use 
RMR01 GCACTGTTAATTAAGAAGGAGATATACCT
ATGCGTTCGAACTCGCAG 
Cloning of processed Mtb ClpP1 into 
pTetOR, pmv (forward) 
RMR02 AGTATACAGCTGTCACTGTGCTTCTCCAT
TGACCTG 
Cloning of processed Mtb ClpP1 into 
pTetOR (reverse) 
RMR03 GCACTGTTAATTAAGAAGGAGATATACCT
ATG CGCTACATCCTGCCGTC 
Cloning of processed Mtb ClpP2 into 
pTetOR, pmv (forward) 
RMR04 AGTATACAGCTGTCAGGCGGTTTGCGCG
GA 
Cloning of processed Mtb ClpP2 into 
pTetOR, pmv (reverse) 
RMR05 AGTATACAGCTGTCACAGGTCCTCCTCC
GAGATCAGCTTCTGCTCCTGTGCTTCTCC
ATTGACCTG 
Cloning of processed Mtb ClpP1-myc 
into pTetOR (reverse) 
RMR06 AGTATACAGCTGGTGGTGGTGGTGGTGG
TGCTGTGCTTCTCCATTGACCTG 
Cloning of processed Mtb ClpP1-his 
into pTetOR (reverse) 
RMR07 AGTATACAGCTGTCACAGGTCCTCCTCC
GAGATCAGCTTCTGCTCGGCGGTTTGCG
CGGA 
Cloning of processed Mtb ClpP2-myc 
into pTetOR, pmv (reverse) 
RMR08 AGTATACAGCTGGTGGTGGTGGTGGTGG
TGGGCGGTTTGCGCGGA 
Cloning of processed Mtb ClpP2-his 
into pTetOR, pmv (reverse) 
RMR09 GATCCGCATGCTTAATTAAGAAGGAG 
 
Cloning of GFP-ssrA into pmv 
(forward) 
RMR10 GTGGTGGTGATGGATGGTGTTTGTATAG
TTCATCCATGCCATG 
Cloning of GFP-ssrA into pmv 
(reverse, first round) 
RMR11 CTGATGTGAATCGGCGTGGTGGTGATGA
TGGTGTTTCTATAG 
Cloning of GFP-ssrA into pmv 
(reverse, second round to add first 
portion SsrA-tag) 
RMR12 CGGAATATCGATCTAGGCAGCGAGAGCG
TAGTCGCGCTGATGTGAATCGGC  
Cloning of GFP-ssrA into pmv 
(reverse, third round to add remaining 
portion SsrA-tag) 
RMR13 CCGCCGTGGCCTGACCATC Generation of linear PCR product 
from p96863 to recombineer strain 
ptet_clpP1P2 (forward) 
RMR14 TCTTCCGCCGACAGCAACAGG  Generation of linear PCR product 
from p96863 to recombineer strain 
ptet_clpP1P2 (reverse) 
RMR15 CATCCAGGGCCAGTTCTC 
 
Generation of linear PCR product 
from p54689 to recombineer strain 
clpP2_ID (forward) 
RMR16 CGTGGTGTTTGCCGTTCT  
 
Generation of linear PCR product 
from p54689 to recombineer strain 
clpP2_ID (reverse) 
RMR17 GCACGGCATACATCATTTCGACGCCG Used in screening for pTet_clpP2 
strain (forward). Binds to the 
tetracycline promoter.  
RMR18 GGCGGTTTGCGCGGAGAGC Used in screening for pTet_clpP2 
strain (reverse). Binds to the 3’-end of 
clpP2.  
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Figure 2.6 PCR confirmation of mycobacterial recombineering 
Primers specific to the 5’-UTR and 3’-UTR (RMR13 and RMR16, arrows) 
were used to distinguish wildtype Msm (expected fragment: 1.8 kb), Msm 
ptet_ClpP1P2 (expected size: 4.8 kb), and Msm clpP2_ID (expected size 3.2 
kb). For each construct, at least one primer was outside homology region used 
for recombineering in order to ensure specific insertion into the endogenous 
chromosome.  
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Inducible degradation of ClpP2 
Mycobacterial recombineering was employed to insert the inducible degradation tag (ID-tag) 
directly downstream of the clpP2 open reading frame. Inducible degradation was performed as 
described previously. Briefly, strain clpP2_ID was transformed with an anhydrotetracycline 
inducible integrated plasmid carrying the HIV-2 protease. Stationary phase cultures were diluted 
1000-fold, and induced with ATc (50 ng/mL). Cleavage by HIV-2 protease and subsequent protein 
degradation was monitored by epitope tags that flanked the ID-tag. To assess the role of the 
mycobacterial SsrA-tag, a constitutively expressing plasmid bearing GFP-SsrA was 
electroporated into clpP2_ID.  Cultures were grown and induced as above, and increase in GFP 
upon HIV-2 protease induction was monitored by fluorescence (emission/excitation: 485/520) and 
by immunoblotting using anti-GFP.  
 
Immunoblotting 
Total protein lysates were prepared from equivalent cell numbers using bead beating and 
immunoblot analysis was performed. For figure 2.3 and 2.4, bacterial cultures were grown to from 
starting OD 0.05 for 3-18 hours in fresh medium with or without ATc. Primary antibodies anti-myc 
(Sigma Aldrich) and anti-FLAG (Sigma Aldrich) were used as specified by manufacturer. 
Detection was performed using secondary HRP conjugated antibodies (Pierce), and SuperSignal 
West Femto Chemiluminescent Substrate (ThermoScientific) according the manufacturerʼs 
protocol. In all cases, blots were stripped and reprobed with anti-RpoB (MyBiosource) to ensure 
equivalent loading of samples 
 
Protein purification and in vitro peptidase assay 
The C-terminally 6x His-tagged wild type clpP1, wild type clpP2, clpP1Ser98Ala, and clpP2Ser110Ala 
subunits were overexpressed in Msm using an anhydrotetracycline (ATc) inducible expression 
system. After overnight induction with ATc (100 ng/mL), cells were lysed by French press, and 
lysates were centrifuged for 1h at 100,000 g. The subunits were purified from the supernatant by 
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Ni-NTA affinity chromatography (Qiagen). Eluted fractions containing ClpP proteins were pooled 
and further purified by size exclusion chromatography on Sephacryl S-300 column. Equal 
amounts of ClpP1 and ClpP2 (1µg each) were mixed in the reaction buffer (50mM K-phosphate 
buffer pH 7,5, 100 mM KCl, 5% glycerol, 2 mM BME, 5 mM Z-Leu-Leu) and peptidase activity 
was measured by a rise in fluorescence at 460nm (Ex at 340 nm) with 0.1 mM Z-Gly-Gly-Leu-
AMC as a substrate. To measure dominant negative effect of active site mutants, same reaction 
was carried out in the presence of 5 µg of the mutant proteins. Mass spectrometry was carried 
out by the Taplin Mass Spectrometry Facility.  
 
Animal infections: 
Six to eight week old C57BL/6 mice (Jackson Laboratory) were used for animal infections. Mice 
were infected via aerosolization with 5 x 106 CFU each of a 3:1 mixture of Mtb pTet::ClpP1 S98A  
and Mtb pTet::GFP (wild type Mtb transformed with a control pTet plasmid containing GFP). Mice 
were fed with chow with or without inducer doxycycline. At 30 days after infection, mice were 
sacrificed, lungs were homogenized and appropriate dilutions were plated on 7H10 plates 
containing hygromycin or kanamycin to select for the Clp mutant or the control respectively. 
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Section 3.1 – Chapter Overview and Attributions 
This chapter focuses on testing the hypothesis that the essentiality of Clp protease in 
mycobacteria is linked to the endogenous proteins that it degrades. In the most straightforward 
scenario, one could imagine that the importance of a degradative protease for growth could be 
explained by the enzyme's action on a toxic protein or repressor of normal growth. Coupling the 
generation of conditional clp mutants in Mtb and Msm with a robust isobaric quantitative 
proteomics methodology, we uncovered a set of proteins that were over-represented upon 
depletion of the protease. After systemic validation of the hits from proteomic screening, we 
identified an essential transcriptional repressor, WhiB1, as a likely Clp substrate. This finding was 
particularly interesting as blocking turnover of WhiB1 in a wildtype background inhibited growth 
and caused cell lysis, just as depletion of Clp protease. We were unable to confirm whether the 
essentiality of Clp was solely due to the turnover of WhiB1, but the potential protease substrates 
presented here (along with WhiB1) provide us with many avenues towards understanding the 
important biological processes that are regulated by Clp-dependent protein turnover.  
 
Attributions. I composed the manuscript that forms this chapter, which we aim to submit shortly 
as a research article to Molecular Cell. Though I performed initial primer design, Jun-Rong Wei 
and Jessica T. Pinkham constructed the Mtb clpP1P2 depletion strain (P750-clpP1P2DAS). With 
this strain, I performed growth curve analysis and protein isolation for both immunoblotting to 
confirm Clp depletion and quantitative proteomics to identify potential substrates of Clp protease. 
I constructed the Msm clpP2 conditional mutant (clpP2_ID), and performed all experiments with 
the strain. I conducted isobaric multiplexed quantitative proteomics in the lab of Professor Steven 
Gygi under the mentorship of Mark Jedrychowski. While I prepped samples for proteomics and 
analyzed the resulting data with Mark's guidance, he graciously coordinated the running of 
samples on the instrumentation in the Gygi lab, and provided the detailed methods write-up for 
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MS analysis below. I performed all experiments related to validating proteins as likely Clp 
substrates, and probing the essentiality of WhiB1 turnover.  
 
Section 3.2 – Proteomic profiling of proteins degraded by ClpP1P2 
protease identifies WhiB1 as a substrate and provides insight into the 
mechanism of Clp essentiality in Mycobacterium tuberculosis 
INTRODUCTION 
Our understanding of how bacteria regulate cellular processes has long focused on the role of 
transcription factors in the activation or repression of responses, through modulation of mRNA 
production. In eukaryotes, however, elucidation of the ubiquitin-proteasome pathway has 
illustrated that targeted degradation of endogenous proteins is frequently employed as a 
regulatory mechanism1,2. Like eukaryotes, bacteria possess an array of compartmentalized 
proteolytic complexes, capable of degrading proteins into smaller polypeptides and amino acids. 
The main enzymes responsible for this in bacteria include Clp, FtsH, Lon, HslUV, the prokaryotic 
proteasome, and the HtrA family3,4. Initially, these complexes were thought to maintain protein 
quality control in their respective locales through the recognition of misfolded, mislocalized, or 
aberrant protein products. Several seminal studies expanded our understanding of these 
complexes by identifying an array of endogenous proteins that were targeted for degradation in 
bacteria5,6. While this suggested an important role of proteolysis in the regulation of bacterial 
physiology, it has been difficult to determine the functional significance of protein degradation by 
these proteolytic machines in bacteria, specifically distinguishing constitutive, passive recognition 
of a protein from coordinated, active proteolysis of a substrate as a regulatory mechanism. 
 
Interestingly, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis that kills 
nearly 1.3 million people annually7, may provide a unique perspective into understanding the 
importance of targeted protein degradation in bacteria. In most model organisms, like Escherichia 
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coli and Bacillus subtilis, where the compartmentalized proteases have been extensively studied, 
they are mostly dispensable for normal growth8,9. However, a genome-wide screen for essential 
genes in Mtb suggested that numerous proteolytic complexes (namely Clp, FtsH, and HtrA) were 
all absolutely required for cell survival, providing evidence for their critical role in bacterial 
physiology10. It has been further shown, through the construction of conditional mutants, that Clp 
protease in mycobacteria is required for growth in vitro and survival in vivo in a mouse model of 
infection11. 
 
In mycobacteria, Clp is an ATP-dependent serine protease that is comprised of two stacked 
heptameric rings of ClpP1 and ClpP2 multimers, which are encoded in the same operon12. Each 
subunit possesses proteolytic activity, and the resulting heterotetradecameric structure is a 
compartmentalized protease with the fourteen active sites buried in an internal chamber. Based 
on homology to Clp in other organisms, it is hypothesized that proteins to be degraded enter 
through an axial pore that is regulated by the interaction of ClpP1P2 with various AAA+ ATPases 
(ClpC1 and ClpX in Mtb)13,14. These adapters have the dual function of recognizing substrates 
and providing the energy for protein unfolding and translocation into the proteolytic core. In Mtb, 
Clp has been implicated in the recycling of abnormal peptides stalled on the ribosome, through 
recognition of SsrA-tagged proteins, but elucidation of the endogenous proteins targeted by Clp 
has been lacking11. In general, the identification of substrates of essential proteases has not been 
systematically studied in bacteria. It is exactly in those cases, however, where a proteolytic 
complex is required for normal growth that understanding the proteins targeted for degradation 
will expand our understanding of how proteolysis is employed as a necessary regulatory 
mechanism.  
 
In this study, we constructed a conditional Clp protease mutant in Mtb, and quantitatively 
compared the proteomes of Clp-deficient cells to cells containing wildtype levels of the enzyme. 
Because Clp is essential in mycobacteria, we hypothesized that degradation of a particular 
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protein (or set of proteins) was required for cell survival. We show here that Clp protease 
degrades WhiB1, an essential transcriptional repressor. Blocking Clp-dependent degradation of 
WhiB1 resulted in stabilization of WhiB1 in mycobacteria. Though still functional, this stabilized 
allele was toxic even at physiological levels, suggesting that proteolysis plays a critical role in 
regulating the amount of WhiB1 present. These data establish a potential mechanism for 
explaining the essentiality of Clp protease in mycobacteria, and provide some of the first evidence 
towards establishing the essential role that protein turnover plays in regulating mycobacterial 
physiology. 
 
RESULTS  
Clp protease is essential in Mycobacterium tuberculosis 
The essentiality of Clp protease has been demonstrated in the non-pathogenic, fast growing 
model organism, Mycobacterium smegmatis (Msm), but not in Mycobacterium tuberculosis (Mtb). 
In order to do so, we constructed a Clp protease conditional mutant in Mtb that took advantage of 
complementary systems of promoter regulation and inducible protein degradation recently 
developed for use in mycobacteria (FIGURE 3.1A).  The strain was constructed by first 
introducing an additional copy of the clpP1P2 operon into the Mtb chromosome at the attachment 
site of the phage L5, creating a clpP1P2 merodiploid strain. This allele was modified to contain an 
anhydrotetracycline-responsive (ATc) promoter (P750) that would shut off transcription of the 
operon upon the addition of ATc (tet-off promoter)15. Additionally, the C-terminus of ClpP2 was 
modified to include a DAS tag. As described previously, the DAS tag facilitates targeted 
degradation of the tagged protein upon inducible expression of SspB16. Normally absent in 
mycobacteria, the expressed SspB recognizes the DAS tag and tethers the tagged protein to 
ClpXP for degradation. By regulating SspB expression with an ATc-inducible promoter (tet-on), 
the DAS inducible degradation system could be combined in the same strain with the tet-off 
promoter. Using mycobacterial recombineering17, the endogenous clpP1P2 operon was deleted, 
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creating a strain (P750-clpP1P2DAS) where clpP1P2 expression could be repressed and 
circulating ClpP2-DAS could be degraded by the addition of ATc.  
 
At low inoculums of 5X105 CFU/mL addition of ATc (1.5 µg/mL) to P750-clpP1P2DAS had a 
bactericidal effect, demonstrating that ClpP1 and ClpP2 were also essential in Mtb (FIGURE 
3.1B). At higher inoculums, ie, 1X107 CFU/mL, depletion also inhibited growth. These higher 
inoculums allowed us to harvest cellular material for protein and transcript expression analysis. 
Though the DAS inducible degradation system requires the ClpP1P2 proteolytic core for depletion 
of ClpP2, expression of SspB resulted in profound depletion of ClpP2-DAS within 48 hours, or two 
replicative cycles (FIGURE 3.1C). Furthermore, qPCR analysis of clpP1 and clpP2 mRNA 
revealed that by 48 hours, transcription at the clpP1P2 locus was significantly repressed in 
cultures exposed to ATc (FIGURE 3.1D).  
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Figure 3.1 Clp protease is required for normal growth in Mycobacterium 
tuberculosis.  
(A) Schematic depicting the construction of a conditional clpP1P2 mutant 
(Mtb P750-clpP1P2DAS). A stable, chromosomal merodiploid was first 
constructed by integrating an additional copy of the clpP1P2 operon at the L5 
site. In this additional operon, the native promoter was replaced with a ATc 
responsive promoter, and the end of clpP2 was modified by appending a DAS 
inducible degradation motif. Next, the original clpP1P2 operon was deleted 
using mycobacterial recombineering. Lastly, a plasmid bearing ATc-inducible 
sspB was integrated into the tweety attB site on the chromosome, allowing for 
inducible degradation of ClpP2-DAS. (B) Growth curves of Mtb P750-
clpP1P2DAS in the presence or absence of ATc (1.5 "g/mL). Data are 
represented as mean CFU/mL +/- standard deviation. (C) Depletion of ClpP2-
DAS was tracked over time by Western blot in wt H37Rv and P750-
clpP1P2DAS  in the presence or absence of ATc (1.5 "g/mL). Blots were 
probed with !-ClpP2 and !-RpoB (loading control). (D) Quantitative PCR to 
determine clpP1 and clpP2 transcript levels using RNA generated from Mtb 
P750-clpP1P2DAS after growth for 48h in the presence or absence of ATc 
(1.5 "g/mL). Relative standard curves were generated for each probe set, and 
sigA transcript was used as an endogenous control. Data are represented as 
mean fold change, normalized to transcript in (-) ATc cultures +/- SEM of 
technical replicates.  
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Proteomic identification of Clp substrates in Mycobacterium tuberculosis 
The P750-clpP1P2DAS strain afforded us a system to conditionally deplete the ClpP1P2 
proteolytic core, and explore the mechanism of essentiality of Clp protease in Mtb. We 
hypothesized that growth inhibition observed in this strain resulted from an accumulation of Clp 
substrates that were either toxic to the cell or repressed normal growth processes. In order to 
determine this set of proteins, we turned to LC/MS3-based multiplexed isobaric quantitative 
proteomics. The use of isobaric tandem mass tags (TMT) has recently been used to 
simultaneously and robustly quantify protein levels in up to six conditions18. The six isobaric TMT 
tags (TMT126-TMT131) all bear the same weight, and so once the labeled peptides from the six 
experimental conditions are combined, the same peptides from each sample co-elute during 
fractionation, enter the mass spectrometer together and form a single peak in the initial mass 
spectrum. However, upon isolation and fragmentation of that single peak in a subsequent MS, the 
TMT reagent fragments. A differential distribution of isotopes on either side of the fragmentation 
site in the reagent results in a set of peaks between the mass range of 126-131 Da that reflects 
the relative ratios of that given peptide in a particular labeled, experimental condition. 
 
In triplicate, we harvested P750-clpP1P2DAS grown up from an initial inoculum of 1X107 CFU/mL 
for 48 hours either in the absence or presence of 1.5 µg/mL of ATc. Western blot analysis 
demonstrated a significant knockdown of ClpP2 in each of the cultures exposed to ATc (FIGURE 
3.2A), and so the six lysates were prepped for quantitative proteomics. Through TMT labeling 
followed by MS3-based quantitative proteomics, we were able to quantify 1564 Mtb proteins 
across the six conditions. Hierarchical clustering using Pearson correlational analysis19 on the 
normalized, summed TMT intensities for each protein revealed a strong correlation between the 
three biological replicates of each condition (FIGURE 3.2B). A total of 132 proteins were 
significantly over-represented in mut bacteria. We defined significant over-representation (or 
under-representation) as an average change of greater than or equal to (or less than or equal to) 
two-fold between mutant and wildtype conditions, and a p-value of less than or equal to 0.01 
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across the biological replicates (FIGURE 3.2C, APPENDIX 2). Unfortunately, gene ontology (GO) 
analysis failed to reveal enrichment of any particular GO class among the over-represented 
proteins in Clp-depleted bacteria (data not shown). However, to support our theory tying Clp 
essentiality to the degradation of repressors of normal growth, there were numerous 
transcriptional modulators with increased abundance in mutant bacteria. Comparing protein 
intensity values between mutant and wildtype bacteria revealed a set of proteins that were highly 
over-represented (> 5 fold increase, 24 proteins), moderately over-represented (2-5 fold increase, 
108 proteins), or under-represented (> 2 fold decrease, 23 proteins). Examples from each class 
are depicted in FIGURE 3.2D. Remarkably, ClpP1 and ClpP2 were the two most under-
represented proteins in the screen, both depleted over 90% in mut cells compared to wt, thus 
confirming the efficiency of Clp depletion.  
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Figure 3.2 Proteomic profiling of P750-clpP1P2DAS in the presence and 
absence of ATc reveals a wide array of potential Clp protease substrates 
(A) In triplicate, P750-clpP1P2DAS was grown for 48 hours in the absence, 
denoted “wt”, or presence of ATc (1.5 "g/mL), denoted “mut”, from a starting 
OD600 of 0.02. Western blotting of protein lysates with !-ClpP2 and !-RpoB 
(loading control) demonstrates degree of ClpP2-DAS depletion in mut cells. 
Samples were then used for TMT6 MS3-based quantitative proteomics. The 
specific TMT reagent used for each condition is listed under the Western blot. 
(B) Normalized, summed intensities for all quantified proteins was used to 
perform Pearson correlational hierarchical clustering of biological replicates. 
(C) The Log2 ratio of average mutant protein intensity to average wildtype 
protein intensity plotted against the p-value determined by t-test, grouping the 
three biological replicates. The threshold for over-representation was set at an 
average ratio of greater than equal to 2, while the cut-off for under-
representation was 0.5. In both instances, p-values below 0.01 were deemed 
significant. Proteins considered for further analysis are denoted in red. (D) 
The relative quantity of specific proteins plotted across the six TMT channels, 
for highly (left) and moderately (center) over-represented, and under-
represented (right) proteins in the mutant versus wildtype conditions.  
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The transcriptional effectors WhiB1 and CarD are likely Clp protease substrates 
There is only one reported Clp protease substrate in Mycobacterium tuberculosis, RseA, but 
unfortunately the anti-sigma factor was not quantified in our screen20. The lack of any other 
reported mycobacterial Clp substrates in the literature hindered our validation of the proteomic 
results. Furthermore, the growth inhibition that results from Clp protease depletion undoubtedly 
results in significant cellular stress and complicates the true cause of protein over-representation 
in the mutant cells. It is possible that an increase in abundance of any given protein in Clp-
deficient bacteria could be due to a transcriptional stress response, and not due to stabilization 
from a lack of turnover. The presence of numerous heat shock proteins identified through our 
screening was suggestive of this. In order to determine the subset of over-represented proteins 
that were likely Clp substrates, we first turned to quantitative PCR analysis. Complementary DNA 
was generated from RNA isolated from P750-clpP1P2DAS grown for 48 hours in the presence or 
absence of ATc (1.5 µg/mL). Probe sets for candidates from the screen were used to compare 
levels of transcript between mutant and wildtype cells. This analysis revealed three groups, one 
where increases in protein abundance upon Clp depletion could be entirely explained by a 
transcriptional response clpS, asnC, dnaK, ndh, hsp20), a second where there was a clear 
discordance between protein abundance and transcript level changes (hspX, whib1, rpsL, merR), 
and a third where the difference was less clear (carD, papA3, hypothetical TF, luxR, sigB) 
(FIGURE 3.4A). We posited that the latter two classes were more likely to contain Clp substrates, 
as the changes in abundance were more likely to be due to regulation at the protein level rather 
than transcriptional upregulation.  
 
To further validate potential substrates of the Clp protease, we turned to a conditional clpP2 
mutant (clpP2_ID Msm) we had previously developed in Mycobacterium smegmatis (Msm), a 
fast-growing, non-pathogenic model organism, closely related to Mtb. Briefly, this strain allowed 
for inducible degradation of ClpP2 upon the addition of ATc. Degradation was facilitated by an 
inducible degradation (ID) tag that was appended to the 3ʼ-end of the chromosomal copy of clpP2. 
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The ID tag contained an SsrA tag that was masked by an HIV-2 protease recognition motif. Upon 
ATc-inducible expression of the HIV-2 protease, the motif was cleaved exposing the SsrA tag, 
and targeting ClpP2-ID for degradation. ClpP2 degradation could be tracked by epitope tags 
placed both upstream (myc) and downstream (FLAG) of the HIV-2 protease recognition site. We 
had previously reported that this mutant allowed for rapid degradation of ClpP2 (within 5 hours), 
and ClpP2 depletion resulted in the accumulation of a reporter substrate (GFP-SsrA), due to 
decreased turnover by Clp protease11. In earlier, unpublished work, we also used this strain to run 
a pilot TMT, MS2-based proteomic screen for potential Clp substrates. Using TMT six-plexing, we 
probed the proteomes of wildtype and clpP2_ID Msm inducibly expressing the HIV-2 protease at 
0h, 5h, and 11h post addition of ATc. Western blot analysis revealed significant depletion of 
ClpP2-ID at both 5h and 11h (FIGURE 3.3A).  
 
In our proteomic screen, we quantified a total of 1776 Msm proteins across the six conditions, 
and hierarchical clustering using Pearson correlational analysis on the normalized, median TMT 
intensities for each protein appropriately revealed a strong correlation between the uninduced 
wildtype and clpP2_ID samples, the 5h and 11h induced wildtype samples, and two induced 
clpP2_ID samples (FIGURE 3.3B). To minimize the probability of non-specific or stress-
dependent protein over-representation, we used the 5h time point of both cultures for further 
analysis. Quantitative TMT analysis revealed that depletion of ClpP2 was nearly 2-fold at this time. 
A total of 107 proteins were over-represented in ClpP2-depleted cells at 5h, with over-
representation defined as greater than or equal to two-fold increase in median protein intensity 
between clpP2_ID and wildtype samples. (FIGURE 3.3C, APPENDIX 3).  
 
Similar to our approach of validating potential substrates in Mtb, we conducted quantitative PCR 
analysis on RNA isolated from wildtype and clpP2_ID Msm cultures 5h post induction of HIV-2 
protease. As in Mtb, this analysis revealed a class of targets that showed discordance between 
protein over-representation and changes in transcript levels between clpP2_ID and wildtype Msm 
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(FIGURE 3.3D). Interestingly, we identified two essential transcriptional effectors, CarD and 
WhiB1, with increased protein abundance in both Mtb and Msm proteomic screens. While whiB1 
showed no significant fluctuations in transcript amount between Clp-deficient and Clp-replete cells 
in both Mtb and Msm, carD was discordant between Mtb and Msm qPCR experiments, with a 
slight increase in Mtb, but no significant change in Msm.   
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Figure 3.3 Proteomic profiling of clpP2-ID Msm in the presence and 
absence of ATc reveals a set of potential Clp protease substrates 
(A) clpP2-ID Msm was grown in the presence or absence of ATc (100 ng/mL) 
from a starting OD600 of 0.04 for 5 or 11 hours. Depletion of ClpP2-ID was 
tracked by Western blot of protein lysates, probing for !-myc and !-RpoB 
(loading control). Samples were then used for TMT6 MS2-based quantitative 
proteomics. (B) Normalized, median intensities for all quantified proteins was 
used to perform Perason correlational hierarchical clustering of the different 
conditions. The specific TMT reagent used for each condition is listed under 
the Western blot. (C) The Log2 ratios of median protein intensity at 5h for 
ClpP2 depleted cells (mut) to ClpP2 containing cells (wt). The threshold for 
over-representation was set at an average ratio of greater than or equal to 2, 
while the cut-off for under-representation was less than or equal to 0.5. Hits 
are denoted in red. (D) For a given set of proteins, the ratio of mutant to 
wildtype protein at 5 hours was compared to the ratio of transcript levels. 
Quantitative PCR was employed to determine transcript levels using RNA 
generated from clpP2-ID Msm after growth for 5h in the presence or absence 
of ATc (100 ng/mL). Relative standard curves were generated for each probe 
set, and sigA transcript was used as an endogenous control. For each target, 
data are represented as mean fold change, of mutant cells normalized to 
wildtype transcript amount +/- SEM of technical replicates. 
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As the clpP2_ID Msm strain appeared suitable for probing specific Clp recognition of endogenous 
proteins with measurable ClpP2 depletion within 5 hours, and CarD and WhiB1 are well 
conserved between Mtb and Msm, we used this strain to further validate the two proteins as Clp 
substrates. To provide complimentary evidence of WhiB1 and CarD degradation by Clp protease, 
we constructed GFP-fusion proteins, where GFP was appended to either the N- or C-terminus of 
each protein, and expressed these fusions in an episomal, ATc-inducible plasmid. By fusing GFP 
to either end of potential substrates, we hoped to track protein turnover via fluorescence while 
also determining whether the exposure of a particular terminus was important for protease 
recognition. Additionally, by tightly regulating the transcription of these constructs on an inducible 
plasmid, we hoped to prevent transcriptional modulation from confounding our findings. 
Expression in wildtype Msm revealed differential abundances, as measured by fluorescence, 
between N- and C-terminal fusions for each protein. For both WhiB1 and CarD, the N-terminal 
GFP fusions appeared to be less abundant than the C-terminal fusions (FIGURE 3.4B, black 
bars). Despite the differential fluorescence between the two WhiB1 fusions, quantitative PCR 
analysis revealed that inducible expression of GFP-WhiB1 and WhiB1-GFP led to similar 
amounts of transcript in the cell, thus suggesting that any differential fluorescence observed was 
regulated at the protein level (FIGURE 3.5). 
 
To demonstrate that this discrepancy was specifically due to destabilization of one particular 
fusion by Clp protease, we introduced the fusions into clpP2_ID Msm, where addition of ATc 
simultaneously induced expression of each fusion construct and HIV-2 protease, and assessed 
protein abundances in the face of ClpP2 depletion. For both WhiB1 and CarD, depletion of ClpP2 
resulted in an increase in the abundance of the N-terminal GFP fusion, relative to wildtype Msm 
(FIGURE 3.4B), presumably reflecting stabilization due to reduced turnover. The differential 
abundance of the two fusions in wildtype Msm, and the selective stabilization of the N-terminal 
GFP fusion upon ClpP2 depletion, demonstrated that CarD and WhiB1 were likely substrates of 
Clp protease, that the Clp recognition motif for both was at the extreme C-terminus of the protein, 
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and that this motif was blocked upon fusion with GFP. Worry of transcriptional upregulation 
explaining the relative stabilization of the N-terminal GFP fusions upon ClpP2 depletion was 
mitigated as wildtype GFP revealed that transcription at the ATc responsive promoter was 
actually slightly repressed upon inducible degradation of the ClpP2 subunit (data not shown).  
 
To ensure that destabilization was not a non-specific effect due to any non-specific N-terminal 
GFP fusions, we tested several other candidates using the same methodology. For both RpL28 
and DnaA, C-terminal GFP fusions were actually less stable than their respective N-terminal 
constructs. In the case of RpL28, depletion of ClpP2 stabilized both fusions, suggesting that the 
motif for Clp recognition was internal and not dependent on an exposed terminus. DnaA fusions 
were not stabilized at all upon ClpP2 depletion suggesting that DnaA was either not a substrate or 
that both free ends were required for proteolysis (FIGURE 3.6A). 
 
 Observing that turnover of WhiB1 required a free C-terminus, we hypothesized that WhiB1ʼs 
degradation motif was at the extreme C-terminus. To show that the C-terminus was sufficient to 
confer destabilization and recognition by Clp protease, we constructed a variety of fusions where 
a variable number of C-terminal WhiB1 residues were appended to the end of GFP. Expressing 
these constructs on a constitutive episomal plasmid in clpP2_ID Msm revealed that the addition 
of the last fifteen, nine, and five amino acids of WhiB1 to GFP destabilized the protein with 
respect to wildtype GFP. Furthermore, wildtype levels of GFP protein expression were restored in 
these constructs upon ClpP2 depletion (FIGURE 3.4C). Though not definitive determination of the 
specific motif, these experiments affirm that the C-terminus of WhiB1 enables Clp recognition, 
and that the terminal five amino acids are sufficient to destabilize GFP relative to the wildtype 
fluorescent protein. The WhiB1 degradation motif is most likely complex and spans several amino 
acids, as the different fusions appeared to progressively destabilize GFP as more C-terminal 
WhiB1 residues were appended. Additionally, we also observed that the C-terminal fifteen 
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residues of CarD destabilized GFP in wildtype Msm, relative to the wildtype fluorescent protein or 
the addition of the first fifteen amino acids of CarD to the N-terminus of GFP (FIGURE 3.6B)     
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Figure 3.4 Validation of proteomic hits reveals that WhiB1 and CarD are 
likely Clp protease substrates 
(A) Quantitative PCR (grey bars) to determine transcript levels of over-
represented proteins upon depletion of Clp protease using RNA generated 
from Mtb P750-clpP1P2DAS after growth for 48h in the presence or absence 
of ATc (1.5 "g/mL). Relative standard curves were generated for each probe 
set, and sigA transcript was used as an endogenous control. Data are 
represented as mean fold change, normalized to transcript in (-) ATc cultures 
+/- SEM of technical replicates. Protein ratios (black bars) are derived from 
TMT experiments described in Figure 2, and represented as average ratios +/- 
standard deviation of biological replicates (B) Fluorescence (485/538) was 
measured for N- and C-terminal GFP fusions constructed for WhiB1 (left) and 
CarD (right), and induced for 8 hours in wildtype or clpP2-ID Msm with ATc 
(100 ng/mL). In clpP2-ID, ATc simultaneously induced fusion protein 
expression and degradation of ClpP2. (C) Fluorescence (485/538) was 
measured for GFP fusions bearing a variable number of C-terminal residues 
from WhiB1 in clpP2-ID Msm, grown in the absence or presence of ATc (100 
ng/mL) for 8 hours. In (B) and (C), data are represented as mean RFU +/- 
standard deviation of biological replicates. Asterisks denote a p-value < 0.05 
determined by t-test .  
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Figure 3.5 Overexpression of WhiB1 fusion constructs (GFP-WhiB1 and 
WhiB1-GFP) confirmed by quantitative PCR.  
Quantitative PCR using a probe set that hybridized to both chromosomal and 
episomal copy of whiB1 to determine transcript abundance of whiB1 in 
strains inducibly over-expressing GFP-WhiB1 and WhiB1-GFP, compared to 
wildtype Msm. RNA was isolated from cultures grown for 6 hours from a 
starting OD600 of 0.06 in the presence of the inducer ATc (100 ng/mL). 
Relative standard curves were generated for each probe set, and sigA 
transcript was used as an endogenous control. Data are represented as mean 
fold change, normalized to transcript in wildtype cultures +/- SEM of 
technical replicates. 
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Figure 3.6 RpL28 is likely a Clp substrate, and the 15 terminal amino 
acids of CarD destabilize GFP relative to the wildtype fluorescent protein 
(A) N- and C-terminal GFP-fusions for DnaA and RpL28, identified as 
potential Clp substrates from proteomic profiling of clpP2-ID Msm.  
Fluorescence (485/538) was measured for N- and C-terminal GFP fusions 
constructed for DnaA (left) and RpL28 (right), and induced for 8 hours in 
wildtype or clpP2-ID Msm with ATc (100 ng/mL). In clpP2-ID, ATc 
simultaneously induced fusion protein expression and degradation of ClpP2. 
(B) Fluorescence (485/538) was measured for wildtype GFP, and GFP fusions 
bearing either the N-terminal or C-terminal 15 amino acids from CarD 
expressed on a constitutive, episomal plasmid in wildtype Msm. In both (A) 
and (B), data are represented as mean RFU +/- standard deviation of 
biological replicates. Asterisks denote a p-value < 0.05 determined by t-test .  
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Stabilization of WhiB1, and blocking Clp-dependent degradation is toxic in mycobacteria 
When performing experiments using the WhiB1 GFP fusion proteins, we made the interesting 
observation that prolonged over-expression of WhiB1-GFP inhibited the growth of wildtype Msm 
(FIGURE 3.7A). This effect appeared to be specific to the C-terminal GFP fusion, as 
overexpression of the GFP-WhiB1 or even wildtype WhiB1 had no effect on growth. Through 
growth curve analysis, we were able to show that WhiB1-GFP was toxic and caused cell lysis 
(FIGURE 3.7B).   
 
Fusion proteins can often have non-specific toxic effects, and so we sought to determine if the 
WhiB1-GFP allele was still functional. As it has been previously shown that WhiB1 is capable of 
auto-repressing itʼs own transcription by binding to a site in the 5ʼutr of the gene21, we determined 
transcript levels of the endogenous whiB1 locus upon overexpression of the two fusion proteins. 
Quantitative PCR revealed that transcription of the chromosomal whib1 5ʼ utr was significantly 
repressed in the WhiB1-GFP compared to wildtype Msm, so the toxic WhiB1-GFP protein was 
still capable of binding DNA and modulating transcription (FIGURE 3.7C). Unfortunately, qPCR 
analysis was unable to definitively determine whether the GFP-WhiB1 allele was functionally 
repressing whiB1 transcription. To rule out the possibility of differential toxicity being due to a non-
functional N-terminal GFP fusion protein, we built a more sensitive reporter of promoter activity by 
fusing the 500 bp upstream of whiB1 to luciferase. By introducing this construct into strains 
inducibly expressing the GFP fusions, we could simultaneously monitor fluorescence for protein 
abundance and stability, and luminescence for whiB1 promoter activity. As expected, 
fluorescence measurements revealed that GFP-WhiB1 was more abundant than WhiB1-GFP. 
Both GFP-WhiB1 and WhiB1-GFP were able to repress transcription of whiB1 promoter 
compared to wildtype Msm, and the amount of repression appeared to correlate inversely with the 
amount of fusion protein present (FIGURE 3.7D). The luciferase reporter demonstrates that both 
fusion proteins are comparably active and that the toxicity observed for WhiB1-GFP could be due 
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to increased WhiB1 abundance, a result of stabilization from lack of recognition of the blocked C-
terminus by Clp protease.  
 
In all of the above experiments, the fusion WhiB1 proteins were expressed on episomal, inducible 
plasmids. It is entirely feasible that the toxicity observed for WhiB1-GFP could be due to the 
dramatic overexpression resulting from the artificially constructed system. Furthermore, the 
increased abundance observed of WhiB1 in the proteomic screens was 2.2 fold in Mtb and 7 fold 
in Msm, much lower than the presumed over-expression from the inducible, episomal constructs. 
In order to test the functional effects of more physiological levels of the degradation-deficient 
WhiB1 protein, we constructed integrative plasmids in which the native whiB1 promoter regulated 
each fusion gene, and wildtype whiB1 as a control. Transformation of these plasmids into Msm 
resulted in significantly lower transformation efficiencies for the plasmid bearing WhiB1-GFP 
compared to those with GFP-WhiB1 and WhiB1wt (FIGURE 3.7E). We believe the toxicity is even 
more severe than represented, as the WhiB1-GFP colonies that did grow were significantly 
smaller and took nearly twice as long to come up than the GFP-WhiB1 or control WhiB1wt 
transformations. The fitness cost associated with the introduction of a single copy of the fusion 
allele regulated by the native promoter demonstrates that slight disruption of WhiB1 turnover also 
effects growth. Furthermore, even though WhiB1 is able to auto-repress its own locus, the 
proteolysis of WhiB1 plays a dominant role in regulating the levels of WhiB1 and coordinating the 
functional effects of this presumed transcriptional repressor.  
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Figure 3.7 Blocking Clp-dependent degradation of WhiB1 is toxic  
(A) Inducible expression of GFP-WhiB1, WhiB1-GFP, and WhiB1wt in Msm 
demonstrates growth inhibition of WhiB1-GFP expressing bacteria. Over-
expression was induced with ATc (100 ng/mL). (B) Growth curves of strains 
expressing WhiB1 constructs in the presence of ATc (100 ng/mL). As a 
control, strains expressing WhiB1wt were grown in the absence of inducer. 
Data are represented as mean OD600 +/- standard deviation of biological 
replicates. (C) Quantitative PCR, using probe sets that hybridize to the whiB1 
5’utr, to determine transcriptional repression at the endogenous whiB1 locus 
in wildtype Msm, or Msm inducibly expressing GFP-WhiB1 or WhiB1-GFP. 
RNA was isolated from cultures grown for 6 hours from a starting OD600 of 
0.06 in the presence of the inducer ATc (100 ng/mL). Relative standard 
curves were generated for each probe set, and sigA transcript was used as an 
endogenous control. Data are represented as mean fold change, normalized to 
transcript in wildtype cultures +/- SEM of technical replicates. (D) Promoter 
reporters were constructed fusing the 500 bp upstream of whiB1 to luciferase. 
Luminescence (RLU, 100ms exposure, grey bars) was measured in wildtype 
Msm, or Msm inducibly expressing GFP-WhiB1 or WhiB1-GFP. Amounts of 
the fusion proteins were monitored by fluorescence (RFU, 485/538, black 
bars). Data are represented as RFU or RLU +/- standard deviation of 
biological replicates. (E) GFP whiB1 fusions and wildtype whiB1 were 
cloned into integrative plasmids, in which expression was driven by the native 
whiB1 promoter. Constructs were transformed into Msm, and transformation 
efficiency was determined by calculating colony forming units (CFU) 
obtained per ng DNA. In (C), (D), and (E), asterisks denote a p-value < 0.05, 
determined by t-test.  
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DISCUSSION 
To date, only one endogenous substrate of Clp protease has been identified in mycobacteria. 
Global substrate identification of essential proteases has been a difficult enterprise. In model 
organisms where Clp is dispensable for normal growth, substrates were identified through pull-
downs with a catalytically dead mutant that replaced the native protease22. In these cases, 
substrate identification was straightforward, but determining the functional importance of 
degradation of a particular protein was more challenging, due to the lack of clear impairment upon 
protease depletion. The essentiality of clpP1 and clpP2 thwarted multiple attempts to conduct 
allelic replacement pull-downs in mycobacteria, and so we employed a recently developed 
method of conditional gene expression for mycobacteria to construct an Mtb strain where the 
levels of ClpP1P2 protease could be tightly regulated. In addition to confirming the essentiality of 
Clp protease in Mtb, we coupled the generation of this strain to a new robust methodology of 
quantitative proteomics to identify a set of proteins in both Mtb and Msm that were over-
represented in protease deficient cells. The TMT-based proteomics method we employed has 
been shown to reliably determine two-fold differences in the protein abundance between 
samples23.  
 
Because protein over-representation in mutant bacteria did not require a direct interaction with 
Clp, proteins identified from this screening method could have been over-represented for a 
multitude of reasons, including transcriptional upregulation in response to the stress of Clp 
depletion. Therefore, the candidates obtained from our proteomics experiments were only seen 
as potential substrates. Through a combination of mRNA transcript analysis, to show that protein 
over-representation in Clp-deficient cells was not due to increases in transcript abundance, and 
the creation of whole protein N-terminal and C-terminal GFP fusions, to monitor protein stability 
and turnover, we isolated two essential transcriptional modulators, WhiB1 and CarD, as likely Clp 
protease substrates. Though limited by the lack of an in vitro assay for testing the degradation of 
whole proteins by the ClpC1P1P2 or ClpXP1P2 complexes, we employed complimentary fusion 
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protein approaches and showed that the isolated C-termini of WhiB1 and CarD were sufficient to 
destabilize GFP in a Clp-dependent manner.  
 
While there are likely other substrates identified in our screen, we chose to focus on WhiB1 in this 
study due to the interesting observation that expression of WhiB1-GFP was toxic to mycobacteria, 
while GFP-WhiB1 was not. Having generated evidence that C-terminal fusion of GFP blocked 
degradation by Clp, we believed that the toxicity of WhiB1-GFP may be linked to lack of 
proteolysis. Further evidence of this hypothesis was provided by the fact that the fusion allele was 
functional, and capable of binding DNA to repress transcription. While there is a chance that 
WhiB1-GFP toxicity is still non-specific, we believe that we have mitigated these concerns by 
showing the allele is still functional, and that it is associated with a fitness cost at physiological 
levels. Given that WhiB1 can auto-repress its own locus, and toxicity still results when a native 
promoter governs the fusion, we believe that tightly regulated turnover of WhiB1 is critical for 
normal growth.   
 
Why could the turnover of WhiB1 be required for growth? In mycobacteria, there is substantial 
controversy regarding the role of the WhiB proteins, though most agree that they play an 
important role in redox biology. WhiB proteins are capable of binding redox-sensitive [4Fe-4S] 
clusters, which can serve as redox-active co-factors or a switches that reflect the reductive and 
oxidative potential of a cell24. Some studies have provided evidence that the WhiB proteins are 
disulfide reductases25, but the prevailing thought is that this family is comprised of transcription 
factors capable of modulating cellular processes that are intimately tied to the redox state of the 
cell or perceived oxidative stress26. In Mtb, WhiB1 was found to be an essential DNA binding 
protein capable of auto-repressing itʼs own transcription21. Beyond this, the WhiB1 regulon or 
functional effects of WhiB1 DNA binding have yet to be definitively elucidated. As blocking Clp 
recognition of WhiB1 stabilizes the repressor, it would be a logical extension to assume that the 
elevated levels of the transcription factor contributes to the lethality of Clp deficient cells by 
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repressing essential genes. Interestingly, ChIP-Seq to determine the WhiB1 regulon in Mtb has 
been undertaken, and preliminary data suggests the presence of 71 binding sites for WhiB1, 
thirteen of which are essential27. For example, some genes in the putative WhiB1 regulon are 
involved in the synthesis of metabolites, such as heme and riboflavin. Insufficient amounts of 
these important co-factors resulting from lack of WhiB1 turnover may explain the lethality of 
degradation-deficient WhiB1, and in turn the essentiality of Clp protease. Alternatively, extremely 
elevated levels of WhiB1, due to absence of turnover, may result in non-canonical binding of the 
transcription factor to other sites not determined by ChIP-Seq methods. In this case, the lethality 
of WhiB1 may result from non-specific repression of other essential genes, and ChIP-Seq on a 
stabilized form of WhiB1 or RNA-Seq would need to be done in order to determine why lack of 
proteolysis is lethal.  
 
While both stabilization of WhiB1-GFP and Clp depletion are lethal, we can only suggest that 
turnover of WhiB1 is the major critical role of Clp protease in mycobacteria. In reality, however, it 
is likely that the mechanism of Clp essentiality is multifactorial.  It has recently been found that the 
tmRNA pathway in mycobacteria is critically required for normal growth (Zhang YJ, manuscript 
submitted). In this pathway, peptides stalled on the ribosome are modified through trans-
translational addition of an SsrA tag, released from the ribosome, and subsequently degraded by 
Clp protease28. The tmRNA pathway is not essential in other organisms, and the reasons for the 
divergent essentiality of the tmRNA pathway in mycobacteria are unknown. It is likely that another 
critical role of Clp protease in cellular physiology is to serve as the effector of SsrA tagging. 
Additionally, genome wide screening suggests that both ATPases that interact with the ClpP1P2 
proteolytic core, ClpC1 and ClpX, are essential in Mtb10. The fact that both these adapters are 
required supports the hypothesis that there are multiple substrates that need to be recognized, at 
least one per ATPase, by Clp protease to facilitate normal growth. The WhiB1 story highlights 
one critically important substrate of Clp protease in mycobacteria, but there are likely several 
others whose stabilization may have similar or more subtle effects than the toxic effect observed 
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upon blocking WhiB1 turnover. Though overexpression of degradation-deficient alleles of CarD 
did not explicitly inhibit growth, it is interesting to note that CarD has been implicated in the 
stringent response, and directly interacts with the beta-subunit of the RNA polymerase to down 
regulate transcription of the translational machinery and amino acid biosynthetic enzymes29. 
While stabilization of CarD alone is not sufficient to cause toxicity in mycobacteria, the 
transcriptional repression of enzymes important for vegetative growth facilitated by CarD may 
contribute to the growth inhibition observed upon depletion of Clp protease, and partially explain 
the essentiality of Clp protease in mycobacteria.  
 
The demonstration that turnover of WhiB1 is specifically required for bacterial viability provides 
unique insight into the active role that targeted protein degradation plays in coordinating cellular 
physiology. WhiB1 is thought to be a transcription factor capable of auto-repression. However, 
even when the native promoter regulates a degradation deficient allele of WhiB1 at physiological 
levels, a fitness cost is associated with the presence of the proteolytically-dysregulated allele. 
This suggests that proteolysis plays a dominant role in regulating the functional impact of WhiB1 
by coordinating the total amount of WhiB1 in the cell. This is especially intriguing considering that 
WhiB1 is essential in mycobacteria and deletion of the gene also prevents normal growth. Thus, 
the levels of WhiB1 in the cell must be tightly titrated, and despite WhiB1ʼs ability to repress itʼs 
own locus, lack of WhiB1 proteolysis results in the presence of an aberrant amount of the 
transcription factor. By demonstrating that proteolysis of a particular protein can be co-dominant 
with transcriptional modulation, we provide evidence that the essential Clp protease in 
mycobacteria is employed to actively coordinate critical aspects of cellular physiology.   
 
To date, there are only a few examples in bacteria where targeted proteolysis has been proven to 
be the dominant player in regulating a vital cellular process. In Caulobacter crescentus, one of the 
few bacteria where Clp protease is also essential, degradation of CtrA by Clp is absolutely 
necessary for the transition of a non-replicating, motile swarmer cell into a replicating, stalked 
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cell30. In most other cases, proteolysis of specific endogenous substrates has been confirmed, 
but proving that targeted turnover is the main mode of regulation of that protein or the pathway 
that the substrate is involved in has proven difficult. Here, we show that proteolysis of WhiB1 by 
Clp protease is required for growth, and absence of this turnover has a profound effect on the 
viability of mycobacteria.  
 
In summary, we have highlighted a potential list of substrates of the essential Clp protease in 
mycobacteria, and provided a framework for confirming degradation and probing the functional 
significance of targeted turnover of endogenous proteins by essential proteases. While our work 
with WhiB1 highlights the importance of proteolysis in maintaining normal cellular physiology for 
one particular protein, the identification of other critical substrates will move us towards a more 
holistic understanding of how bacteria coordinate cellular activities through the integration of 
transcriptional and proteolytic regulation, both of which are likely equally important in maintaining 
bacterial viability.  
 
MATERIALS AND METHODS 
Bacterial strains and plasmids 
Msm mc2155 (Msm) or Mtb H37Rv were grown at 37°C in Middlebrook 7H9 broth with 0.05% 
Tween 80 and ADC (0.5% BSA, 0.2% dextrose, 0.085% NaCl, 0.003 g catalase/1L media). Mtb 
was additionally supplemented with oleic acid (0.006%). For growth curves, overnight cultures 
were diluted into the appropriate media and growth was either measured by OD600 or colony 
forming units per mL. 
 
A complete list of plasmids and primers used for cloning this study can be found in TABLE 3.1 
and TABLE 3.2. The construction of strain clpP2_ID Msm has been described in depth in 
Chapter 2.   
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TABLE 3.1 – Plasmids utilized in this study 
Plasmid Properties/Uses 
pNIT(zeo)::RecET-SacB Nitrile inducible plasmid to make Mtb 
competent for recombineering 
pEXPR(kan)::RT38-p750-clpP1P2DAS L5 integrating plasmid used to construct 
clpP1P2 merodiploid Mtb 
pGMCtKq22(zeo)::TSC10M1-pUV15-sspB ATc-inducible expression of sspB for 
DAS inducible degradation of ClpP2-DAS 
pTetOR(zeo)::gfp-attR Gateway destination vector for N-terminal 
GFP tagging 
pTetOR(zeo)::attR-gfp Gateway destination vector for C-terminal 
GFP tagging 
pTetOR(zeo)::gfp-carD ATc-inducible expression of GFP-CarD 
pTetOR(zeo)::gfp-whiB1 ATc-inducible expression of GFP-WhiB1 
pTetOR(zeo)::gfp-rpL28 ATc-inducible expression of GFP-RpL28 
pTetOR(zeo)::gfp-dnaA ATc-inducible expression of GFP-DnaA 
pTetOR(zeo)::carD-gfp ATc-inducible expression of CarD-GFP 
pTetOR(zeo)::whiB1-gfp ATc-inducible expression of WhiB1-GFP 
pTetOR(zeo)::rpL28-gfp ATc-inducible expression of RpL28-GFP 
pTetOR(zeo)::dnaA-gfp ATc-inducible expression of DnaA-GFP 
pMV762(zeo)::gfp-whiB1(last15) Constitutive expression of GFP-
WhiB1(last 15 amino acids) 
pMV762(zeo)::gfp-whiB1(last9) Constitutive expression of GFP-
WhiB1(last 9 amino acids) 
pMV762(zeo)::gfp-whiB1(last5) Constitutive expression of GFP-
WhiB1(last 5 amino acids) 
pMV762(zeo)::gfp-whiB1(last3) Constitutive expression of GFP-
WhiB1(last 3 amino acids) 
pMV762(zeo)::gfp-carD(last15) Constitutive expression of GFP-CarD(last 
15 amino acids) 
pGH1000A(hyg)::PwhiB1(500)-Luciferase Integrative luciferase reporter to monitor 
whiB1 promoter activity 
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TABLE 3.2 – Primers utilized in this study 
Primer Name Primer Sequence (5’ to 3’) Use 
attB4-RT38F GGGGACAACTTTGTATAGAAAAGTTG
CAGCTGGCTAGCGAGTCATG 
Cloning of RT38 into multisite 
gateway destination vector (forward) 
attB1-RT38R GGGGACTGCTTTTTTGTACAAACTTG
AATATTGGATCACGCCGCGA 
Cloning of RT38 into multisite 
gateway destination vector (reverse) 
attB1-p750F GGGGACAAGTTTGTACAAAAAAGCAG
GCTGCTACCAGGCCTAGATCTGG 
Cloning of p750 into multiple 
gateway destination vector (forward) 
attB2-p750R GGGGACCACTTTGTACAAGAAAGCTG
GGTGGTGGTGCATGCGGTTGTGA 
Cloning of p750 into multiple 
gateway destination vector (reverse) 
attB2-
clpP1P2DASF 
GGGGACAGCTTTCTTGTACAAAGTGG
GAAGGAGATATACCTGTGAGCCAAGT
GACTGAC 
Cloning of clpP1P2DAS into multiple 
gateway destination vector (forward) 
attB3-DASR GGGGACAACTTGTATAATAAAGTTGT
CACTAGCTGGCGTCCGCGTAGTTCTC
GGAGTAGT 
Cloning of clpP1P2DAS into multiple 
gateway destination vector (round 2, 
reverse) 
clpP1P2DASR GTAGTTCTCGGAGTAGTTCTCGTCGT
TGGCGGCGGCGGTTTGCGCGGAGAG
CTTC 
Cloning of clpP1P2DAS into multiple 
gateway destination vector (round 1, 
reverse) 
5flankF GCTCGTCACGCGCGGCGTT Cloning of upstream fragment for 
stitch PCR to generate 
recombineering product to delete 
clpP1P2 operon (forward) 
5flankR GGGGAGTATAACTTGGGGCACCTGCT
TTCCTCGA 
Cloning of upstream fragment for 
stitch PCR to generate 
recombineering product to delete 
clpP1P2 operon (reverse) 
hygkoF AAGCAGGTGCCCCAAGTTATACTCCC
CGACGTGGCC 
Cloning of hygR for stitch PCR to 
generate recombineering product to 
delete clpP1P2 operon (forward) 
hygkoR TCAGGCGGTTTGCGTCTAGACTCGAG
GTACCGGCG 
Cloning of hygR for stitch PCR to 
generate recombineering product to 
delete clpP1P2 operon (reverse) 
3flankF CTCGAGTCTAGACGCAAACCGCCTGA
GCCATGG 
Cloning of downstream fragment for 
stitch PCR to generate 
recombineering product to delete 
clpP1P2 operon (forward) 
3flankR ATGCTCAATCTGCAGCGGTCGC Cloning of downstream fragment for 
stitch PCR to generate 
recombineering product to delete 
clpP1P2 operon (reverse) 
clpPkoF GGAAGCTCAGGTTACCGTCA Primer to check deletion of clpP1P2 
operon in Mtb (forward) 
hygR GCGTAGGAATCATCCGAATC Primer to check deletion of clpP1P2 
operon in Mtb (forward) 
RMR257 AAACCCTTAATTAAGAAGGAGATATA
CCTATGGCTA 
Cloning of gfp for stitch PCR to 
generate N-terminal GFP Gateway 
tagging insert (forward) 
RMR258 ACAAACTTGTTTTGTATAGTTCATCCA
TGCCATG 
Cloning of gfp for stitch PCR to 
generate N-terminal GFP Gateway 
tagging insert (reverse) 
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TABLE 3.2 (continued) – Primers utilized in this study 
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TABLE 3.2 (continued) – Primers utilized in this study 
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The first step in the construction of P750-clpP1P2DAS was transformation of the attB L5 site 
integrating plasmid, pEXPR(kan)::RT38-p750-P1P2DAS into H37Rv/pNIT(zeo)::RecET-SacB to 
create a clpP1P2 merodiploid. The pEXPR(kan) plasmid was generated using multi-site gateway 
to insert the tetracycline-off repressor (RT38, PCR amplified using primers: attB4-RT38F, attB1-
RT38R), the tetracycline-off promoter (p750, PCR amplified using primers: attB1-p750F, attB2-
p750R), and the DAS-modified clpP1P2 operon (P1P2DAS, 2 rounds of PCR used to append 
DAS tag using primers: attB2-clpP1P2DASF, clpP1P2DASR, attB3-DASR) into the multisite 
gateway entry vector, pEN23A(kan). The DAS modification, which appends the DAS tag to the 3ʼ-
end of clpP2, was inserted to facilitate inducible degradation of ClpP2 upon expression of SspB. 
The plasmid pNIT(zeo)::RecET-SacB, which contains the machinery for mycobacterial 
recombineering, was a gift from Dirk Schnappinger. Next, hygromycin-containing knockout-out 
fragments were generated using stitch PCR to ligate 500 bp upstream (primers: 5flankF, 5flankR) 
and downstream (primers: 3flankF, 3flankR) of the clpP1P2 operon to a hygromycin resistance 
marker (primers: hygkoF, hygkoR). This linear PCR fragment was transformed into the above Mtb 
strain that was made competent for recombineering. This was done by addition of 1 mM 
isovaleronitrile (IVN, Sigma Aldrich) to a culture at OD600 0.8.  IVN addition induced expression of 
the recombineering machinery on pNit(zeo)::RecET-SacB. After 8h, 10 mL of 2M glycine was 
added, and the culture was grown overnight to yield recombineering-competent Mtb. 
Electroporation was performed as previously described31. Positive clones were plated on 7H10 
agar containing 10% sucrose to counterselect against the recombinase plasmid, and scored for 
growth on zeocin-containing agar to confirm the loss of pNit::RecET. Deletion of the endogenous 
clpP1P2 operon was confirmed by PCR screening using primers that annealed outside of the 
region deleted and to the hygromycin resistance marker (primers: clpPkoF, hygR). In a final step, 
the tweety site integrating plasmid, pGMCtKq22(zeo)::TSC10M1-pUV15-sspB, was transformed 
into the strain. This plasmid, a gift from Dirk Schnappinger, inducibly expressed SspB and 
enabled degradation of the DAS-modified ClpP2 protein, 
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To construct GFP whole protein fusions, tetracycline-inducible, Gateway destination vectors were 
generated that enabled either N- or C-terminal fusion of an Mtb open reading frame to GFP. For 
N-terminal tagging, stitch PCR was used to append GFP, with a ribosome binding site upstream 
of the translational start site, (primers: RMR257, RMR258) upstream of an attR ccdB-CmR 
cassette (primers: RMR259, RMR260).  For C-terminal tagging, stich PCR was used to append 
GFP (primers: RMR263, RMR264) downstream of an attR ccdB-CMR cassette (primers: RMR261, 
RMR262). Both products were digested with PacI and EcoRV and then ligated into the 
tetracycline-inducible episomal pTetOR(zeo) plasmid, a gift from Mike Chao, to yield the final 
destination vectors. For N-terminal GFP tagging to carD, whiB1, rpL28, and dnaA, genes were 
amplified using primers containing attB sites (primers: RMR271,RMR272 [carD]; RMR275, 
RMR276 [whiB1]; RMR279, RMR280 [rpL28]; RMR283, RMR284 [dnaA]). The only difference for 
C-terminal tagging of Mtb genes was that the 5ʼ end primer contained a ribosome-binding site 
between the attB1 sequence and ATG start of the gene (primers: RMR273, RMR274 [carD], 
RMR277, RMR278 [whiB1], RMR281, RMR282 [rpL28], RMR285, RMR286 [dnaA]).  
 
The constitutively expressing GFP fusions, bearing the truncated C-termini of WhiB1 or CarD 
were generated using primers to amplify GFP, in which the reverse complement primer contained 
3ʼ end bases of carD or whiB1 (primers: RMR248, RMR249, RMR294, RMR295, RMR296, 
RMR298). These modified gfp PCR products were then digested with PacI and ClaI and ligated 
into the episomal plasmid pMV762(zeo), a gift from Meera Unnikrishnan, in which inserted 
products were regulated by the constitutive groEL promoter.   
 
The luciferase reporter to monitor whiB1 promoter activity was generated using stich PCR to 
ligate the 500 bp upstream of whiB1 (primers: RMR313, RMR310) to the firefly luciferase gene 
(primers: RMR311, RMR312). This fused construct was then digested with XbaI and HindII and 
ligated into pGH100A(hyg), a promoter-less plasmid that integrates into the chromosome at the 
Giles integration site.  
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Immunoblotting 
Total protein lysates were prepared from equivalent cell numbers (determined by OD600 values) 
using bead beating and immunoblot analysis was performed. For figure 3.1C, Mtb cultures were 
grown for the specified times from a starting OD 0.05, in the presence of 1.5 µg/mL ATc. For 
figure 3.2A, Mtb cultures were grown for 48 hours from a starting OD 0.02, in the presence or 
absence of 1.5 µg/mL ATc. In Figure 3.3, Msm cultures were grown to from starting OD 0.05 for 
3-18 hours in fresh medium with or without ATc. The primary polyclonal antibody anti-ClpP2 (gift 
from Olga Kandror and Alfred Goldberg) was used at a 1:10,000 dilution in 5% milk powder in 
TBS-T, and the primary monoclonal anti-myc (Sigma Aldrich) was used as specified by 
manufacturer. Detection was performed using secondary HRP conjugated antibodies (Pierce), 
and SuperSignal West Femto Chemiluminescent Substrate (ThermoScientific) according the 
manufacturerʼs protocol. In all cases, blots were reprobed with anti-RpoB (MyBiosource), or initial 
protein gels were stained with SimplyBlue SafeStain (Life Technologies), to ensure equivalent 
loading of samples. 
 
Fluorescence and Luminescence Measurements 
In order to measure the abundance of GFP fusion proteins, cultures within one experiment were 
normalized based on OD600 values, spun down to remove media, and resuspended in 100 uL of 
PBS in a clear bottom 96 well plate. For luminescence, cultures were normalized based on OD600 
values, and 150 uL of culture was used for measuring luciferase activity. 50 uL of Cell Culture 5X 
Lysis Reagent (Promega) was added to cultures, and samples were agitated for 10min on an 
orbital shaker, at room temperature. Next, 75 uL of Luciferase Assay Substrate (Promega) was 
added to each sample and directly taken for measurement. Fluorescence was measured at 
485/538 nm, and luminescence was measured at an exposure time of 10 milliseconds, by the 
Fluroskan Ascent FL plate reader (ThermoScientific). Results represent the median +/- standard 
deviation of biological replicates.  
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Quantitative PCR 
In Mtb and Msm, RNA was generated from equivalent of 20 mLs  of cells at OD600 0.5. Cultures 
were spun down, and subjected to bead beating (3X 45 sec each, 5 min on ice between pulses) 
after resuspension in TRIzol. After chloroform phase separation, genetic material was precipitated 
with isopropanol, resuspended in dH2O, and RNA was purified using RNeasy Mini Kit (Qiagen). 
To ensure no contamination from genomic DNA, purified RNA was subjected to an additional 
round of DNase digestion using the TURBO DNA-free Kit (Invitrogen). cDNA was created from 
isolated equal concentrations of RNA with the SuperScript III First Strand Synthesis System 
(Invitrogen). Quantitative PCR was performed with the SYBR FAST qPCR kit (Kapa Biosystems) 
using the Applied Biosystems 7500 Fast Real-Time PCR System. Primers for each gene were 
designed using Primer3 (http://frodo.wi.mit.edu/), to have a melting temp of 60°C and a product 
length of 100-120 bp. All experiments were done using biological replicates, and representative 
experiments are depicted +/- standard error of mean of technical replicates.  
 
Sample preparation, protein digestion, and peptide TMT labeling  
For Mtb proteomics, P750-clpP1P2DAS was diluted to a starting OD600 0.02 in 900 mLs of 7H9 
media. This culture was split into six 150 mL cultures, and 1.5 µg/mL ATc was added to three 
batches, while three were left to grow with induction. After 48 hours, cultures were spun down 
(10min, 4000rpm, 4°C) and washed 3X with PBS. Cultures were then resuspended in 1 mL Urea 
Lysis Buffer (8M urea in 50 mM Tris pH 8.2, 75 mM NaCl, 50 mM NaF, 50 mM !-
glycerophosphate, 1mM Na orthovanadate, Roche Complete EDTA-free Protease Inhibitor 
Cocktail tablets), and subjected to bead beating (3X 45 sec each, 5 min on ice between pulses). 
Cell lysates were spun down (10 min, 13,000rpm, 4°C), and samples were reduced with DTT 
(final concentration of 5 mM) for 30 min at 37°C. Samples were then alkylated with iodoacetamide 
(final concentration of 14 mM) for 30 min at room temperature in the dark. Adding an additional 5 
mM DTT and incubating samples at room temperature in the dark for 15 min quenched excess 
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iodoacetamide. To remove samples from the BL3-level facility, proteins were precipitated with 
20% trichloroacetic acid and incubated on ice for an hour. Proteins were pelleted by centrifugation 
(30 min, 13,000rpm, 4°C), and pellets were washed twice with acetone. Samples were 
resuspended in 8M urea, diluted, and protein amounts were quantified using a BCA assay 
(ThermoScientific).  
 
As the proteomics screen in Msm was performed prior to the development of MS3-based 
proteomics for TMT analysis, we performed MS2-based quantitation of TMT peptide signals. For 
Msm proteomics, Msm/pTet(OR)::HIV2pr and clpP2_ID Msm were diluted to a starting OD600 0.05 
in 450 mLs. ATc (100 ng/mL) was added to each strain, and cultures were divided into 150 mL 
batches. Samples were harvested at 0h, 5h, and 11h post addition of ATc, spun down (10min, 
4000rpm, 4°C), and washed 3X with PBS. Protein samples were prepared in a similar fashion as 
above, except no TCA precipitation was needed, and protein quantitation by the BCA assay was 
done prior to sample reduction and alkylation.  
 
Proteins isolated from Mtb and Msm were digested overnight with Lys-C (Wako) in a 1:100 
enzyme:protein ratio in 4M urea and 50 mM Tris-HCl (pH 8.2). Digests were acidified with formic 
acid to a pH of ~2-3, and subjected to C18 solid-phase extraction (Sep-Pak, Waters). Isobaric 
labeling of the peptides was accomplished with sixplex TMT reagents (Thermo Scientific). 
Reagents (0.8 mg) were dis- solved in 40 μl acetonitrile, and 10 μl of the solution was added to 
250 μg of peptides dissolved in 100 μl of 50 mM HEPES (pH 8.5). After 1 h at room temperature 
(22 °C), the reaction was quenched by adding 8 μl of 5% hydroxylamine. Half of each of the 
labeled reactions was pooled into one vial, and combined fractions were subjected to C18 solid-
phase extraction.  
 
Sample fractionation by high pH reverse phase and strong cation exchange 
chromatography  
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Fractionation of Mtb TMT-labeled peptides was performed by high pH reverse phase liquid 
chromatography. Briefly, the sample was resuspended in high pH buffer A (10 mM ammonium 
formate pH 8.5, 5% acetonitrile), and separated over a 4.6 mm X C-18 analytical HPLC column (5 
μm, 300 Å, Agilent). Separation involved a two-buffer (high pH buffers A and B) gradient from 0% 
to 20% high pH buffer B (10 mM ammonium formate pH 8.5, 96% acetonitrile) in 5 min at a flow 
rate of 0.8 ml min-1, followed by 20% to 45% high pH buffer B in 50 min at a flow rate of 0.8 ml 
min-1, followed by 45 to 100% high pH buffer B in 4 min at a flow rate of 0.8 ml min-1 using an 
Agilent 1100 quaternary pump outfitted with a degasser and a photodiode array detector (PDA) 
(Thermo Scientific). Samples were collected in 30-s increments into a 96-well plate and dried 
under vacuum. For even columns in the 96 well plate, wells A,C,E,G were combined into one 
fraction, while for odd columns, wells B,D,F,H were combined, resulting in 12 total fractions, 
which were dried under vacuum. Fractions were then redissolved with 1% formic acid, desalted 
by C18 solid phase extraction and re-dried under vacuum. 
 
Fractionation of Msm TMT-labeled peptides was performed by SCX chromatography. Briefly, the 
sample was resuspended in SCX chromatography buffer A (7 mM KH2PO4 (pH 2.6) and 30% 
acetonitrile) and separated over a 4.6 mm × 200 mm polysulfoethyl A HPLC column (5 μm, 200 Å, 
PolyLC). Separation involved a two-buffer (SCX chromatography buffers A and B) gradient from 0 
to 50% SCX chromatography buffer B (7 mM KH2PO4, 350 mM KCl (pH 2.6) and 30% 
acetonitrile) in 47 min at a flow rate of 0.9 ml min−1, followed by 50 to 100% SCX 
chromatography buffer A to buffer B in 4.5 min using an Agilent 1100 quaternary pump outfitted 
with a degasser and a photodiode array detector (PDA) (Thermo Scientific). Samples were 
collected in 30-s increments into a 96-well plate and dried under vacuum. Fractions were then 
redissolved with 1% formic acid and, based on the intensity from the SCX chromatographic UV-
light trace, combined into a total of 20 samples of similar peptide amount, which were desalted by 
C18 solid phase extraction and dried under vacuum. 
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Liquid chromatography electrospray ionization tandem mass spectrometry 
All proteomic methodology was adapted from a methods paper published on comparing MS2 to  
MS3 based quantitative proteomics using TMT isobaric labeling23. Briefly, all LC-MS2(MS3) 
experiments were performed on an LTQ Orbitrap Velos (Thermo Fischer Scientific) equipped with 
a Famos autosampler (LC Packings) and an Agilent 1100 binary high-pressure liquid 
chromatography (HPLC) pump (Agilent Technologies). Peptides were separated on a 100 μm 
inner diameter microcapillary column packed first with approximately 0.5 cm of Magic C4 resin (5 
μm, 100 Å, Michrom Bioresources) followed by 20 cm of Maccel C18AQ resin (3 μm, 200 Å, Nest 
Group). Separation was achieved by applying a 9–32% acetonitrile gradient in 0.125% formic acid 
over 150 min at ~300 nl min−1. Electrospray ionization was enabled through applying a voltage of 
1.8 kV through a polyetheretherketone (PEEK) junction at the inlet of the microcapillary column. 
 
The LTQ Orbitrap Velos was operated in data-dependent mode for both MS2 and MS3 methods. 
For the MS2 method, the survey scan was performed in the Orbitrap in the range of 300–1,500 
m/z at a resolution of 3 × 104, followed by the selection of the ten most intense ions (top 10) for 
HCD-MS2 fragmentation using a precursor isolation width window of 2 m/z. The automatic gain 
control (AGC) settings were 3 × 106 ions and 2.5 × 105 ions for survey and MS2 scans, 
respectively. Ions were selected for MS2 when their intensity reached a threshold of 500 counts 
and an isotopic envelope was assigned. Maximum ion accumulation times were set to 1,000 ms 
for survey MS scans and to 250 ms for MS2 scans. The normalized collision energy for HCD-MS2 
experiments was set to 45% at a 30-ms activation time. Singly charged ion species and ions for 
which a charge state could not be determined were not subjected to MS2. Ions within a 10 p.p.m. 
m/z window around ions selected for MS2 were excluded from further selection for fragmentation 
for 120 s. 
 
The survey MS scan settings were identical for the MS3 method, where the ten most intense ions 
were first isolated for ion trap CID-MS2 at a precursor ion isolation width of 2 m/z, using an AGC 
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setting of 2 × 103, a maximum ion accumulation time of 150 ms and wide band activation. Directly 
after each MS2 experiment, the most intense fragment ion in an m/z range between 110–160% of 
the precursor m/z was selected for HCD-MS3. The fragment-ion isolation width was set to 4 m/z, 
the MS3 AGC was 20 × 104 and the maximum ion time 250 ms. We chose an isolation width of 4 
m/z to avoid space charging in preliminary experiments with very high AGC settings for the MS3 
scan; but with the AGC set- tings used in the experiments described here, setting 2 or 4 m/z as 
the MS3 isolation width had a negligible effect on the results (data not shown). Normalized 
collision energy was set to 35% and 60% at an activation time of 20 ms and 50 ms for MS2 and 
MS3 scans, respectively. It is important to note that charge state screening has to be disabled to 
allow fragment ions to be selected for MS3; this setting nevertheless allows for charge state-
based exclusion of singly charged ions and ions for which no charge state was determined from 
MS2. 
 
Data processing: MS2 spectra assignment, data filtering and quantitative data analysis 
A suite of in-house–developed software tools was used to convert mass spectrometric data from 
the RAW file to the mzXML format, as well as to correct erroneous assignments of peptide ion 
charge state and monoisotopic m/z (ref. 13). We modified the ReAdW.exe to include ion 
accumulation time in the output during conver- sion to the mzXML file format 
(http://sashimi.svn.sourceforge. net/viewvc/sashimi/). Assignment of MS2 spectra was performed 
using the Sequest algorithm by searching the data against a protein sequence database 
containing all known translated proteins from either Mtb or Msm, and known contaminants such 
as porcine trypsin, and human keratin32. This forward (target) database component was followed 
by a decoy component including all listed protein sequences in reversed order. Searches were 
performed using a 50 p.p.m. precursor ion tolerance, where both peptide termini were required to 
be consistent with Lys-C specificity, while allowing up to two missed cleavages. Sixplex TMT tags 
on lysine residues and peptide N termini (+ 229.162932 Da) and carbamido- methylation of 
cysteine residues (+57.02146 Da) were set as static modifications, oxidation of methionine 
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residues (+ 15.99492 Da) as a variable modification. An MS2 spectral assignment false dis- 
covery rate of less than 1% was achieved by applying the target- decoy database search 
strategy33. Filtering was performed using a linear discrimination analysis method to create one 
combined filter parameter from the following peptide ion and MS2 spectra properties: Sequest 
parameters XCorr and ∆Cn, peptide ion mass accuracy and charge state, predicted low pH (2.7) 
in-solution charge of peptide and peptide length. Linear discrimination scores were used to assign 
probabilities to each MS2 spectrum for being assigned correctly and these probabilities were 
used to filter the dataset with an MS2 spectra assignment false discovery rate of less than 1% to 
obtain a protein identification false discovery rate of less than 1.5%34. 
 
For quantification, a 0.06 m/z window centered on the theoretical m/z value of each reporter ion 
was monitored for ions, and the intensity of the signal closest to the theoretical m/z value was 
recorded. Reporter ion intensities were denormalized by multiplication with the ion accumulation 
time for each MS2 or MS3 spectrum and adjusted based on the overlap of isotopic envelopes of 
all reporter ions. Intensity distributions of isotopic envelopes were as provided by the 
manufacturer. The total signal intensity across all peptides quantified were summed for each TMT 
channel, and all intensity values were normalized to account for potentially uneven TMT labeling. 
For MS3-based Mtb proteomics, the intensities for all peptides of a given protein were summed to 
derive an overall protein abundance value for each TMT signal. For MS2-based Msm proteomics, 
the overall protein abundance was calculated by taking the median intensity value of all peptides 
of that protein within each TMT channel. Hierarchical clustering using Pearsons correlational 
analysis was conducting using MultiExperiment Viewer (TM4 Microarray Software Suite)19.  
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Targeting Clp protease for the development of new antibiotics effective 
against Mycobacterium tuberculosis 
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Section 4.1 – Chapter Overview and Attributions 
Given its essentiality, and that genetic depletion of the enzyme had a rapid bactericidal effect, we 
believed Clp protease to be an attractive therapeutic target against Mycobacterium tuberculosis 
(Mtb). In this chapter, we partnered with collaborators who developed a series of !-lactone 
compounds that inhibit Clp protease in Staphylococcus aureus and Listeria monocytogenes. In 
these organisms, Clp is not required for in vitro growth, but is necessary for virulence, and so the 
!-lactones are currently being pursued as anti-virulence agents for Gram-positive pathogens. As 
Clp is essential for normal growth in mycobacteria, we wanted to evaluate their potential as 
traditional growth inhibitors in Mtb. One !-lactone, EZ120, had a superb killing profile, with an 
MIC of 1.6 µM and an MBC between 3-6 µM. Furthermore, we were able to show that EZ120 
inhibited ClpP1P2 proteolysis in an in vitro purified protein assay, and that the compound 
interacted with the enzyme complex in intact cells. Together, this evidence validates the !-
lactones as a potential class of antimycobacterials and Clp protease as a suitable target for more 
focused drug development.  
 
Attributions. I drafted the manuscript that forms this chapter, which we aim to submit shortly as a 
brief communications to Nature Chemical Biology. The article will be a joint first-authored piece, 
with my close collaborator, Evelyn Zeiler, who is a graduate student in the laboratory of Professor 
Stephan Sieber at the Technical University Munich.  The !-lactone compounds used in this study 
were synthesized and graciously provided by Evelyn (along with the detailed synthesis protocols 
below). I performed all MIC and MBC testing of the compounds in Mtb and Msm. I also conducted 
the in vitro and in vivo activity based protein profiling (ABPP) labeling experiments, and sent 
prepped samples to Evelyn who did the mass spectrometry workup and analysis. In vitro activity 
assays were carried out with tremendous help from Tatos Akopian, a senior scientist in the 
laboratory of Professor Alfred Goldberg. Finally, Evelyn performed the testing of !-lactone toxicity 
J774 mouse macrophages.  
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Section 4.2 – !-lactones kill Mycobacterium tuberculosis via inhibition of 
proteolysis by the essential Clp protease  
ABSTRACT 
Here, we show that !-lactones have potent activity against Mycobacterium tuberculosis (Mtb).  
These compounds inhibit proteolysis in vitro by the ClpP1P2 proteolytic core from Mtb, and 
interact with the protease in whole cells. Together, this data demonstrates that !-lactones exhibit 
a bactericidal effect in Mtb through inhibition of Clp protease, and suggests a unique mechanism 
of action compared to traditional protease suicide inhibitors. 
 
MAIN ARTICLE 
There is an urgent need to discover novel drugs with activity against Mycobacterium tuberculosis 
(Mtb), the causative agent of tuberculosis. Almost more troubling than the 1.3 million deaths 
annually1, is the significant proportion of mortality now caused by multi- and extremely-drug 
resistant strains (MDR-TB, XDR-TB). In 2010 alone, there was an estimated MDR-TB prevalence 
of 650,000, accounting for 150,000 deaths2. To make matters worse, totally-drug resistant 
infections have been documented3,4, and in the face of inadequate surveillance and ineffective 
drug regimens, these strains will surely proliferate. Chemotherapeutic options to deal with this 
challenge are limited; so much so that surgical intervention is now being employed, as was 
mandated in the pre-antibiotic era5. There are a few reports of drugs in clinical trials and lead 
candidates6, but there is still a significant need to identify small molecules that exploit novel 
pathways and can serve as starting points for new antimycobacterial drugs.  
 
In certain Gram-positive pathogens, such as Staphylococcus aureus, !-lactones have been found 
to abolish virulence through inhibition of Clp protease7. Though not essential for growth in defined 
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media, Clp is required for virulence factor production, presumably through proteolytic action on 
virulence-associated transcriptional repressors8. Beta-lactones had no MIC in S. aureus, but did 
phenocopy Clp depletion by abolishing secretion of several key virulence factors and severely 
attenuating virulence9. Furthermore, activity-based protein profiling (ABPP) using derivatized !-
lactones demonstrated that the compounds interacted with the ClpP proteolytic subunit.  
 
In bacteria, Clp is a compartmentalized protease found as a complex of proteolytic and ATPase 
subunits10. Canonically, the proteolytic core is a tetradecamer of ClpP subunits, each which 
possesses a serine-based catalytic triad. This core is governed by a hexameric ATPase complex 
that interacts with the apical surface of the tetradecamer and regulates substrate entry for 
proteolysis. In most organisms, Clp is dispensable for normal growth, but it has recently been 
found that the complex is required for normal growth of mycobacteria, and that genetic depletion 
of the protease had a rapid bactericidal effect11. 
  
To assess whether this divergent essentiality of Clp could be exploited to yield !-lactones as 
traditional growth inhibitors in mycobacteria, we first tested the ability of a panel of derivatives 
(FIGURE 4.1) to inhibit proteolysis by the enzyme in vitro. In Mycobacterium tuberculosis, the 
proteolytic tetradecamer has a unique structure, and is a heteromer of two distinct subunits ClpP1 
and ClpP2. We have previously reported the establishment of an in vitro Mtb ClpP1P2 peptidase 
assay12. Briefly, a small, di-peptide activator (Z-Leu-Leu) is added to equimolar ratios of ClpP1 
and ClpP2 and proteolysis is monitored by cleavage of a flurogenic peptide substrate with a C-
terminal aminomethylcoumarin group (Z-Gly-Gly-Leu-AMC). Incubation of the ClpP1P2 complex 
with a small panel of !-lactones revealed that two compounds, P1 and EZ120, significantly 
inhibited peptide hydrolysis at a concentration of 200 µM (FIGURE 4.2A). Inhibition was dose-
dependent, and plotting enzyme activity against drug concentration, revealed IC50 values of 10 
µM and 75 µM for P1 (FIGURE 4.2B) and EZ120 (FIGURE 4.2C), respectively.  
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In order to determine how the !-lactones interacted with the protease, we used alkyne-derivitized 
probe forms (EZ120P and P1, which was already derivatized) of the active compounds to label 
the tetradecamer in vitro (FIGURE 4.2D). The alkyne handle permitted us to append an azide-
rhodamine tag to the !-lactone probes via click chemistry (CC) after compound incubation with 
the purified proteins13. In vitro testing revealed that the probe EZ120P inhibited proteolysis to a 
similar degree as the parent compound, EZ120. SDS PAGE analysis revealed that EZ120P and 
P1 interacted with both ClpP1 and ClpP2. Labeling in vitro revealed three surprising findings. First, 
as the probes labeled individual preparations of ClpP1 and ClpP2 alone, it appears that 
heterotetradecameric formation is not required for !-lactone interaction. Second, the addition of 
activator appears to compete with !-lactone suggesting that the two may access the same site 
within the protease. The in vivo significance of the di-peptide activator is still disputed, but the 
presence of a mycobacterial specific activator of protease complex formation was suggested by 
our in vitro findings12 and the inability to reconstitute Mtb ClpP1P2 in Escherichia coli whole cells 
and extracts with ClpP1 and ClpP2 alone.  Third, the !-lactones were still able to bind ClpP1 and 
ClpP2 when serine in the catalytic triad was inactivated by alanine substitution. This was entirely 
unexpected as we believed the !-lactones to be suicide inhibitors that acted by irreversibly 
reacting with the active site serine. MS/MS analysis of the labeled complex revealed that the !-
lactones reacted with ClpP1 and ClpP2 at C58 and C105, respectively (FIGURE 4.2E, 4.3). 
Surprisingly, the nucleophilic serine in both subunits was unmodified. We believe this to be a 
specific interaction as other cysteines and nucleophilic residues in the ClpP1 and ClpP2 were not 
modified, and, furthermore, !-lactone incubation did have an effect on proteolysis suggesting that 
this modification had a functional consequence.   
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Figure 4.1 Structures of !-lactones used in this study.  
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Figure 4.2 !-lactones react with purified Mtb ClpP1 and ClpP2,and 
inhibit proteolysis in vitro 
(A) Inhibition of in vitro ClpP1P2 proteolytic activity on a fluorogenic 
peptide substrate was measured for a panel of !-lactones, at a concentration of 
200 µM. Inhibitory potential of each !-lactone is reported as a percent 
inhibition +/- standard deviation, which is the average loss of enzyme activity 
over triplicate runs in the presence of compound divided by the average 
activity in the absence of compound. (B) Inhibitory potential for !-lactone P1 
was assessed by determining ClpP1P2 activity on a fluorogenic peptide 
substrate (enzyme activity, RFU) as a function of drug concentration (µM). 
(C) Inhibitory potential for !-lactone EZ120, determined in the same manner 
as the compound P1. For (B) and (C), data are plotted as the average of 
triplicate runs +/- standard deviation. (D) Fluorescent SDS PAGE analysis of 
purified preparations of ClpP1, ClpP1S98A (ClpP1S), ClpP2, ClpP2S110A 
(ClpP2S), ClpP1P2, and ClpP1SP2S in the presence or absence of activator 
(denoted A), after incubation with EZ120P or P1 and click chemistry with a 
rhodamine-azide reagent. (E) ClpP1 and ClpP2 residues modified by !-
lactones were identified by MS/MS analysis of purified proteins incubated 
with the compound P1 (150 µM). Modified sites that were identified are 
boxed in orange, while the residues that comprise the catalytic triad are boxed 
in red.    
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Figure 4.3 MS/MS analysis of purified protease subunits incubated with 
compound P1 in vitro.  
MS2 spectra depicting the b and y ions for !-lactone modified peptides of 
ClpP1 (top left), ClpP1S98A (top right), ClpP2 (bottom left), and 
ClpP2S110A (bottom right). Spectra reveal that the !-lactone reactive 
residues are C54 and C105 in ClpP1 and ClpP2, respectively. 
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The inability of small molecules that exhibit promising activity in vitro to access the intracellular 
bacterial environment has largely thwarted drug discovery for novel antibiotics14. The permeability 
conundrum is especially pertinent for mycobacteria, which is largely resistant to many commonly 
used antibiotics due to a thick waxy-coat cell wall comprised of covalently linked peptidoglycan, 
arabinogalactan, and long chain fatty acids known as mycolic acids15. Having demonstrated an 
effect on ClpP1P2 proteolysis in vitro, we asked whether the !-lactones could penetrate 
mycobacterial defenses and access the essential protease in the bacterial cytoplasm. Minimum 
inhibitory concentration (MIC) determination of the !-lactones revealed that EZ120 effectively 
inhibited growth of mycobacteria with an MIC of 1.5 µM in Mtb and 50 µM Mycobacterium 
smegmatis (Msm), a fast-growing, non-pathogenic model organism, closely related to Mtb 
(FIGURE 4.4A). The most active !-lactone in vitro, P1, did not affect the growth of mycobacteria, 
nor did the open-ring amide form of EZ120, EZ612.  
 
Genetic depletion of the ClpP1P2 protease has a bactericidal effect in mycobacteria11. To 
determine if EZ120 phenocopied genetic perturbation and was also bactericidal in Mtb, we tested 
the compoundʼs ability to kill actively growing Mtb. Varying concentrations of EZ120 were 
incubated with cultures at an initial inoculum of 4X105 CFU/mL, and after three days the number 
of remaining viable bacteria in each culture was determined by plating for CFU/mL.  FIGURE 
4.4B reveals that EZ120 was potently bactericidal with nearly two logs of killing seen at 
concentrations as low as 3.125 µM, and no retrievable viable bacteria at 25 µM within three days. 
As a control, cultures exposed to varying concentrations of EZ612 revealed no effect on growth. 
The lack of an in vivo effect of EZ612 confirmed that the lactone moiety was critical for the activity 
of these compounds and further affirmed that the mechanism of action was related to irreversible 
interaction with nucleophilic amino acids. 
 
While the core structure of the compound appears to be important for killing in Mtb, multiple !-
lactones have also been reported as inhibitors of the eukaryotic proteasome16. Significant 
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inhibition of the eukaryotic proteasome and the resulting toxicity would undoubtedly limit the 
therapeutic potential of the !-lactones. MTT testing of EZ120 in J774 macrophages, revealed an 
IC50 of 325 µM for metabolic inhibition (FIGURE 4.4C), nearly 200 fold higher than the MIC of the 
compound in Mtb. Through robust determination of the therapeutic window of EZ120 will require 
further testing, this initial difference validates the pursuit of EZ120 as an initial hit for further 
development of a novel antimycobacterial compound.   
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Compound MIC Mtb (µM) 
MIC Msm 
(µM) 
EZ120 1.6 50 
EZ612 >200 >200 
E2 >200 >200 
P1 100 >200 
EZ120P 1.6 50 
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Figure 4.4 !-lactones are bactericidal in Mtb, and demonstrate a good 
therapeutic window.  
(A) Minimum inhibitory concentrations (MICs) were determined for a panel 
of !-lactones in Mtb and Msm, using the colorimetric resazurin microtiter 
assay. (B) !-lactones EZ120 and EZ612 were assessed for their ability to kill 
actively growing Mtb. A mid-log phase culture of Mtb was diluted to an 
inoculum of 4X105 CFU/mL (top dotted line) and incubated with a two-fold 
serial dilution of each lactone. After 3d, cultures were plated to determine 
viable bacteria, represented by CFU/mL. Data points are the average growth 
among biological replicates +/- standard deviation. (C) Cytotoxicity of EZ120 
was measured in mouse macrophages (J774), using the MTT assay. Data 
points are represented as the average metabolic activity of biological 
triplicates +/- standard deviation.  
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Though EZ120 inhibited ClpP1P2 proteolysis in vitro, this was not conclusive evidence that the !-
lactones exhibited the same effect in vivo. We were encouraged to pursue in vivo determination 
of the target based on the finding that EZ120P had a similar MIC in Mtb as the parent compound 
EZ120. Therefore, we turned to in situ ABPP experiments to identify the proteins that the active !-
lactones interacted with in intact cells (FIGURE 4.5A). Incubation of Mtb and Msm with EZ120P 
followed by cell lysis and click chemistry to append a rhodamine-bioitin-azide to !-lactone 
modified proteins showed that the !-lactones interacted with a variety of proteins in vivo (FIGURE 
4.5B). Streptavidin-based purification of tagged proteins, followed by MS/MS identification of 
major protein bands revealed that EZ120P bound several deyhdrogenases, an "/!-hydrolase and 
ClpP1P2 in Msm (FIGURE 4.5C). Interestingly, the only essential proteins, as determined by 
genome wide transposon mutagenesis (Dragset et al, unpublished data), that we identified 
through in situ ABPP in Msm were ClpP1 and ClpP2. As one would expect that growth inhibition 
results from the inhibition of essential gene products, the presence of multiple !-lactone non-
essential interacting proteins could be largely ignored. Further affirmation of Clp as the target of 
!-lactones resulted from identifying that the only overlapping band between Mtb and Msm, which 
are both sensitive to EZ120, was ClpP1.   
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B 
Protein Protein ID 
MW 
(kDa) 
Sequence 
Coverage 
(%) 
Max 
Xcorr 
Num. 
peptides Essential? 
Eptc-inducible 
aldehyde 
dehyrdogenases 
A0QSN7/
A0QQW5  
55.94/
55.09 47.5/37.9 5.64/6.14 15/12 No 
Alcohol 
dehydrogenase A0QU52 33.87 60.5 6.94 14 No 
!,"-hydrolase A0R0N6 33.89 33.8 5.03 6 No 
ClpP2/ClpP1 A0R198/A0R197 
21.84/
24.05 41.9/9.6 6.18/2.91 5/2 Yes 
C Mycobacterium smegmatis 
Mycobacterium tuberculosis 
Protein Protein ID 
MW 
(kDa) 
Sequence 
Coverage 
(%) 
Max 
Xcorr 
Num. 
peptides Essential? 
ClpP1 P0A526 21.69 42.5 5.56 5 Yes 
A 
Figure 4.5 Activity based protein profiling (ABPP) in situ demonstrates 
that EZ120P reacts with the Clp proteolytic core in Msm and Mtb.  
(A) Schematic outline of ABPP experiments conducted to determine EZ120P 
interacting proteins in situ in Mtb and Msm. (B) Fluorescent SDS-PAGE 
analysis of the Mtb (left) and Msm (right) proteomes after in situ labeling 
with EZ120P, cell lysis, and click chemistry with a rhodamine-bioitin-azide 
reagent. (C) After click chemistry, samples were purified by streptavidin pull-
down, and streptavidin-bound proteins were identified by MS/MS analysis. 
Major proteins from each band are denoted in (B), and details regarding 
MS/MS identification as well as essentiality of !-lactone interacting proteins 
are given in the table.  
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It is puzzling that Mtb in situ ABPP did not reveal an interaction with both ClpP1 and ClpP2. Even 
in Msm, EZ120P appeared to have a stronger affinity for ClpP1 compared to ClpP2. This in vivo 
preference may be reflected by our in vitro findings in Figure 4.2D, where equal amounts of 
protein and compound reveal that the !-lactones more strongly label ClpP1. There are some key 
differences in the protein sequence of ClpP1 and ClpP2, and these may translate to structural 
differences that could explain the preference of the !-lactones for ClpP1.  
 
Given that certain !-lactones have been found to inhibit the eukaryotic proteasome, it is plausible 
that EZ120 may covalent modify the active site of the Mtb proteasome. We believe this is not the 
case, as none of the major or minor bands in Mtb or Msm analyzed by MS/MS corresponded to 
the proteasome subunits. Furthermore, evidence has emerged that proteolysis by the proteasome 
is dispensable for cell survival17, and so inhibitors of the Mtb proteasome would not likely have 
the bactericidal effect observed with EZ120.  
 
Several significant questions remain regarding the targeting of the ClpP1P2 proteolytic core by 
the !-lactones. How does the non-canonical !-lactone interaction result in ClpP1P2 inhibition and 
bacterial death ultimately? Our finding of discrete bands upon in situ ABPP further confirmed the 
specificity of this non-canonical !-lactone interaction with ClpP1 and ClpP2. The locations of 
these interactions reveal that they may block access of proteins and peptides to the active site or 
crowd the active sites and prevent substrate access to the catalytic residues. However, the 
absence of any structural information on the ClpP1P2 complex is limiting, and in order to 
determine this definitively, crystal structures of the !-lactones in complex with the tetradecamer 
must be solved. Visualization of the !-lactones with the ClpP1P2 complex would also elucidate 
potential reasons for the differential affinity of the compounds for ClpP1 compared to ClpP2.  
 
In summary, we believe that the combination of in vitro enzyme activity and in situ activity based 
profiling, used here for the first time in Mtb, reveal that !-lactones exhibit a potent, bactericidal 
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effect through inhibition of the ClpP1P2 protease. Work is still needed to elucidate the mechanism 
of the non-canonical interaction we have observed, but these findings (along with the lack of 
toxicity in eukaryotic cell lines) validate for the first time the !-lactones and the essential 
mycobacterial Clp protease as the ideal therapeutic agent and target for the development of 
severely-needed antibiotics effective against Mycobacterium tuberculosis.  
 
MATERIALS AND METHODS 
 
Synthesis of the EZ120 probe (EZ120P) and EZ612 
All chemicals were of reagent grade or better and used without further purification. Chemicals and 
solvents were purchased from Sigma Aldrich and Acros Organics. For all reactions, only 
commercially available solvents of purissimum grade, dried over molecular sieve and stored 
under argon atmosphere were used. Solvents for chromatography and workup purposes were 
generally of technical grade and purified before use by distillation. Temperatures were measured 
externally. All experiments were performed under nitrogen or argon atmosphere. Column 
chromatography was performed on silica gel (Merck, 0.035–0.070 mm, mesh 60 Å). For TLC 
analysis, Merck TLC silica gel 60 F254 aluminium sheets were used. Preparative HPLC was 
performed on a Waters 2998 system with a XBridge Prep C18 column (5 μm, 30 x 150 mm) or a 
YMC-Triart C18 column (5 μm, 10 x 250 mm).1H NMR and 13C NMR spectra were recorded on a 
Varian NMR-System 600 or 300 (600 MHz, 300 MHz), a Bruker AV 500 or AV 360 (500 MHz, 
360 MHz) and referenced to the residual proton and carbon signal of the deuterated solvent, 
respectively. HRMS (ESI) was obtained by a LTQ-FT from Thermo Scientific.  
 
The compounds EZ12018, U1, U1P19, P1, and E220 were synthesized as described before. 
 
The β-Lactone EZ120P was prepared according to a method developed by Danheiser and 
Novick21 and as applied before9,18,20.  
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2,5-Dioxopyrrolidin-1-yl 4-(N,N-dimethylamino)benzoate (1) EZ100 
 
4-(N,N-Dimethylamino)benzoic acid (332 mg, 2.00 mmol), N-hydroxysuccinimide (244 mg, 
2.10 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, (EDAC) (402 mg, 2.1 mmol) 
were suspended in CH2Cl2 (10 mL). After 20 min the suspension became a clear violet solution. 
The reaction mixture was monitored by TLC (iso-hexane/ethyl acetate 1:1, 1% AcOH, Rf = 0.30) 
and the reaction was completed after 2.5 h. Then water (10 mL) was added and the aqueous 
layer was extracted with dichloromethane (2 x 10 mL). The combined organic layers were washed 
with brine (10 mL), dried over MgSO4 and the solvent was removed under reduced pressure to 
yield 451 mg (86%) of 1 as a white solid. − Mp 181 °C. − 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J 
= 9.1 Hz, 2 H, Harom), 6.67 (d, J = 9.2 Hz, 2 H, Harom), 3.09 (s, 6 H, N(CH3)2), 2.89 (s, 4 H, 
(CH2)2). − 13C NMR (75 MHz, CDCl3) δ 169.83, 161.92, 154.41, 132.55, 110.81, 110.65, 39.98, 
25.70. – IR (film) ν = 1735 cm-1, 1604, 1535, 1436, 1375, 1269, 1248, 1207, 1182, 1070, 1012, 
979, 944, 825, 755. − HRMS (ESI) calcd. for C13H15N2O4 [M+H]+ 263.1032, found 263.1028. The 
spectral data are identical to those published in literature22. 
 
4-(N,N-Dimethylamino)-Nʼ-(6-hydroxyhexyl)benzamide (2) EZ108 
 
To a stirred solution of 2,5-dioxopyrrolidin-1-yl 4-(N,N-dimethylamino)benzoate (1) (850 mg, 
3.24 mmol) in acetonitril/water 1:1.2 (11 mL) was added NEt3 (2.72 mL, 19.7 mmol) and 6-amino-
1-hexanol (380 mg, 3.24 mmol). The reaction was monitored by TLC (ethyl acetate, Rf = 0.24) 
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and was completed after 30 min. Then the mixture was extracted with ethyl acetate (3 x 40 mL), 
the combined organic layers were washed with brine (10 mL) and dried over MgSO4. Purification 
by flash column chromatography on silica yielded 368 mg (43%) 4-(N,N-dimethylamino)-Nʼ-(6-
hydroxyhexyl)benzamide (2) as white solid. − Mp 101 °C. − 1H NMR (360 MHz, CDCl3) δ 7.69 (d, 
J = 8.8 Hz, 2 H, Harom), 6.66 (d, J = 8.9 Hz, 2 H, Harom), 6.25 (bs, 1 H, NH), 3.62 (t, J = 6.3 Hz, 
2 H, NHCH2), 3.42 (m, 2 H, CH2OH), 3.00 (s, 6 H, N(CH3)2), 2.23 (bs, 1 H, OH), 1.67–1.51 (m, 4 
H), 1.48−1.33 (m, 4 H). − 13C NMR (91 MHz, CDCl3) δ 167.55, 152.39, 128.29, 121.52, 111.09, 
62.58, 45.82, 40.12, 39.62, 26.53, 8.60. – IR (film) ν = 3318 cm-1, 2926, 2856, 2816, 1747, 1684, 
1604, 1549, 1513, 1444, 1412, 1364, 1328, 1300, 1230, 1204, 1173, 1131, 1061, 946, 925, 872, 
829, 807, 768. – HRMS (ESI) calcd. for C15H25N2O2 [M+H]+ 265.1916, found 265.1907. 
 
4-(N,N-Dimethylamino)-Nʼ-(6-oxohexyl)benzamide (3) EZ112 
 
To a solution of oxalyl chloride (60 μL, 0.72 mmol) in CH2Cl2 (2 mL) was added at −78 °C DMSO 
(102 μL, 1.44 mmol), 4-(N,N-dimethylamino)-Nʼ-(6-hydroxyhexyl)benzamide (2) (159 mg, 
0.60 mmol) in CH2Cl2 (3 mL) and NEt3 (460 μL, 3.30 mmol). The reaction mixture was stirred at 
−78 °C for 5 h and was then warmed up to −5 °C. After work up and flash column 
chromatography on silica (iso-hexane/ethyl acetate 1:2) 103 mg (65%) of the product 3 was 
obtained as white solid, Rf = 0.27. − Mp 66 °C. − 1H NMR (300 MHz, CDCl3) δ 9.77 (t, J = 1.7 Hz, 
1 H, CHO), 8.02–7.43 (m, 2 H, Harom), 6.71–6.65 (m, 2 H, Harom), 6.15 (bs, 1 H, NH), 3.45 (td, J 
= 7.0, 6.0 Hz, 2 H, NHCH2), 3.02 (s, 6 H, N(CH3)2), 2.46 (td, J = 7.2, 1.7 Hz, 2 H, CH2CHO), 1.75–
1.57 (m, 4 H, (CH2)2), 1.49–1.35 (m, 2 H, CH2). − 13C NMR (75 MHz, CDCl3) δ 202.55, 167.46, 
152.36, 128.30, 121.53, 111.13, 43.74, 40.16, 39.50, 29.62, 26.45, 21.65. – IR (film) ν = 3335 
cm-1, 2922, 2859, 2818, 1717, 1685, 1607, 1542, 1513, 1444, 1411, 1363, 1328, 1299, 1229, 
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1203, 1173, 1134, 1064, 993, 946, 829, 768, 732. − HRMS (ESI) calcd. for C15H23N2O2 [M+H]+ 
263.1760, found 263.1755. 
 
S-Phenyl-10-undecyne thioate (4) EZJS15 
 
To a solution of 10-undecynoic acid (1.00 g, 5.49 mmol) in CH2Cl2 (28 mL) was added thiophenol 
(840 μL, 8.23 mmol), DCC (1.25 g, 6.06 mmol), and DMAP (67 mg, 0.55 mmol) and the reaction 
mixture was stirred for 16 h. The remaining precipitate was filtered off and the residue was 
washed with CH2Cl2 (50 mL). The solvent was removed under reduced pressure and purification 
by flash column chromatography on silica (hexane/ethyl acetate 25:1) afforded 1.15 g (76%) of 
the product 4 as a colourless oil, Rf = 0.50. − 1H NMR (360 MHz, CDCl3) δ 7.43 (s, 5H), 2.67 (t, J 
= 7.5 Hz, 1H), 2.21 (td, J = 7.0, 2.7 Hz, 2H), 1.96 (t, J = 2.6 Hz, 1H), 1.73 (p, J = 7.3 Hz, 2H), 1.62 
– 1.48 (m, 2H), 1.48 – 1.28 (m, 5H). − 13C NMR (91 MHz, CDCl3) δ 197.50 , 134.47 , 129.28 , 
129.14 , 84.69 , 68.13 , 43.69 , 29.10 , 28.88 , 28.86 , 28.65 , 28.42 , 25.55 , 18.39 . − IR (film) ν 
= 2927 cm-1, 2854, 1704, 1583, 1478, 1457, 1441, 1327, 1139, 1105, 1067, 1023, 962, 743, 705, 
688. − HRMS (ESI) calcd. for C17H23OS [M+H]+ 275.14696, found 275.14637. The spectral data 
are identical to those published in literature19. 
 
(3R*,4R*)-4-(4-(N,N-Dimethylamino)benzamido-5-pentyl)-3-(non-8-ynyl)oxetan-2-one 
(EZ120P) 
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A solution of diisopropylethylamine (122 μL, 0.863 mmol) in THF (7 mL) was cooled in an ice bath 
to 0 °C and under stirring n-butyllithium (540 μL, 0.863 mmol, 1.6 M in hexane) was gradually 
added via a syringe. The reaction mixture was stirred for 30 min at 0 °C. Then the ice bath was 
replaced with an acetone/dry ice bath and the mixture was cooled to −78 °C. A solution of S-
phenyl-10-undecyne thioate (4) (189 mg, 0.690 mmol) in THF (4 mL) was injected dropwise over 
15 min. After stirring the mixture at −78 °C for 2.5 h a solution of 4-(N,N-dimethylamino)-Nʼ-(6-
oxohexyl)benzamide (3) (181 mg, 0.690 mmol) in THF (3 mL) was added drop wise over 1 h via a 
syringe that was externally cooled by an aluminium funnel filled with dry ice. The reaction mixture 
was stirred for 2 h while gradually warmed up to 0°C. Then half saturated NH4Cl solution (15 ml) 
was added and the mixture was diluted with ethyl acetate (50 ml). The aqueous layer was 
extracted with ethyl acetate (3 x 50 ml) and the combined organic layers were washed with 
K2CO3 solution (10%, 5 mL) and brine (5 ml) and dried over MgSO4. The solvent was removed 
under reduced pressure to give 368 mg of crude product as yellow oil. Purification by flash 
column chromatography on silica (hexane/ethyl acetate 8:5) yielded 48 mg (16%) of the product 
as colourless oil, Rf = 0.14. − 1H NMR (500 MHz, CDCl3) δ 7.69 (d, J = 9.0 Hz, 2H), 6.70 (d, J = 
9.0 Hz, 2H), 6.01 (t, J = 6.0 Hz, 1H), 4.24 (ddd, J = 7.6, 5.7, 4.0 Hz, 1H), 3.47 (qd, J = 7.0, 1.2 Hz, 
2H), 3.19 (ddd, J = 8.6, 6.7, 4.0 Hz, 1H), 3.04 (s, 6H), 2.21 (td, J = 7.1, 2.6 Hz, 2H), 2.02 – 1.92 
(m, 1H), 1.92 – 1.71 (m, 4H), 1.71 – 1.30 (m, 16H). − 13C NMR (91 MHz, CDCl3) δ 171.48, 167.43, 
152.41, 128.25, 121.40, 111.08, 84.62, 77.96, 68.18, 56.18, 40.14, 39.60, 34.36, 29.74, 29.14, 
28.76, 28.55, 28.36, 27.83, 26.89, 26.59, 24.87, 18.35. − IR (film) ν = 2931 cm-1, 2857, 1812, 
1608, 1540, 1511, 1445, 1363, 1297, 1204, 1173, 1126, 1065, 947, 874, 830, 768, 743. − HRMS 
(ESI) calcd. for C26H39N2O3 [M+H]+ 427.2961, found 427.2952. 
 
(6R*,7R*)-N-(7-Carbamoyl-6-hydroxy-hexadec–15–ynyl)–4–dimethylamino-benzamide 
(EZ612) 
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A solution of (3R*,4R*)-4-(4-(N,N-Dimethylamino)benzamido – 5 - pentyl) – 3 - (non-8-
ynyl)oxetan-2-one (EZ120P) (11 mg, 0.025 mmol) in 7 N NH3/MeOH (1 mL) was stirred at rt for 
1.5 h. The solvent was removed under reduced pressure and purification by flash column 
chromatography on silica (Ethyl acetate) yielded 6.2 mg (54%) of a white solid, Rf = 0.18. − Mp 
93 °C. − 1H NMR (360 MHz, CDCl3) δ 7.67 (d, J = 8.9 Hz, 2H, Harom), 6.68 (d, J = 8.9 Hz, 2H, 
Harom), 6.62 (s, 1H, NH2CO), 6.09 (t, J = 6.0 Hz, 1H, NHCO), 5.42 (s, 1H, NH2CO), 3.68 – 3.41 
(m, 5H, CHOH, OH, CH2NH), 3.04 (s, 6H, N(CH3)2), 2.29 – 2.22 (m, 2H), 2.18 (td, J = 7.1, 2.7 Hz, 
2H, CH2−#), 1.95 (t, J = 2.7 Hz, 1H, #−H), 1.82 – 1.20 (m, 18H). − 13C NMR (91 MHz, CDCl3) δ 
178.12, 167.74, 152.48, 128.26, 121.10, 111.08, 84.75, 71.78, 68.10, 50.20, 40.12, 38.66, 35.78, 
30.51, 29.65, 29.55, 28.94, 28.69, 28.44, 27.49, 25.75, 24.86, 18.38. − HRMS (ESI) calcd. for 
C26H42N3O3 [M+H]+ 444.32262, found 444.32192. 
 
Bacterial strains and growth experiments 
For all drug assays, Msm mc2155 and Mtb H37Rv were grown at 37°C in Sautonʼs medium 
supplemented with 0.05% Tween 80. Per 1000 mL, Sautonʼs medium contains KH2PO4 (0.5 g), 
MgSO4-7H2O (0.5 g), citric acid (2.0 g), ferric ammonium citrate (0.05 g), glycerol (60 mL), 
asparagine (4.0 g), ZnSO4 (0.1 mL of 1% solution), and NaOH (to adjust pH to 7.4).  
 
Minimum inhibitory concentrations (MIC) of the !-lactones in Mtb and Msm were determined 
using the colorimetric resazurin microtiter assay as described previously. Sautonʼs media was 
dispensed in each well of a sterile flat-bottom 96 well plate. In this media, !-lactones to be tested 
were serially diluted two-fold across the plate. Bacteria were diluted to a calculated OD600 0.003, 
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and equal volumes of culture were added to the media containing the serially diluted compounds. 
Plates were grown at 37°C for 24h (Msm) or 5d (Mtb). After the specified amount of time, 20 µL 
resazurin (0.05% w:v in dH2O) was added to each well, and plates were placed back at 37°C for 
12h (Msm) or 3d (Mtb). Growth and active metabolism by bacteria is reflected by the reduction of 
resazurin, a blue non-fluorescent dye, to resorufin, a pink highly fluorescent dye. MICs for each !-
lactone were defined as the highest drug concentration that resulted in no color change upon the 
addition of resazurin. Prior to testing, !-lactones were tested for their ability to alter the color of 
resazurin, and were found to have no effect on the dye for the duration of Mtb and Msm 
experiments.  
 
Minimum bactericidal concentrations of EZ120 and EZ612 in Mtb were determined by incubating 
various concentrations of !-lactones in 200 µL culture at an OD600 0.002. After 4d, cultures were 
serially diluted ten-fold and plated to determine colony forming units per mL (CFU/mL).  
 
Purification of Mtb ClpP1 and ClpP2 
For all in vitro experiments, Mtb ClpP1, ClpP2, ClpP1S98A, and ClpP2S110A were purified as 
described previously. Briefly, subunits were individually expressed in Msm on an episomal, 
tetracycline (ATc)-inducible plasmid. Cultures were grown up to mid-log phase, induced with ATc 
(100 ng/mL) overnight, and the collected. Frozen cells (typically 5-10 g) were suspended in two 
volumes of buffer A (100 mM KCl, 5 mM MgCl2, !-mercaptoethanol, 10% glycerol in 50 mM 
potassium phosphate buffer, pH 7.6) and broken by French press at 1500 p.s.i. Extracts were 
centrifuged at 100,000g for 1h and supernatant was mixed with 5 mL Ni-NTA agarose (Qiagen) 
previously equilibrated in buffer A. Resin was incubated with lysate for 4h at 4°C, and then 
transferred to an empty column. Proteins were eluted using a step gradient of imidazole (0, 25, 50, 
100 and 200 mM) in buffer B (100 mM KCl, 5 mM MgCl2, 5% glycerol in 50 mM potassium 
phosphate buffer, pH 7.6). Fractions containing near homogenous proteins were combined, 
concentrated on MWCO 10,000 cut filter (Millipore), and purified further by gel filtration on a 
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Sephacryl S-300 column (1.5 X 12 cm) equilibrated with buffer B. Samples were concentrated to 
2-5 mg/mL and stored at -80°C.  
 
In vitro enzyme activity assay 
Activity of the ClpP1P2 complex was measured as described previously. All assays were 
performed at 37°C in a 96-well plate using the SpectraMax M5 Plate Reader (Molecular Devices). 
!-lactones were added to 0.3-3 µg ClpP1P2 (equimolar ratios of ClpP1 and ClpP2) and 5 mM 
activator (Z-Leu-Leu) in 80 µL of activity buffer (100 mM KCl, 5% glycerol in 50 mM potassium 
phosphate buffer, pH 7.6).  After 10 min pre-incubation at room temperature, 50 µM fluorescent 
peptide substrate (Z-Gly-Gly-Leu-amc) was added to each reaction, plates were shaken for 20s, 
and then peptidase activities were assayed at 37°C by continuously monitoring the rate of 
production of fluorescent 7-amino-4-methylcoumarin (amc) from the flurogenic peptide substrate 
at 460 nm (Ex at 380 nm). All assays were performed in triplicate.  
 
In Vitro Labeling Experiments 
Protein samples were adjusted to a final concentration of 0.04 mg protein/mL by dilution in buffer 
B (100 mM KCl, 5 mM MgCl2, 5% glycerol in 50 mM potassium phosphate buffer, pH 7.6) prior to 
probe labelling. Analytical experiments were carried out in 43 μL total volume, such that once CC 
reagents were added, the total reaction volume was 50 μL. Reactions were initiated by addition of 
150 μM probe (1 μL, 7.5 mM stock in DMSO) and allowed to incubate for 1 h at room temperature. 
The samples (43 μL) were then subjected to CC and SDS-PAGE analysis as described further. 
 
In Situ Labeling Experiments 
For analytical and preparative in situ studies, bacteria were grown in Sautonʼs medium and 
harvested at an OD600 between 1.0 and 3.0 by centrifugation at 6000 g. 3 mL of culture were 
harvested for analytical and 15 mL for preparative studies, respectively. The cells were washed 
with PBS (1 mL) and resuspended in 100 and 500 μL of PBS for analytical and preparative 
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experiments. Unless indicated otherwise, bacteria were incubated for 2 h with 150 μM probe at 
room temperature for analytical preparative studies. Subsequently, the cells were washed with 
PBS (3 x 1 mL) and lysed by bead beating (MP Biomedicals, 4 x 30 sec, 5min on ice between 
each round) in 100 and 500 μL of PBS for analytical and preparative experiments respectively. 
The proteomes were subjected to CC and SDS-PAGE analysis as described further.  
 
Click Chemistry (CC) and Target Identification 
Reactions for preparative enrichment were carried out together with a control lacking the probe to 
subtract unspecific background protein binding on avidin-agarose beads in the final MS results of 
the biotin-avidin-enriched samples. To 43 μL of the probe pre-incubated protein/proteome 
samples were added the reporter-tagged azide reagents rhodamine-azide (100 μM, 1 μL of 5 mM 
stock in DMSO) for analytical or rhodamine-biotin-azide (50 μM, 2.5 μL of 10 mM stock in DMSO) 
for preparative scale, followed by tris(2-carboxyethyl)phosphine hydrochloride (1 mM, 1 μL for 
analytical or 0.5 mM, 5 μL for preparative scale of 52 mM stock in H2O) and as ligand tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl] amine (100 μM, 3 μL for analytical or 50 μM, 15 μL for 
preparative scale of 1.7 mM stock in tert-BuOH/DMSO 4.4:1). Samples were gently vortexed, and 
the 1,3-dipolar cycloaddition was initiated by the addition of CuSO4 (1 mM, 1 μL for analytical or 
0.5 mM, 5 μL for preparative scale of 50 mM stock in H2O). The reactions were incubated at room 
temperature for 1 h13,20,23. For analytical gel electrophoresis (SDS-PAGE), 50 μL of 2×SDS 
loading buffer was added, the samples were heated at 96 °C for 20 min for Mtb samples and 6 
min for Msm samples, and 50 μL were applied on the gel. For preparative scale proteins were 
precipitated after CC using an equal volume of pre-chilled acetone (500 μL). The samples were 
then stored on ice for 20 min and centrifuged at 13000 rpm for 20 min. The supernatant was 
discarded, and the pellet was washed with pre-chilled methanol (2 x 200 μL) and resuspended by 
sonication (Bandelin Sonopuls, 5 sec, 20%). Subsequently, the pellet was dissolved in 0.4% SDS 
in PBS (1 mL) by sonication and incubated under gentle mixing with 50 μL of washed avidin-
agarose beads (Sigma-Aldrich) for 1 h at room temperature. The beads were washed with 0.4% 
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SDS in PBS (3 x 1 mL), with urea (2 x 1 mL, 6 M) and with PBS (3 x 1 mL). 50 μL of 2×SDS 
loading buffer were added to the beads and the proteins released for preparative SDS-PAGE by 
20 min incubation for Mtb samples and 6 min incubation for Msm samples at 96 °C. Fluorescence 
was recorded in a Fujifilm Las-4000 luminescent image analyzer with a Fujinon VRF43LMD3 lens 
and a 575DF20 filter. Gel bands were isolated, washed, and tryptically digested as described 
previously24. 
 
Mass Spectrometry and Bioinformatics 
Tryptic peptides were loaded onto a Dionex C18 Nano Trap column (100 μm) and subsequently 
eluted and separated by a Dionex C18 PepMap 100 (3 μm) column for analysis by tandem MS, 
followed by high resolution MS using a coupled Dionex Ultimate 3000 LC Thermo Finnegan LTQ-
FT MS system. The mass spectrometry data were searched using the SEQUEST algorithm 
against the corresponding databases via the software “Proteome Discoverer 1.3”. The search 
was limited to only tryptic peptides, two missed cleavage sites, monoisotopic precursor ions, and 
a peptide tolerance of <10 ppm. Filters were set to further refine the search results. The Xcorr vs 
charge state filter was set to Xcorr values of 1.5, 2.0, and 2.5 for charge states 1+, 2+, and 3+, 
respectively. The number of different peptides has to be ≥2, and the peptide probability filter was 
set to <0.001. These filter values are similar to others previously reported for SEQUEST 
analysis25. Maximum Xcorr values of each run as well as the total number of obtained peptides are 
reported in FIGURE 4.5D. Comparison of labelling with genetic properties and characteristics of 
the species was conducted by BLAST search for homologous sequences in the strains.  
 
Binding Site Identification 
To discover the binding site of ClpP1 and ClpP2, a 1:1 mixture of both enzymes as well as a 1:1 
mixture of the active serine mutants (ClpP1-S98A, ClpP2-S110A) was incubated with probe P1 
and after chymotryptic digestion the peptide fragments were analyzed by MS. First, 0.68 μg of 
Protein in 17 μL buffer B (100 mM KCl, 5 mM MgCl2, 5% glycerol in 50 mM potassium phosphate 
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buffer, pH 7.6) was incubated for 1 h at room temperature with 150 μM of P1. The buffer was 
exchanged and adjusted to 25 mM NH4HCO3, giving a total volume of 100 μL. For digestion with 
chymotrypsin (sequencing grade, Roche Diagnostics) 1 mM CaCl2 was added prior and after 
addition of 250 ng chymotrypsin the samples were incubated for 18 h at room temperature. The 
samples were dried, solved in 100 μL 0.1% formic acid and analyzed by LC-MS with MS-MS and 
high-resolution mass spectra. The spectra of the modified peptides are shown in FIGURE 4.3.  
 
Determination of cytotoxicity / MTT assay  
The cytotoxicity of the compound EZ120 against mouse macrophages (J774) was measured 
using the MTT test (Sigma-Aldrich). The principle of the MTT assay consists in the reduction of 
the tetrazolium compound MTT by metabolically active cells to insoluble purple formazan dye 
crystals as a measure of cells viability. Cells were cultured in DMEM low glucose supplemented 
with 10% FCS gold (PAA). Cells from subconfluent cultures were used for the assay. In a 96well 
flat-bottom plate (Nunclon) 1·104 cells were plated in 100 μL medium and cultured for 24 h to 
obtain 40% confluent cultures. The compound was diluted 1:100 from DMSO stocks of various 
concentrations in 100 μL of culture medium and added to the cells after careful removal of the 
blank medium. After 24 h incubation, 20 µL of MTT substrate solution (5 mg/ml in PBS) were 
added and the cells were incubated for 2 h. The medium was discarded and the cells were lysed 
in 200 μL DMSO. The complete dissolution of the formazan salt was determined and the optical 
density measured at 570 nm (background subtraction at 630 nm). The assay was performed in 
triplicates. 
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Section 5.1 – Clp protease as a critical regulator of growth and adaptation 
in mycobacteria 
It was initial inquiries into determining how bacteria dealt with abnormal proteins that led to the 
discovery and characterization of ATP-dependent protein turnover1. Since that time, the array of 
proteolytic complexes responsible for this turnover in bacteria has been extremely well 
characterized from a structural and biochemical perspective2,3. Numerous researchers have 
focused on developing an intricate picture of how these enzymes maintain quality control in the 
cell through the degradation of mislocalized, misfolded, and abnormal protein products4. What 
has become increasingly clear, however, is that the proteases also play a critical role in the 
coordination of cellular activity through the proteolysis of endogenous proteins. Many studies 
have shown an association (either directly or through mutational pathway analysis) between the 
protease and a particular protein, but deciphering the functional consequence of targeted protein 
degradation has been far more challenging5,6. It is often difficult to determine whether degradation 
of a particular protein is a passive process or an active one that is required for regulation. As 
numerous proteolytic complexes appear to be required for normal growth of Mycobacterium 
tuberculosis (Mtb), a divergence from most bacteria, the field of protease biology may have found 
an unlikely model organism in the slow-growing, persistent pathogen that causes nearly 1.3 
million deaths annually7. Depletion of these enzymes and accumulation of their substrates in Mtb 
should have a visible growth effect, and so identifying the proteins they degrade could uncover 
pathways that must be critically regulated through targeted protein turnover.  
 
It was in this ambitious hope that my thesis work was forged. We chose to work on the Clp 
proteolytic complex in mycobacteria for several reasons. First, genome wide-screens in Mtb 
suggested that all components of the complex (proteolytic core and ATPase adapter proteins) 
were absolutely required for growth8. This was strikingly different from most model organisms, like 
Escherichia coli and Bacillus subtilis, where Clp has been extensively studied but found to be 
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dispensable for vegetative growth9,10. Second, the genetic structure of Clp appeared to be 
different in mycobacteria, which appeared to encode two proteolytic subunit genes (clpP1 and 
clpP2) in a single operon, instead of the canonical single proteolytic subunit (clpP). This led to the 
question of whether Mtb had two functional Clp proteases or one enzyme made up of multiple 
proteolytic subunits.  
 
Partnering with skilled collaborators in the laboratory of Alfred Goldberg, where Clp was first 
discovered in E. coli in 1980s11, we epitope-tagged ClpP1 and ClpP2, showing that the proteins 
interacted intimately in vivo. Purifying the subunits and reconstituting activity in an in vitro 
peptidase assay further demonstrated that equimolar amounts of ClpP1 and ClpP2 were required 
for efficient proteolysis, and that neither subunit could support proteolysis individually. Together, 
this data suggested that ClpP1 and ClpP2 formed a single, proteolytic heterotetradecameric core 
in mycobacteria, denoted ClpP1P2. To validate the importance of these genes in vivo, I 
constructed conditional Clp protease mutants in Mycobacterium smegmatis (Msm). Both clpP1 
and clpP2 were independently required for growth, and deletion of either subunit resulted in rapid 
bacterial death. As depletion of a gene rarely leads to a bactericidal effect, this finding further 
stressed the central role of the mycobacterial Clp protease. In order to disrupt the ClpP1P2 
proteolytic core in Mtb, we constructed active site mutants of ClpP1, in which the serine 
responsible for peptide bond hydrolysis was mutated to an alanine. Expression of these mutant 
subunits had a visible (but slight) dominant negative effect on growth in vitro, presumably by 
displacing wildtype ClpP1 subunits from the heteromeric complex and reducing the efficiency of 
proteolysis. In contrast to the minor dominant negative effect in vitro, expression of the active site 
mutants profoundly reduced in vivo survival of Mtb in a mouse model of infection, leading us to 
believe that Clp protease has additional roles during infection and could be an important effector 
of virulence.  
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Having validated the stringent requirements of Clp protease, we next turned towards 
understanding the functional significance of the complex in mycobacteria. In E. coli, Clp is 
involved in the ribosome rescue pathway, through the degradation of SsrA-tagged peptides that 
are released from stalled ribosomes by the translation of a tmRNA substrate12. Using a 
conditional Msm mutant, in which the ClpP2 protein could be inducibly degraded, I showed that 
this general feature is conserved in mycobacteria. Clp appears to be generally important in 
maintaining protein quality control in the cell, as cells with suboptimal amounts of the protease 
were highly susceptible to antibiotics that induce mistranslation but showed no less susceptibility, 
when compared to wildtype bacteria, to agents that simply halt translation.  
 
Because the quality control functions of Clp protease are conserved across most bacteria, these 
studies did not necessarily move us towards understanding why Clp was divergently essential in 
mycobacteria. We hypothesized that the requirements of Clp protease for normal growth were 
tied to the endogenous proteins it was degrading. For example, if Clp degraded a toxic protein or 
a repressor of normal growth, then the accumulation of those substrates that occurred upon 
depletion of the protease would have a deleterious effect on the cell. This hypothesis was difficult 
to test, because we were not probing the function of an important protein when it was present, but 
rather the necessity of certain proteins to be absent, or actively removed from the cell. In order to 
identify the set of proteins whose Clp-dependent degradation might be important for cell survival, 
we turned to proteomic profiling of conditional Clp mutants in both Mtb and Msm, which revealed 
a slew of proteins that were over-represented in bacterial populations that lacked wildtype levels 
of the enzyme. Through a set of validation experiments, we provided multiple lines of evidence 
that the transcriptional repressor WhiB1 was a substrate of Clp protease.   
 
This observation was intriguing for multiple reasons. First, WhiB1 is an essential DNA-binding 
protein that is known to repress itʼs own transcription, and thought to act as a repressor at 
multiple operators13. Thus, we thought the essentiality of Clp protease could potentially be 
  153 
explained by its action on WhiB1, if elevated amounts of the repressor suppress transcription of 
these essential loci to a level that inhibits growth. Accordingly, blocking of Clp recognition of 
WhiB1 resulted in a degradation-deficient WhiB1 allele that was ultra-stable and toxic. Though 
hard to eliminate non-specific causes of fusion protein toxicity, we demonstrated that this allele 
was still functional as a transcriptional repressor and expression still exhibited a fitness cost even 
at physiological levels of protein expression. Second, deregulation of WhiB1 proteolysis could not 
be overcome by transcriptional control, suggesting that protein turnover was at least a co-
dominant modality of WhiB1 regulation. It is interesting that both depletion and stabilization of 
WhiB1 result in bacterial death, and in this light, it would make sense that there would be multiple 
regulatory mechanisms to keep levels of WhiB1 tightly regulated. There are only a few examples 
where proteolysis has been shown to be the primary regulatory mechanism of an essential 
process, but here we have shown that turnover of WhiB1 by Clp protease is required, and in the 
absence of effective proteolysis, cell death ensues.  
 
While we have provided evidence for the importance of Clp-dependent WhiB1 degradation, a 
major unanswered question is why is WhiB1 turnover critically required for growth? While we 
hypothesized that stabilization of WhiB1 may overly repress the transcription of essential genes, 
this must be confirmed by transcriptional analysis of the degradation-deficient allele. Extremely 
preliminary studies that I have conducted suggest that the picture may be more complicated than 
presented. Taking WhiB1 ChIP-Seq data deposited in the Tuberculosis Database (www.tbdb.org), 
which reported 72 genes regulated by WhiB1 in Mtb, I found Msm homologs for the thirteen 
essential Mtb genes in the putative regulon14. Quantitative PCR analysis in Msm strains over-
expressing GFP-WhiB1 (the rapidly degraded allele) and WhiB1-GFP (the stabilized allele) 
revealed a very jumbled picture (APPENDIX 4). In some cases, repression of the essential loci 
was equal for both fusions, while with other genes there was actually transcriptional activation by 
WhiB1-GFP. This initial inquiry is flawed for many reasons (ie. using preliminary ChIP-Seq data, 
validating ChIP-Seq in a different species), but it does make one wonder that perhaps the toxicity 
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of WhiB1-GFP may be more complex than excessive repression of essential genes in the 
canonical WhiB1 regulon. To this end, it would be interesting to conduct ChIP-Seq analysis on the 
stabilized allele to see if elevated concentrations of WhiB1 result in additional DNA-binding sites. 
Ideally, the lethality of WhiB1 stabilization will be explained by highlighting the transcriptional 
effects of having excessive concentrations of the essential transcription factor in the cell.  
 
WhiB1 is just one potential substrate revealed from screening, but the combination of qPCR and 
fusion protein analysis has highlighted an efficient method of validating proteins degraded by Clp 
protease that were identified from our initial proteomic screens. Using this methodology, we have 
also shown that CarD and RpL28 are likely Clp substrates. Though blocking degradation of these 
proteins failed to have an observable effect on growth, turnover of these proteins may still be an 
important regulatory mechanism in mycobacteria. We hope to apply this validation framework to a 
larger set of the 132 Mtb and 107 Msm proteins identified as putative Clp substrates through 
proteomic screening. While gene ontology analysis failed to reveal the enrichment of any 
particular pathways among the over-represented proteins in Clp-deficient Mtb, there were 
numerous essential hypothetical proteins and uncharacterized DNA-binding proteins identified. 
Determining if these effectors are true substrates, and subsequently analyzing the cellular effects 
of stabilized allelic forms, will highlight proteins and pathways that are critically regulated through 
targeted degradation. 
 
In reality, however, there is unlikely one “silver bullet” substrate that explains why Clp protease is 
essential in mycobacteria. Evidence for this is derived from whole-genome screens for essential 
genes, which found both the ATPase adapters, ClpX and ClpC1, to also be required for normal 
growth8. As these adapters dock with the ClpP1P2 proteolytic core and govern substrate 
recognition, their essentiality suggests that they independently regulate the degradation of 
different sets of substrates. It may be that the integration of inefficient proteolysis of numerous 
proteins explains the growth inhibition that results from Clp depletion.  
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Our work has simply scratched the surface in understanding the importance of the Clp protease 
complex in mycobacteria. As is the nature of science, countless questions remain. Given the 
essentiality of the ATPase adapters, how substrates are recognized for degradation is another 
interesting question that remains to be solved. Our work to date has focused on the essentiality 
and biology surrounding the proteolytic core of Clp, ClpP1P2. However, this core is simply a blind 
chamber that is governed by ATPase adapters, ClpX and ClpC1, which are responsible for 
substrate recognition and providing the energy for translocation of proteins into the proteolytic 
chamber15. Our lab is currently constructing conditional mutants of both ATPase adapters in Mtb. 
Once developed, these strains should be subjected to similar proteomic analysis to determine the 
set of proteins whose turnover is regulated specifically by each of the adapters.  
 
Observations from model organisms suggest that the adapters may coordinate distinct biology. In 
B. subtilis, the ClpCP complex shuts down central biosynthetic pathways by degrading rate-
limiting enzymes responsible for cell wall (GlmS, MurAA), branched chain amino acid (IlvB), 
purine (PurF), and pyrimidine (PyrB) synthesis16. While the functional significance of this turnover 
has yet to be shown, one could imagine that ClpCP might be critically important in the transition of 
B. subtilis from nutrient-rich to nutrient-depleted environments. In contrast, ClpXP in E. coli has 
been shown to degrade the enzymes isocitrate lyase and malate synthase, and the DNA 
crystallization protein (Dps), which are required for survival during starvation, and would need to 
be degraded upon shifting of E. coli from nutrient-depleted to nutrient rich environments5,17. In 
mycobacteria, the ClpP1P2 proteolytic core may, likewise, be the common endpoint of numerous 
proteins whose fates are actually determined through regulation at the ATPase adapter level. In 
this model, the ATPases are the keys to understanding how Clp regulates the degradation of 
particular substrates and controls various cellular activities.  
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Understanding how the ATPases govern protein recognition and facilitate proteolysis would be 
greatly enhanced with the reconstitution of substrate degradation in vitro. Currently, we have 
developed ClpC1P1P2 peptidase assays, but have yet to test the degradation of any putative Clp 
substrates. The purification of ClpX has proven challenging, and considerable effort must be 
invested into obtaining a functional ClpXP1P2 enzyme complex in vitro. Demonstration of in vitro 
degradation by one of the two complexes would be the most direct way to validate substrates of 
Clp protease. In addition, once these assays are up and running, the testing of substrate 
degradation could also help to reveal additional co-factors and adapters that might be required for 
recognition by Clp. In E. coli, for example, the small SspB protein is required to tether SsrA-
tagged peptides to ClpXP for degradation18. Despite lacking an SspB homolog, we have shown 
that mycobacteria are still able to degrade SsrA-tagged substrates. In vitro testing of GFP-SsrA 
degradation by the ClpXP1P2 complex could ascertain whether mycobacteria simply did away 
with SspB or employ a non-homologous small protein adapter to facilitate SsrA recognition.  
 
While the Clp complexes are clearly important regulators of cellular activity, they too must also be 
regulated. Several groups have shown that the positive regulator ClgR induces expression of 
clpP1, clpP2, and clpX19. Interestingly, clgR is highly induced upon reaeration of a hypoxic Mtb 
culture, suggesting that the ClpXP1P2 protease may be critically required in rapidly facilitating 
adaptation to oxygen-replete environments20. Coupling such transcriptional analysis, with protein 
turnover analysis to see which proteins are destabilized upon reaeration could highlight the critical 
substrates that must be degraded to reprogram the cells.  Beyond this, though, we know next to 
nothing about how Clp is regulated. Studying the induction or repression of clpP1, clpP2, clpC1, 
and clpX transcript in various conditions or growth phases would be a good place to start, offering 
us a view of critical time points or environments in which Clp activity is called upon by 
mycobacteria.  
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Section 5.2 – Clp protease as a chemotherapy target for the treatment of 
tuberculosis  
As we continue to unearth the important biological processes regulated by the essential Clp 
protease, it is critical that we harness this knowledge to aid in the fight against Mycobacterium 
tuberculosis. The rapid bacterial death that ensued from genetic depletion of Clp protease excited 
us tremendously, as it validated the enzyme as an ideal drug target, and suggested that chemical 
inhibition could be effective for treatment. Fortuitously, we came across a class of compounds, !-
lactones, that had been described as Clp-specific inhibitors in both Staphylococcus aureus and 
Listeria monocytogenes21,22. In these pathogens, Clp is dispensable for growth in vitro, but is 
absolutely required for virulence during infection. For this reason, the compounds were being 
pursued as anti-virulence agents in S. aureus and L. monocytogenes, but we wanted to evaluate 
their potential as traditional growth inhibitors in Mycobacterium tuberculosis. One !-lactone, 
EZ120, had a superb killing profile, with an MIC of 1.6 µM and an MBC between 3-6 µM. 
Furthermore, we were able to show that EZ120 inhibited ClpP1P2 proteolysis in an in vitro 
purified protein assay, and that the compound interacted with the enzyme complex in intact cells. 
Together, this evidence validates the !-lactones as a potential class of antimycobacterial 
compounds and Clp protease as a suitable target for more focused drug development.  
 
Extremely preliminary studies in eukaryotic macrophages suggests that EZ120 has a therapeutic 
index of 200:1, but many issues still surround the development of this compound and the broader 
class of !-lactones as suitable, lead candidates for drug development. For example, they have an 
extremely short half-life in plasma, and are poorly soluble in aqueous media. Our collaborators in 
the laboratory of Stephan Sieber are working to create libraries of more pharmaceutically 
attractive compounds, and it will be important to test these new chemical entities for bactericidal 
activity and Clp inhibition.  
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On other fronts, we have also preliminary tested a set of peptidomimetic compounds from the 
laboratory of Alfred Goldberg, and shown that they that inhibit ClpP1P2 proteolysis in vitro and 
the growth of Mtb and Msm. As velcade, a peptidomimemtic eukaryotic proteasome inhibitor used 
in the treatment of multiple myeloma, is already approved and in clinical use, the path to 
development of the boronate compounds may be less tortuous than the !-lactones23. However, 
these compounds come with their own slew of issues, namely ensuring that they do not have 
significant toxicity through inhibition of eukaryotic proteases.  
 
Given that descriptions of total-drug resistant tuberculosis are now cropping up in the literature, 
and the drug pipeline for tuberculosis is disparagingly barren, we must ramp up efforts to exploit 
essential pathways in mycobacteria. While we have demonstrated the inhibitory activity of a few 
compounds, presumably via Clp protease inhibition, significant work is still needed to take these 
compounds from the initial discovery phase to the generation of ideal lead compounds for 
antibiotic drug development.  
 
Section 5.3 – Why are the proteolytic complexes so critical for survival in 
mycobacteria?  
While this thesis has focused on the biological and therapeutic significance of the Clp protease, it 
is interesting to consider, in closing, why mycobacteria would have evolved to rely so heavily on 
protein turnover. As stated above, genome wide screens for essential genes in mycobacteria 
have found that multiple proteolytic complexes (Clp, FtsH, HtrA) are required for growth, a 
surprising discovery given that these enzymes are mostly dispensable for vegetative growth in 
most other organisms where they have been studied. Though territory full of conjecture, we can 
posit several hypotheses as to why the class in general may be divergently important in 
mycobacteria.  
 
  159 
The first is the “stress” hypothesis. While it is true that the proteolytic complexes are dispensable 
for normal growth in most organisms, they become critically required in almost all cases during 
more stringent growth conditions. Using Clp as an example, the protease is absolutely required 
for survival during infection in nearly every pathogenic organism where it has been studied24-26. 
And for the non-pathogenic organisms, Clp is required for survival in most forms of in vitro stress, 
and depletion of the protease is associated with impaired transition between certain growth 
phases27. Taking this into account, it could just be that mycobacteria are more sensitive to stress, 
and that “normal” growth actually requires continual adaptation carried out by the proteolytic 
complexes. Alternatively, the ability of Mtb to survive for decades in harsh, competitive niches 
may have necessitated an expansion of targeted proteolysis as a regulatory mechanism. In 
support of this, one preliminary experiment I ran during my doctoral work suggested that the E. 
coli Clp machinery did not degrade WhiB1. This suggests that different rules may govern the 
recognition of proteins by Clp in mycobacteria. Especially given that they may apply to WhiB1 
degradation, these differential recognition patterns may be linked to the expanded role of Clp and 
explain why the protease is divergently essential in mycobacteria. Survival of Mtb in stress-filled 
environments, like the human macrophage, may also require adaptation to be rapid in order to 
prevent death. The fact that ClgR expression and activation of various proteases are required for 
the intracellular parasitism of Mtb28 suggests that proteolysis is a key regulatory feature in the 
adaptation of Mtb. The essentiality of these enzymes may have arisen from the evolutionary 
benefit of rapid adaptation afforded by protein turnover, as opposed to slower transcriptional 
modulation.  
 
The second possible explanation of why multiple proteases are divergently essential in 
mycobacteria is the “slow grower” hypothesis. With a replication rate of 20 minutes, E. coli is 
quickly able to dilute the presence of toxic proteins or growth repressors through repeated rounds 
of division. Mtb, on the other hand, divides once every 1,440 minutes, nearly 2 orders of 
magnitude slower. The presence of harmful proteins in Mtb may have a much more deleterious 
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effect on the bacteria simply because their effective concentrations are much higher for far longer. 
Thus, the slow growth rate of mycobacteria may have necessitated the development of active 
enzymatic mechanisms to deal with proteins (both regulatory and toxic) that inhibit growth, while 
the fast growing bacteria may have just relied on divisional dilution for the same effect.   
 
Regardless of the reason why, the essentiality of these enzymes gives us an interesting entrée 
into understanding how protein turnover is employed as a regulatory feature in mycobacteria, and 
prokaryotes in general. As a young biology student, I remember learning the central dogma and 
never questioning what happened to proteins when they were no longer needed. In hindsight, as I 
quickly learned through my doctoral work, a transcriptional-centric view of the central dogma 
highlights important regulatory features, but fails to address where proteins go to die when they 
have outlived their utility, or what cells must do when a response must be initiated within seconds 
of encountering an environmental stress. We have just begun to probe these mechanisms in 
mycobacteria, but their elucidation will undoubtedly lead us to novel biology, and facilitate a more 
holistic understanding of how bacteria regulate essential cellular processes.  
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Appendix 1 – The active ClpP protease from M. tuberculosis is a complex 
composed of a heptameric ClpP1 and a ClpP2 ring 
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Appendix 2 – Over and under represented proteins identified through 
proteomic profiling of P750-clpP1P2DAS Mtb in the presence (mutant) and 
absence (wildtype) of ATc 
The tables below denote significantly over and under represented proteins identified from our 
quantitative proteomics screen to identify potential protease substrates that accumulated upon 
the depletion of Clp in Mtb. For each protein, the following are listed: Rv number, protein name, 
number of peptides identified, normalized summed intensity for each TMT channel (wildtype: 
TMT126-TMT128; mutant: TMT129-TMT131), the average ratio of mutant/wildtype (mut/wt) 
protein intensity, and the p-value as determined by a t-test grouping the three biological replicates 
for each condition. Proteins are sorted from the largest to smallest average mut/wt ratio.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  178 
OVER-REPRESENTED PROTEINS 
 
RV Protein # pep. 126 (wt) 127 (wt) 128 (wt) 129 (mut) 130 (mut) 131 (mut)
mut/wt 
ratio p-value
Rv0251c heat shock protein Hsp20 22 0.61 0.43 0.26 31.45 35.32 31.93 75.92 0.0013
Rv1741 hypothetical protein Rv1741 1 1.96 1.51 0.61 32.59 30.78 32.55 23.51 0.0000
Rv2979c resolvase 1 2.21 1.39 1.85 31.31 30.59 32.64 17.35 0.0001
Rv2031c heat shock protein hspX 28 1.90 1.94 1.66 31.24 31.00 32.27 17.18 0.0001
Rv1915 isocitrate lyase 4 2.25 2.26 1.79 32.47 29.29 31.93 14.87 0.0009
Rv0605 resolvase 6 2.09 2.12 2.20 29.55 31.78 32.26 14.60 0.0008
Rv1072 transmembrane protein 14 2.38 2.87 1.64 35.02 25.07 33.01 13.51 0.0102
Rv2710 RNA polymerase sigma factor SigB 12 3.17 3.05 2.22 33.75 27.88 29.93 10.85 0.0031
Rv3334 MerR family transcriptional regulator 2 2.62 3.82 2.15 31.86 22.77 36.79 10.64 0.0202
Rv1916 isocitrate lyase 2 3.17 2.87 2.77 25.38 30.89 34.92 10.35 0.0099
Rv2079 hypothetical protein Rv2079 2 3.13 2.70 2.98 31.55 28.94 30.70 10.35 0.0006
Rv2791c transposase 7 2.99 3.33 2.57 29.45 28.36 33.30 10.25 0.0025
Rv1765c hypothetical protein Rv1765c 1 3.74 3.34 2.61 29.14 31.81 29.36 9.32 0.0002
Rv2107 PE family protein 2 3.58 3.63 2.79 26.70 29.85 33.46 9.00 0.0047
Rv2917 hypothetical protein Rv2917 1 3.36 3.45 3.36 29.29 29.98 30.56 8.83 0.0002
Rv3408 hypothetical protein Rv3408 1 3.19 4.47 2.51 30.09 22.86 36.87 8.83 0.0207
Rv0192 hypothetical protein Rv0192 2 3.96 3.33 3.00 26.02 30.21 33.48 8.72 0.0059
Rv2652c phiRv2 prophage protein 1 4.20 3.65 3.88 28.33 28.07 31.86 7.52 0.0020
Rv2850c magnesium chelatase 1 4.69 3.34 4.42 28.09 29.29 30.17 7.03 0.0000
Rv1945 hypothetical protein Rv1945 1 4.46 4.61 3.40 30.48 28.60 28.45 7.02 0.0000
Rv3053c
glutaredoxin electron transport 
protein NrdH 4 5.42 4.30 2.91 32.20 25.19 29.99 6.92 0.0033
Rv1128c hypothetical protein Rv1128c 3 3.86 4.44 4.41 25.92 31.05 30.32 6.87 0.0037
Rv0369c membrane oxidoreductase 1 4.74 3.77 4.42 28.57 30.58 27.92 6.73 0.0003
Rv2016 hypothetical protein Rv2016 4 5.75 4.89 4.59 23.85 30.86 30.05 5.57 0.0078
Rv0220 esterase LipC 2 5.65 4.93 4.70 27.77 28.28 28.67 5.54 0.0000
Rv3769 hypothetical protein Rv3769 2 8.93 4.21 3.17 24.31 28.88 30.49 5.13 0.0009
Rv0945 short chain dehydrogenase 5 5.75 6.45 4.64 30.86 22.89 29.41 4.94 0.0095
Rv2688c
antibiotic ABC transporter ATP-
binding protein 3 6.85 5.59 5.55 25.52 28.46 28.02 4.56 0.0003
Rv1471 thioredoxin TRXB1 8 5.64 7.95 4.66 29.34 21.37 31.05 4.48 0.0126
Rv0425c
metal cation transporting P-type 
ATPase CtpH 1 6.49 6.07 5.73 26.93 24.74 30.04 4.47 0.0046
Rv1854c NADH dehydrogenase 16 5.68 6.20 7.44 23.96 27.09 29.63 4.18 0.0034
Rv1169c PE family protein 1 7.04 6.96 5.36 23.81 28.14 28.69 4.17 0.0026
Rv0984
pterin-4-alpha-carbinolamine 
dehydratase MoaB2 1 5.15 10.41 3.89 20.16 28.41 31.98 4.14 0.0130
Rv1148c hypothetical protein Rv1148c 6 7.14 6.41 6.10 26.29 26.63 27.43 4.09 0.0000
Rv2601A hypothetical protein Rv2601A 1 7.74 7.08 5.19 23.02 28.72 28.26 4.00 0.0033
Rv0275c TetR family transcriptional regulator 2 6.29 7.12 6.61 28.25 24.80 26.93 4.00 0.0016
Rv0516c hypothetical protein Rv0516c 3 6.29 6.92 6.82 24.88 28.52 26.57 3.99 0.0021
Rv2324 AsnC family transcriptional regulator 2 7.43 6.36 6.51 24.57 27.02 28.11 3.93 0.0013
Rv0384c endopeptidase ATP binding protein 112 7.10 6.74 6.58 25.32 27.47 26.78 3.90 0.0006
Rv2431c PE family protein 2 6.33 7.32 6.87 25.39 28.21 25.88 3.87 0.0008
Rv1431 hypothetical protein Rv1431 2 6.83 6.96 6.99 24.27 26.69 28.25 3.81 0.0035
Rv1343c lipoprotein LprD 1 9.55 5.47 6.19 27.22 25.33 26.24 3.71 0.0013
Rv1256c cytochrome P450 130 CYP130 1 7.67 7.06 6.59 24.43 27.26 26.98 3.69 0.0008
Rv0336 13E12 repeat family protein 2 7.04 7.34 6.99 24.36 25.31 28.96 3.68 0.0051
Rv0663 arylsulfatase AtsD 5 6.74 7.40 7.51 25.00 25.37 27.96 3.62 0.0014
Rv2218 lipoyl synthase 2 7.41 7.71 6.54 26.33 24.70 27.31 3.62 0.0003
Rv1182
polyketide synthase associated 
protein PapA3 1 7.36 8.05 6.54 25.41 25.33 27.31 3.56 0.0001
Rv1331
ATP-dependent Clp protease adaptor 
protein ClpS 14 7.97 7.65 6.74 25.38 27.37 24.89 3.47 0.0003
Rv2629 hypothetical protein Rv2629 2 6.92 7.15 8.51 23.52 24.62 29.28 3.43 0.0060
N/A TetR-off repressor protein 9 7.58 7.70 7.33 24.96 26.56 25.86 3.42 0.0004
Rv0805 hypothetical protein Rv0805 2 7.84 7.58 7.23 24.89 25.28 27.19 3.42 0.0009
Rv3054c hypothetical protein Rv3054c 5 7.71 8.14 7.25 25.28 23.88 27.75 3.33 0.0027
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RV Protein # pep. 126 (wt) 127 (wt) 128 (wt) 129 (mut) 130 (mut) 131 (mut)
mut/wt 
ratio p-value
Rv3406 dioxygenase 2 8.04 8.16 6.99 25.91 25.85 25.06 3.31 0.0000
Rv3190c hypothetical protein Rv3190c 7 8.04 7.74 7.73 23.79 25.27 27.44 3.25 0.0033
Rv1814
membrane-bound C-5 sterol 
desaturase erg3 (sterol-c5-
desaturase) 1 8.44 7.51 7.74 25.38 25.60 25.34 3.22 0.0001
Rv3884c CBXX/CFQX family protein 1 8.58 6.96 8.43 24.73 25.42 25.88 3.17 0.0000
Rv0197 oxidoreductase 2 8.66 6.51 8.81 22.88 25.80 27.33 3.17 0.0011
Rv2496c
pyruvate dehydrogenase E1 
component beta subunit PdhB 5 7.68 8.66 8.05 25.70 24.80 25.12 3.10 0.0000
Rv2182c
1-acylglycerol-3-phosphate O-
acyltransferase 3 7.29 9.30 7.88 29.11 19.18 27.26 3.09 0.0269
Rv1123c peroxidase BpoB 3 10.01 7.44 7.19 27.07 24.20 24.09 3.06 0.0002
Rv0892 monooxygenase 5 8.15 8.09 8.61 24.50 22.15 28.50 3.02 0.0115
Rv3052c
ribonucleotide reductase stimulatory 
protein 2 8.38 8.78 7.79 23.16 26.31 25.57 3.01 0.0016
Rv2777c hypothetical protein Rv2777c 3 7.88 7.43 9.67 22.05 26.60 26.36 3.00 0.0026
Rv2900c formate dehydrogenase H 2 9.60 7.03 8.37 25.80 22.43 26.77 3.00 0.0013
Rv1047 transposase 1 8.22 7.79 9.15 24.78 24.75 25.32 2.97 0.0001
Rv0938 ATP-dependent DNA ligase 7 8.36 8.36 8.69 22.55 25.60 26.43 2.94 0.0048
Rv3601c aspartate alpha-decarboxylase 1 12.07 6.39 6.97 27.36 24.79 22.43 2.93 0.0025
Rv0307c hypothetical protein Rv0307c 2 8.39 7.98 9.09 21.22 24.99 28.33 2.93 0.0137
Rv0507
transmembrane transport protein 
MmpL2 2 7.91 8.39 9.27 23.03 23.50 27.89 2.91 0.0062
Rv0298 hypothetical protein Rv0298 2 8.22 9.24 8.15 24.55 24.42 25.42 2.90 0.0000
Rv2733c hypothetical protein Rv2733c 5 8.76 8.47 8.77 23.89 23.82 26.28 2.85 0.0023
Rv3814c acyltransferase 3 8.65 8.40 9.02 22.29 26.30 25.34 2.84 0.0049
Rv1322A hypothetical protein Rv1322A 1 8.98 8.85 8.34 24.36 24.19 25.28 2.82 0.0000
Rv0726c hypothetical protein Rv0726c 1 11.85 7.06 7.79 24.55 26.80 21.96 2.75 0.0016
Rv0103c cation-transporter P-type ATPase B 5 7.68 9.42 9.88 21.16 24.06 27.81 2.71 0.0091
Rv2633c hypothetical protein Rv2633c 2 8.91 9.43 8.69 24.18 25.42 23.37 2.70 0.0005
Rv3051c
ribonucleotide-diphosphate 
reductase subunit alpha 53 9.56 8.04 9.52 23.17 25.34 24.37 2.69 0.0001
Rv0959 hypothetical protein Rv0959 2 9.38 8.68 9.24 23.81 25.11 23.79 2.66 0.0001
Rv0920c transposase 2 8.60 8.44 10.38 21.94 24.61 26.03 2.65 0.0015
Rv0058 replicative DNA helicase 5 9.14 9.36 8.92 23.24 24.54 24.79 2.65 0.0005
Rv0430 hypothetical protein Rv0430 1 8.54 10.25 8.94 20.55 22.84 28.89 2.61 0.0231
Rv2816c hypothetical protein Rv2816c 1 8.28 10.61 9.14 22.27 23.95 25.74 2.57 0.0005
Rv0569 hypothetical protein Rv0569 2 9.62 10.32 8.15 25.01 22.38 24.51 2.56 0.0002
Rv2251 flavoprotein 2 9.60 8.87 9.65 21.42 25.28 25.18 2.56 0.0059
Rv3852 histone-like protein HNS 2 7.63 11.74 8.84 22.26 22.42 27.10 2.54 0.0024
Rv0004 hypothetical protein Rv0004 2 10.14 8.91 9.25 21.94 25.74 24.02 2.53 0.0029
Rv2830c hypothetical protein Rv2830c 3 10.18 8.69 9.47 22.18 25.93 23.54 2.53 0.0023
Rv0386
LuxR/UHPA family transcriptional 
regulator 1 8.77 11.25 8.40 30.03 19.63 21.92 2.52 0.0366
Rv0233
ribonucleotide-diphosphate 
reductase subunit beta 1 9.31 10.24 8.93 25.38 21.19 24.95 2.51 0.0053
Rv1828 hypothetical protein Rv1828 1 10.31 9.81 8.50 24.40 23.31 23.66 2.49 0.0001
Rv1207 dihydropteroate synthase 2 FolP2 2 9.48 9.75 9.41 21.95 23.63 25.79 2.49 0.0057
Rv0486 mannosyltransferase 1 9.59 9.56 9.68 25.07 22.09 24.01 2.47 0.0037
Rv3241c hypothetical protein Rv3241c 5 10.25 9.44 9.19 22.48 25.43 23.21 2.46 0.0016
Rv0327c cytochrome P450 135A1 1 10.09 9.39 9.44 21.69 23.80 25.58 2.46 0.0049
Rv2466c hypothetical protein Rv2466c 9 10.34 8.95 9.73 23.50 24.47 23.01 2.45 0.0000
Rv0426c hypothetical protein Rv0426c 7 10.30 9.64 9.19 24.78 23.86 22.23 2.43 0.0007
Rv2250A flavoprotein 5 10.16 8.92 10.09 22.91 24.04 23.88 2.43 0.0000
Rv2933
phenolpthiocerol synthesis type-I 
polyketide synthase PPSC 3 9.04 9.12 11.30 19.24 24.81 26.49 2.39 0.0166
Rv1129c transcriptional regulator protein 2 10.05 8.87 10.54 21.25 25.56 23.73 2.39 0.0036
Rv1956 transcriptional regulatory protein 6 10.28 11.26 8.00 23.60 23.21 23.64 2.38 0.0043
Rv2017 transcriptional regulatory protein 1 10.10 9.91 9.54 27.11 20.55 22.79 2.38 0.0188
Rv3815c acyltransferase 1 6.69 11.95 11.10 26.22 16.93 27.11 2.36 0.0351
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RV Protein # pep. 126 (wt) 127 (wt) 128 (wt) 129 (mut) 130 (mut) 131 (mut)
mut/wt 
ratio p-value
Rv3130c triacylglycerol synthase 3 9.56 9.12 11.07 20.74 24.70 24.81 2.36 0.0038
Rv2252 diacylglycerol kinase 5 10.02 9.94 9.89 23.64 22.80 23.71 2.35 0.0004
Rv3378c hypothetical protein Rv3378c 1 9.84 8.88 11.20 20.92 24.61 24.55 2.34 0.0020
Rv1633 excinuclease ABC subunit B 10 10.06 9.65 10.35 22.11 24.04 23.78 2.33 0.0008
Rv1500 glycosyltransferase 3 9.52 10.11 10.45 21.89 20.46 27.57 2.32 0.0242
Rv0939
bifunctional 2-hydroxyhepta-2,4-
diene-1,7-dioate 
isomerase/cyclase/dehydrase 2 9.88 9.65 10.67 20.87 25.18 23.75 2.31 0.0065
Rv2702
polyphosphate glucokinase PPGK 
(polyphosphate-glucose 
phosphotransferase) 2 10.04 9.59 10.78 24.00 23.12 22.46 2.29 0.0000
Rv3768 hypothetical protein Rv3768 3 9.69 10.50 10.25 22.52 22.28 24.76 2.29 0.0019
Rv1265 hypothetical protein Rv1265 4 10.85 9.65 10.01 20.93 25.50 23.05 2.28 0.0069
Rv0781 oligopeptidase B 2 10.03 10.57 9.92 22.89 23.62 22.97 2.28 0.0000
Rv3173c
TetR/ACRR family transcriptional 
regulator 1 16.25 7.98 6.29 21.32 26.99 21.16 2.28 0.0311
Rv1992c
metal cation transporter P-type 
ATPase G CtpG 1 9.71 11.64 9.22 26.61 16.34 26.49 2.27 0.0567
Rv3219
transcriptional regulatory protein 
WHIB-like WHIB1 1 11.35 10.02 9.32 20.22 26.09 23.00 2.26 0.0102
Rv0676c
transmembrane transport protein 
MmpL5 1 10.77 9.49 10.46 22.35 24.84 22.10 2.26 0.0014
Rv0869c
molybdenum cofactor biosynthesis 
protein A 2 11.28 9.71 9.74 23.95 22.32 23.00 2.25 0.0001
Rv0274 hypothetical protein Rv0274 7 9.89 10.53 10.36 22.64 22.30 24.27 2.25 0.0010
Rv2823c hypothetical protein Rv2823c 2 11.13 8.79 10.92 21.40 24.93 22.83 2.24 0.0008
Rv2386c salicylate synthase MbtI 1 10.33 10.36 10.24 21.97 22.80 24.30 2.23 0.0028
Rv2206 transmembrane protein 6 9.60 9.94 11.40 22.11 22.93 24.02 2.23 0.0001
Rv2050 hypothetical protein Rv2050 1 11.04 10.67 9.26 21.37 22.66 25.00 2.23 0.0018
Rv3116
molybdenum cofactor biosynthesis 
protein MoeB 5 9.53 9.31 12.24 20.14 24.47 24.31 2.22 0.0030
Rv0350 molecular chaperone DnaK 235 10.63 11.04 9.53 24.52 21.62 22.67 2.21 0.0009
Rv2326c
transmembrane ATP-binding protein 
ABC transorter 3 10.09 10.71 10.61 21.90 22.24 24.45 2.18 0.0027
Rv0753c
methylmalonate-semialdehyde 
dehydrogenase 15 9.48 11.61 10.49 22.05 22.20 24.17 2.17 0.0002
Rv0677c hypothetical protein Rv0677c 3 13.47 7.83 10.65 24.20 21.98 21.87 2.13 0.0081
Rv3874 10 kDa culture filtrate antigen EsxB 2 10.14 11.98 9.88 20.72 21.91 25.37 2.13 0.0053
Rv0885 hypothetical protein Rv0885 2 9.15 10.10 12.81 18.45 23.92 25.58 2.12 0.0162
Rv0752c acyl-CoA dehydrogenase FADE9 4 11.04 10.07 11.00 21.44 24.32 22.14 2.11 0.0023
Rv1635c transmembrane protein 2 10.75 9.56 11.81 21.82 23.02 23.06 2.11 0.0003
Rv0776c hypothetical protein Rv0776c 2 10.26 10.54 11.47 21.05 22.66 24.01 2.10 0.0017
Rv3765c
two component transcriptional 
regulatory protein 3 10.63 10.05 11.65 21.76 22.95 22.96 2.09 0.0001
Rv1249c hypothetical protein Rv1249c 3 11.67 10.73 9.93 23.61 21.14 22.92 2.09 0.0004
Rv2559c recombination factor protein RarA 2 9.70 11.49 11.21 20.96 21.69 24.95 2.09 0.0042
Rv3583c transcription factor, CarD 18 11.33 11.06 10.02 22.21 23.59 21.79 2.09 0.0001
Rv3526 oxidoreductase 5 14.29 8.17 10.10 26.20 19.81 21.44 2.07 0.0116
Rv3875
6 kDa early secretory antigenic target 
ESXA (ESAT-6) 10 9.93 10.99 11.66 20.25 19.40 27.76 2.07 0.0443
Rv2108 PPE family protein 3 11.67 10.62 10.32 22.11 23.09 22.19 2.07 0.0000
Rv3627c hypothetical protein Rv3627c 3 10.42 10.59 11.62 21.99 21.55 23.82 2.06 0.0006
Rv2124c
5-methyltetrahydrofolate--
homocystein methyltransferase 35 10.75 10.86 11.23 22.12 21.74 23.30 2.05 0.0007
Rv2276 cytochrome P450 121 CYP121 4 9.84 12.17 10.92 22.20 20.56 24.31 2.04 0.0019
Rv0352 chaperone protein DnaJ1 19 11.10 12.54 9.38 22.66 20.75 23.57 2.03 0.0008
Rv1783 hypothetical protein Rv1783 5 10.57 10.50 12.00 21.97 21.80 23.16 2.02 0.0001
Rv2714 hypothetical protein Rv2714 3 10.44 11.59 11.07 22.32 21.30 23.28 2.02 0.0003
Rv2725c GTP-binding protein HflX 3 10.81 11.62 10.67 22.45 21.07 23.38 2.02 0.0010
Rv1446c putative OXPP cycle protein OPCA 6 10.76 10.45 11.89 20.20 23.90 22.79 2.02 0.0042
Rv1784 hypothetical protein Rv1784 7 10.02 11.28 11.91 20.92 22.24 23.63 2.01 0.0005
RV Protein # pep. 126 (wt) 127 (wt) 128 (wt) 129 (mut) 130 (mut) 131 (mut)
mut/wt 
ratio p-value
Rv1037c
putative ESAT-6 like protein ESXI 
(ESAT-6 like protein 1) 1 12.68 8.48 12.11 20.72 22.54 23.47 2.01 0.0039
Rv0790c hypothetical protein Rv0790c 1 9.15 11.76 12.37 22.62 20.14 23.95 2.00 0.0018
Rv2808 hypothetical protein Rv2808 1 12.00 11.36 9.94 24.25 19.19 23.27 2.00 0.0105
Rv1278 hypothetical protein Rv1278 9 9.05 13.48 10.82 21.50 19.74 25.41 2.00 0.0075
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Rv3618 monooxygenase 1 20.05 21.60 25.16 10.84 11.10 11.25 0.50 0.0172
Rv1130 hypothetical protein Rv1130 2 21.22 21.32 24.36 11.14 9.86 12.10 0.49 0.0016
Rv0987
adhesion component transport 
transmembrane protein ABC 
transporter 2 20.96 22.14 24.07 10.82 10.59 11.41 0.49 0.0039
Rv3587c hypothetical protein Rv3587c 11 22.69 21.57 22.95 10.55 11.71 10.53 0.49 0.0000
Rv0986
adhesion component transport ATP-
binding protein ABC transporter 10 20.98 23.81 22.84 11.00 10.27 11.11 0.48 0.0026
Rv0108c hypothetical protein Rv0108c 1 20.63 28.23 19.29 9.07 10.91 11.87 0.47 0.0400
Rv0467 isocitrate lyase 35 23.49 22.11 22.69 10.55 11.13 10.03 0.46 0.0000
Rv1774 oxidoreductase 2 20.09 22.18 26.21 9.59 10.67 11.26 0.46 0.0154
Rv2590 fatty-acid-CoA ligase 8 21.73 20.90 25.98 9.51 11.12 10.76 0.46 0.0103
Rv1477 invasion protein 5 22.29 23.98 23.06 9.81 10.60 10.27 0.44 0.0002
Rv2243
acyl-carrier-protein S-
malonyltransferase 10 22.41 21.96 25.00 9.60 10.60 10.43 0.44 0.0027
Rv0129c
secreted antigen 85-C FBPC (85C) 
(antigen 85 complex C) (AG58C) 
(Mycolyl transferase 85C) (fibronectin-
binding protein C) 4 21.70 23.93 23.78 9.98 11.50 9.12 0.44 0.0002
Rv2721c hypothetical protein Rv2721c 31 21.84 23.99 23.85 10.05 10.15 10.12 0.44 0.0027
Rv2240c hypothetical protein Rv2240c 2 22.18 23.56 23.98 9.54 10.83 9.91 0.43 0.0001
Rv3048c
ribonucleotide-diphosphate 
reductase subunit beta 9 21.93 21.88 26.04 9.63 10.61 9.91 0.43 0.0084
Rv3825c polyketide synthase PKS2 2 23.03 20.88 26.02 9.45 10.03 10.59 0.43 0.0097
Rv3873 PPE family protein 2 17.77 25.33 26.87 9.70 9.57 10.76 0.43 0.0397
Rv2429
alkyl hydroperoxide reductase 
subunit D 4 22.83 22.90 24.28 9.80 10.30 9.89 0.43 0.0005
Rv3310 acid phosphatase 2 21.99 23.55 24.63 8.70 11.07 10.06 0.43 0.0002
Rv1387 PPE family protein 1 22.12 25.91 22.82 7.27 10.05 11.84 0.41 0.0015
Rv1698 hypothetical protein Rv1698 1 23.07 22.11 26.13 9.19 9.29 10.20 0.40 0.0047
Rv3330 penicillin-binding protein DacB1 3 21.46 24.14 26.86 8.82 9.14 9.57 0.38 0.0096
Rv2780
secreted L-alanine dehydrogenase 
ALD (40 kDa antigen) (TB43) 6 21.16 24.67 26.71 8.22 9.48 9.77 0.38 0.0074
Rv2525c hypothetical protein Rv2525c 4 29.73 20.59 23.67 9.60 7.99 8.42 0.35 0.0241
Rv1754c hypothetical protein Rv1754c 1 24.41 27.31 27.98 6.71 7.58 6.02 0.25 0.0009
Rv1566c inv protein 4 26.35 27.63 26.31 6.73 6.40 6.58 0.25 0.0003
Rv0063 oxidoreductase 3 26.77 25.54 28.17 6.37 6.70 6.45 0.24 0.0012
Rv0888 hypothetical protein Rv0888 1 21.86 31.23 28.26 4.63 6.45 7.56 0.23 0.0114
Rv2350c
membrane-associated phospholipase 
C 2 24.74 29.15 35.20 3.26 3.22 4.43 0.12 0.0122
Rv2460c
ATP-dependent ClpP2 protease 
proteolytic subunit 9 26.54 33.69 32.24 2.18 2.59 2.76 0.08 0.0056
Rv2461c
ATP-dependent ClpP1 protease 
proteolytic subunit 2 27.58 33.25 33.66 1.35 1.92 2.24 0.06 0.0038
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Appendix 3 – Over and under represented proteins identified through 
quantitative proteomics comparing the proteomes of clpP2_ID Msm and 
wildtype Msm, both inducibly expressing HIV-2 protease 
The tables below denote significantly over and under represented proteins identified from our 
quantitative proteomics screen to identify potential protease substrates that accumulated upon 
the depletion of ClpP2 in Msm. ClpP2 depletion was achieved with the clpP2_ID Msm strain in 
which tetracycline (ATc) inducible HIV-2 expression led to degradation of ClpP2 that was modified 
to bear a C-terminal inducible degradation tag. Wildtype bacteria also containing an ATc nducible 
copy of the HIV-2 protease were used as a control to which the clpP2_ID proteome was 
compared.   
 
For each protein, the following are listed: Rv number, protein name, number of peptides identified, 
normalized median intensity for each TMT channel, and the ratio of mutant/wildtype (mut/wt) 
protein intensity at 5h post ATc addition. Proteins are sorted from the largest to smallest mut/wt 
ratio. TMT reagents were used for each condition as follows: TMT126 (wildtype 0h ATc), TMT127 
(wildtype 5h ATc), TMT128 (wildtype 11h ATc), TMT129 (clpP2_ID 0h ATc), TMT130 (clpP2_ID 
5h ATc), and TMT131 (clpP2_ID 11h ATc).  
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NCBI ID Protein # pep.
TMT126 
(wt 0h)
TMT127 
(wt 5h)
TMT128 
(wt 11h)
TMT129
 (clpP2 0h)
TMT130
 (clpP2 5h)
TMT131
(clpP2 11h)
clpP2/wt 
5h
YP_884588.1 transmembrane protein, putative 2 228.50 304.66 347.69 529.32 5401.97 5320.27 17.73
YP_887885.1 ATP-dependent protease La 9 1500.00 537.64 644.88 1308.32 9124.08 20441.50 16.97
YP_888562.1 lipoyltransferase 2 572.00 104.91 145.66 351.50 1569.43 1988.94 14.96
YP_887343.1 orro 2 3790.00 651.29 568.21 1372.81 5934.92 5119.50 9.11
YP_889521.1
permease of the major facilitator 
superfamily protein 10 783.50 208.94 816.69 755.51 1888.77 1738.44 9.04
YP_884837.1 Hsp20/alpha crystallin family protein 5 193.00 193.20 244.42 175.98 1603.11 3860.16 8.30
YP_886115.1 Fatty acid desaturase 4 1219.00 476.89 335.07 558.80 3632.58 2244.91 7.62
YP_886285.1 transcription factor WhiB 7 9080.00 1975.73 1434.06 6016.42 13302.40 7619.93 6.73
YP_885824.1 50S ribosomal protein L22 10 176000.00 24871.49 8284.19 77762.02 160310.98 127759.37 6.45
YP_886199.1 F420-0--gamma-glutamyl ligase 2 4835.00 813.02 1591.90 3183.27 5180.26 6465.54 6.37
YP_887337.1 hypothetical protein MSMEG_3019 10 1525.00 324.33 335.07 971.10 2033.73 2071.53 6.27
YP_888583.1 hypothetical protein MSMEG_4306 3 1240.00 262.27 108.23 823.69 1628.69 1633.49 6.21
YP_888841.1 hypothetical protein MSMEG_4572 6 3300.00 854.98 916.81 1689.76 5158.94 6004.69 6.03
YP_889750.1 serine/threonine-protein kinase PknE 17 1750.00 495.68 340.03 1335.96 2779.86 1971.14 5.61
YP_888931.1
oxidoreductase alpha 
(molybdopterin) subunit 14 6435.00 1958.25 1772.28 3814.39 10104.71 9787.28 5.16
YP_885585.1 TROVE domain-containing protein 1 5350.00 4502.22 5330.38 13175.32 22938.11 45172.06 5.10
YP_889314.1 malyl-CoA lyase 9 3170.00 710.74 1208.58 2745.63 3427.93 3257.86 4.82
YP_887229.1
transcriptional regulator, GntR family 
protein 3 23400.00 5498.83 3815.15 14557.35 26348.99 23544.23 4.79
YP_888942.1 hypothetical protein MSMEG_4681 9 934.00 686.26 827.07 620.99 3146.53 3120.98 4.59
YP_885131.1 IS1137, transposase orfB 1 589.00 267.51 471.71 669.82 1219.39 1733.88 4.56
YP_885853.1 50S ribosomal protein L18 5 35700.00 8672.24 4617.86 24784.34 39310.30 19346.42 4.53
YP_890290.1 ribosomal protein L28 3 740.00 532.40 397.75 590.59 2396.14 1487.48 4.50
YP_889219.1
two-component system sensor 
kinase 1 10700.00 1940.76 1307.79 13728.13 8697.72 6944.63 4.48
YP_887797.1 putative secreted protein 2 10800.00 3033.54 2205.21 5670.92 12833.41 12912.82 4.23
YP_888186.1 hypothetical protein MSMEG_3896 4 426.50 141.62 176.33 330.30 593.49 513.32 4.19
YP_891115.1 hypothetical protein MSMEG_6920 3 266.00 150.37 245.32 384.20 618.22 380.54 4.11
YP_889745.1 hypothetical protein MSMEG_5507 2 120.00 228.61 204.29 138.20 935.86 649.29 4.09
YP_890272.1 cobalamin synthesis protein/P47K 2 750.00 6176.35 2435.20 1557.08 24814.09 11954.63 4.02
YP_886110.1 transmembrane protein 3 4530.00 6469.21 8586.33 5002.94 25837.36 37962.78 3.99
YP_885379.1 hypothetical protein MSMEG_0977 3 19100.00 7404.62 5492.73 17782.07 29418.77 26008.16 3.97
YP_889430.1
alpha-methylacyl-CoA racemase, 
putative 8 3830.00 1232.65 1177.01 2206.64 4813.59 5630.54 3.91
YP_888359.1 butyryl-CoA dehydrogenase 1 30200.00 6032.10 5862.52 52332.73 23023.39 17795.06 3.82
YP_888187.1 proteasome component 9 8160.00 2535.23 3283.01 6974.63 9550.44 10768.29 3.77
YP_888936.1
ATP-dependent Clp protease 
proteolytic subunit 1 216.00 104.91 108.23 110.56 385.43 661.61 3.67
YP_887771.1 AMP-binding enzyme 5 1410.00 501.80 548.37 1253.04 1790.71 1861.64 3.57
YP_887617.1
universal stress protein family 
protein, putative 4 5450.00 1320.07 1366.42 3662.37 4664.37 4302.75 3.53
YP_885332.1 ErfK/YbiS/YcfS/YnhG family protein 10 497.00 739.15 900.12 436.72 2498.46 1451.44 3.38
YP_885700.1 TnpC protein 1 5970.00 3365.74 3896.32 5878.22 11341.15 25916.90 3.37
YP_886388.1 short chain dehydrogenase 8 3025.00 974.75 1402.49 1939.44 3244.59 9335.56 3.33
YP_889845.1 spore protein 2 7605.00 11233.70 10642.72 8264.52 37349.05 47909.76 3.33
YP_890530.1 cytochrome P450 107B1 3 1680.00 1932.02 2868.12 2856.19 6335.69 7108.90 3.28
YP_889680.1 methionyl-tRNA synthetase 6 8650.00 2548.34 2340.50 6767.32 8177.57 8454.93 3.21
YP_890261.1
2-hydroxy-6-ketonona-2,4-dienedioic 
acid hydrolase 6 2430.00 1028.95 1609.94 1575.51 3261.65 3107.29 3.17
YP_889159.1 rhomboid family protein 3 2420.00 789.42 705.31 2340.23 2481.41 1359.72 3.14
YP_889661.1 hypothetical protein MSMEG_5421 4 287.50 440.17 635.86 276.41 1325.98 3034.29 3.01
YP_887804.1 hypothetical protein MSMEG_3500 8 4600.00 2098.12 2069.92 4063.16 6288.80 6278.46 3.00
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NCBI ID Protein # pep.
TMT126 
(wt 0h)
TMT127 
(wt 5h)
TMT128 
(wt 11h)
TMT129
 (clpP2 0h)
TMT130
 (clpP2 5h)
TMT131
(clpP2 11h)
clpP2/wt 
5h
YP_887416.1
glucose-6-phosphate 1-
dehydrogenase 13 1380.00 497.43 611.51 667.98 1475.20 1679.12 2.97
YP_890470.1 hypothetical protein MSMEG_6251 3 4290.00 1862.08 1821.89 3703.83 5508.56 6415.35 2.96
YP_889537.1 acyl-CoA synthetase 1 4040.00 1477.43 1533.27 4081.58 4357.39 3203.11 2.95
YP_887239.1 aldo/keto reductase 1 120.00 1626.04 1614.45 2948.32 4732.58 4946.11 2.91
YP_886323.1 hypothetical protein MSMEG_1957 18 894.50 750.08 942.51 740.31 2178.69 2710.32 2.91
YP_884783.1 hypothetical protein MSMEG_0370 17 5670.00 2640.14 1794.83 5620.24 7606.24 7893.70 2.88
YP_890805.1 ATP-binding protein 4 2025.00 846.68 1100.35 1796.63 2421.72 2920.21 2.86
YP_886528.1
superfamily protein I DNA or RNA 
helicase 4 11720.00 3552.38 3130.13 8889.65 10128.16 9737.55 2.85
YP_889373.1 hypothetical protein MSMEG_5127 6 677.00 583.54 662.46 863.31 1654.27 2345.30 2.84
YP_890257.1 hypothetical protein MSMEG_6033 6 703.00 818.27 948.37 678.57 2319.39 1874.41 2.84
YP_886128.1
endonuclease VIII and DNA n-
glycosylase with an AP lyase activity 1 2430.00 1835.86 2281.87 4081.58 5201.58 6214.58 2.83
YP_889001.1 clavaldehyde dehydrogenase 2 10790.00 3151.55 4496.10 6822.60 8761.68 9933.29 2.78
YP_884446.1 putative septation inhibitor protein 3 2300.00 1162.71 1397.98 2128.32 3231.80 2874.59 2.78
YP_890299.1
transcriptional regulator, CarD family 
protein 40 1350.00 697.63 701.25 990.45 1858.93 2071.53 2.67
YP_888640.1 hypothetical protein MSMEG_4365 2 676.50 576.98 650.74 772.09 1526.37 2111.68 2.65
YP_888514.1 transmembrane protein 2 68250.00 79291.54 87576.97 53208.02 209086.45 228232.99 2.64
YP_888491.1 glutamine amidotransferase 3 15700.00 5254.05 4392.38 12069.70 13814.03 11498.34 2.63
YP_885452.1
hexapeptide transferase family 
protein 18 2755.00 1792.15 1988.75 2717.99 4707.00 5516.47 2.63
YP_886165.1 dehydrogenase 1 588.00 143.37 427.51 592.43 362.41 280.16 2.53
YP_889350.1
indolepyruvate ferredoxin 
oxidoreductase 10 2565.00 1897.05 1411.51 3381.36 4792.28 5165.13 2.53
YP_885199.1 hypothetical protein MSMEG_0794 1 7370.00 4965.56 8892.99 5242.49 12364.41 12228.40 2.49
YP_887869.1 FadD16 protein 4 4710.00 3330.77 3887.30 4551.47 8279.89 8833.65 2.49
YP_888615.1
NAD/mycothiol-dependent 
formaldehyde dehydrogenase 50 3300.00 1687.24 1803.85 2197.42 4169.79 5940.81 2.47
YP_886244.1 S30AE family protein 1 9300.00 10315.77 15603.31 9130.59 25325.72 30844.76 2.46
YP_885675.1 TPR repeat-containing protein 3 1360.00 591.85 928.98 1234.61 1449.62 1551.36 2.45
YP_889261.1 hypothetical protein MSMEG_5010 2 2273.50 2304.44 2523.14 2727.66 5614.30 7446.55 2.44
YP_884959.1 ISMsm5, transposase 10 1730.00 1289.47 1065.17 1833.49 3138.00 4695.16 2.43
YP_885614.1 ISMsm6, transposase 2 2347.50 2516.87 1933.28 2551.68 6101.20 7711.19 2.42
YP_884473.1 hypothetical protein MSMEG_0055 2 3055.00 1276.36 1781.30 3367.54 3086.84 4800.10 2.42
YP_884796.1 hypothetical protein MSMEG_0383 10 644.00 477.76 1470.14 395.26 1151.17 650.66 2.41
YP_887260.1
NAD dependent 
epimerase/dehydratase family 
protein 3 12700.00 5629.96 5844.48 12253.97 13472.94 9764.47 2.39
YP_887795.1 hypothetical protein MSMEG_3491 6 3495.00 1870.83 4153.37 2962.14 4446.92 4676.91 2.38
YP_891092.1 replicative DNA helicase 8 5955.00 2723.19 4951.57 4924.62 6403.91 15180.55 2.35
YP_887087.1 hypothetical protein MSMEG_2756 7 941.00 771.06 983.10 1041.13 1807.76 2619.07 2.35
YP_886830.1 D-lactate dehydrogenase 1 212.00 104.91 108.23 181.51 245.58 204.41 2.34
YP_886345.1 hypothetical protein MSMEG_1981 3 120.00 219.43 108.23 110.56 511.63 377.80 2.33
YP_885429.1 monooxygenase 31 1030.00 858.48 1470.14 1151.69 1995.36 2619.07 2.32
YP_888563.1 lipoyl synthase 4 10950.00 6976.26 9064.35 9766.32 16201.64 15650.52 2.32
YP_889372.1 FO synthase 4 1820.00 1128.61 1350.63 1907.20 2596.53 3741.52 2.30
YP_888098.1 hypothetical protein MSMEG_3806 6 5155.00 3304.54 3476.92 4486.98 7563.61 9413.13 2.29
YP_886850.1 lactate 2-monooxygenase 2 3095.00 1599.82 761.23 2644.28 3649.63 4101.99 2.28
YP_885727.1 ribosomal protein L33 40 5720.00 2207.40 1591.90 5002.94 5018.25 4772.73 2.27
YP_888037.1 GTP-binding protein EngA 8 2605.00 1175.82 1170.70 2335.62 2647.69 2568.88 2.25
YP_885528.1 heat shock protein HtpX 1 571.00 581.35 901.93 589.66 1304.66 1806.88 2.24
YP_890529.1 saccharopine dehydrogenase 3 8130.00 7990.35 8938.08 9130.59 17907.08 31757.33 2.24
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YP_887529.1
ABC-type molybdenum transport 
system, ATPase 
component/photorepair protein PhrA 3 21300.00 10927.72 21014.87 55281.06 24387.73 15787.41 2.23
YP_886211.1 rubredoxin 1 12900.00 3374.48 10281.95 13451.72 7478.34 3924.04 2.22
YP_888108.1 excinuclease ABC subunit B 11 2060.00 2474.04 2236.78 2423.15 5457.40 6962.89 2.21
YP_887936.1
inositol-5-monophosphate 
dehydrogenase 16 193.50 104.91 120.86 166.76 230.23 320.77 2.20
YP_885030.1 PPE family protein 2 120.00 104.91 108.23 150.64 228.53 136.89 2.18
YP_890280.1 cadmium transporting P-type ATPase 2 1880.00 4365.84 2768.91 1805.85 9332.15 5393.27 2.14
YP_891101.1 hypothetical protein MSMEG_6901 2 7530.00 7015.60 7598.72 7614.97 14752.02 21673.46 2.10
YP_884953.1 ANTAR domain-containing protein 6 9960.00 5940.31 6272.89 11254.30 12108.60 10590.34 2.04
YP_889351.1 ABC transporter ATP-binding protein 2 6215.00 5485.72 5303.32 9591.26 11127.97 16234.57 2.03
YP_885118.1 chaperone protein DnaJ 17 1570.00 2194.29 2750.87 2155.96 4451.19 5329.39 2.03
YP_888525.1
1-acylglycerol-3-phosphate O-
acyltransferase 3 3360.00 2954.86 3120.66 3565.63 5986.08 8559.88 2.03
YP_887058.1 recombination regulator RecX 3 6600.00 3619.26 2471.28 4920.01 7333.37 6634.36 2.03
YP_890829.1 hypothetical protein MSMEG_6620 1 5880.00 5061.72 7287.56 6440.24 10232.62 17247.52 2.02
YP_891139.1
chromosomal replication initiation 
protein 4 5455.00 2570.20 2254.81 2925.29 5184.53 5730.92 2.02
YP_887414.1 6-phosphogluconolactonase 6 2485.00 1311.33 1379.95 2413.94 2639.16 3499.69 2.01
YP_890515.1 aldehyde dehydrogenase 1 28400.00 15910.76 13077.92 54083.30 31976.93 17247.52 2.01
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YP_888935.1 ATP-dependent Clp protease proteolytic subunit 20 12950 13768.927 13619.076 11655.09 7559.3451 9764.46629 0.549
YP_890980.1 hypothetical protein MSMEG_6772 8 13590 12671.784 14611.194 14373.075 6233.3686 15253.5565 0.492
YP_886029.1 O-acetylhomoserine aminocarboxypropyltransferase 2 486 579.16915 405.41553 350.11337 281.8233 1559.57691 0.487
YP_884500.1 phosphocarrier protein HPr 3 3260 5525.0552 7882.8292 3298.4365 2651.953 3139.23028 0.480
YP_888642.1 formamidase 2 13125 12357.066 12572.842 11733.405 5909.3357 10165.9957 0.478
YP_885552.1 5-oxovalerate dehydrogenase 2 2138 2266.4091 2611.9764 2146.7478 1076.5565 1266.64292 0.475
YP_886058.1 flavin-containing monooxygenase FMO 2 113700 103813.34 50417.638 115583.48 47922.752 8692.20013 0.462
YP_888190.1 diaminobutyrate--2-oxoglutarate aminotransferase 4 3905 7269.1193 8198.5031 4076.978 3334.1274 2459.36791 0.459
YP_890773.1 nonspecific lipid-transfer protein 3 4300 4519.7049 4139.8382 4505.4062 2012.4145 1496.60979 0.445
YP_884970.1 hypothetical protein MSMEG_0559 7 8490 16784.978 6926.7881 7997.3264 7017.8691 8176.59981 0.418
YP_887577.1 maltose/maltodextrin-binding protein 3 566 840.1231 690.87496 448.69792 338.52905 158.786648 0.403
YP_888096.1 lipoprotein LpqH 5 630 2307.9344 4617.8588 770.24941 895.3539 1022.07498 0.388
YP_884657.1 hypothetical protein MSMEG_0242 1 4080 8602.3011 11093.684 3851.247 3300.0187 3111.85328 0.384
YP_886054.1 aspartate ammonia-lyase 1 14200 12938.42 8369.869 15755.102 4928.71 3285.241 0.381
YP_889726.1 DNA-binding response regulator 1 340 274.50432 195.71784 372.22579 102.32616 109.508033 0.373
YP_885732.1 transcription antitermination protein NusG 5 1280 1818.3726 454.57047 1124.0482 410.15736 397.879187 0.226
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Appendix 4 – Quantitative PCR to assess regulation of the putative WhiB1 
regulon in Msm upon expression of GFP-WhiB1 and GFP-WhIB1 
Quantitative PCR, using probe sets that hybridize to essential genes in the putative WhiB1 
regulon to determine transcriptional modulation in wildtype Msm, or Msm inducibly expressing 
GFP-WhiB1 or WhiB1-GFP on tetracycline (ATc) inducible, episomal plasmids. The putative 
regulon in Msm was determined by finding homologs for Mtb genes identified as potential 
downstream targets of WhiB1 through ChIP-Seq data deposited in the Tuberculosis Database 
(www.tbdb.org).  
 
RNA was isolated from cultures grown for 6 hours from a starting OD600 of 0.06 in the presence of 
the inducer ATc (100 ng/mL). Relative standard curves were generated for each probe set, and 
sigA transcript was used as an endogenous control. Data are represented as mean fold change, 
normalized to transcript in wildtype cultures +/- SEM of technical replicates. 
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